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Potassium (K+) channels have been found to regulate the background ‘leak’ 
current maintaining resting membrane potential and therefore controlling the 
excitability of mammalian cells. The two-pore domain K+ channel (K2P) family 
has been suggested to underlie the K+ channels responsible for this leak 
current and can be regulated by a variety of stimuli. This study investigated 
multiple K2P channels and their role within pulmonary disorders using a 
combination of electrophysiological, imaging and biochemical approaches.  
Carotid bodies are responsible for oxygen sensing within the carotid artery. 
TASK channels (TASK-1 and TASK-3) are highly expressed in the carotid 
body and are sensitive to changes in the chemical composition of the blood, 
stimulating ventilatory responses. This study shows that doxapram, a 
ventilatory stimulant, is a highly potent inhibitor of both human TASK-1 and 
TASK-3 channels, despite being a more selective inhibitor of rodent TASK-1 
channels. I provide further evidence of the importance of key amino acids, 
previously identified in rodents, involved in the effect of doxapram on TASK-3. 
I also show that the M1P1 loop of the channel is important for doxapram 
inhibition.  
TASK-1 channels have been implicated in pulmonary arterial hypertension 
(PAH). I characterised homozygous mutations of TASK-1, G106R and L214R, 
found in patients diagnosed with an aggressive form of PAH. I show that whilst 
the mutated TASK-1 channels are expressed and trafficked to the membrane, 
they appear to be non-functional. Riociguat and sildenafil, used in the 
treatment of PAH, enhanced current through WT TASK-1 channels but were 
unable to restore function through the mutated TASK-1 channels. 
TREK-1 and TREK-2 channels have been shown to play a role in neuronal 
pain signalling. The majority of patients undergoing treprostinil therapy, as part 
of their treatment, experience severe pain at the site of infusion. This study 
shows that treprostinil rapidly inhibits TREK-1 and TREK-2 channels, 
suggesting they may play a role in the site pain experienced by patients. I also 
show that the N-terminus of TREK-1 is not important for treprostinil effect.  
K2P channels play a key role within the pulmonary system and their ability to 
be regulated by a variety of stimuli makes them a key therapeutic target when 
treating pulmonary disorders.  
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TRESK Twik-Related Spinal Cord Potassium Channel 
TRP Transient Receptor Potential Channel 
TTE Transthoracic Echocardiogram 
TWIK Tandem Pore Weak Inward Rectifier Potassium Channel  
UV Ultraviolet 
V Voltage 
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1.1 Background 
In the 1780s, the studies of Luigi Galvani, observed contractions upon frog 
nerve preparations stimulated by electricity, which he coined “animal 
electricity” (Piccolino, 2008). The phenomenon that animals contained the 
“powers” of electricity was widely contested by an opposing theory from 
Alessandro Volta that Galvani’s findings, were a result of the apparatus used 
and not the frog preparation (Pera, 1992). This dispute was resolved by the 
work of Emil du Bois-Reymond, in the 1840s, who detected what we now know 
as action potentials, within frog muscles (Finkelstein, 2015). du Bois-Reymond 
developed the concept that biological tissue has constituents capable of 
electrical activity and the practice of electrophysiology was born.  
It was then Sydney Ringer, who was first responsible for revealing the 
importance of ions in electrophysiological process with a series of papers in 
the 1880s (Ringer, 1882a, 1882b, 1883a, 1883b, 1884, 1885, 1887). In these 
papers, Ringer highlighted the importance of the concentration of calcium 
(Ca2+), potassium (K+) and sodium (Na+) for the contraction of a frog’s heart. 
Following on from this in 1902 (and the following years), Julius Bernstein, 
correctly developed his “membrane hypothesis” which stated that cells have 
negative resting potentials due to the membrane being selectively permeable 
to K+ ions and upon excitation the membrane becomes permeable to other 
ions (Bernstein, 1902a, 1902b, 1912). Bernstein adopted the work of a 
physical chemist, Walther Nernst, and applied his formula known as the Nernst 
equation (Figure 1.1) to physiological conditions. The Nernst equation 
calculates the membrane potential (V) in which there is no net flow of a specific 
ion across a membrane. ∑ =�௢௡ ܴܶ�ܨ ln [݁�ݐ�݈݈ܽܿ݁ݑ݈ܽ� �݋݊][�݊ݐ�݈݈ܽܿ݁ݑ݈ܽ� �݋݊] 
Figure 1.1 – Nernst Equation 
Nernst equation, where Σion is the ion reversal potential (V), R is the universal gas 
constant (8.314 J K-1 mol-1), T is the temperature (K), z is the electron charge of the 
ion, F is Faraday’s constant (C mol-1). 
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A series of papers by Cole & Curtis (1939, 1949), Hodgkin & Huxley (1939, 
1945, 1952) and Hodgkin & Katz (1949), interrupted by the 2nd World War, 
provided an understanding of the critical role Na+ plays in the generation of 
action potentials, as well as the ion channel kinetics involved in calculating the 
membrane potential. It should be noted that Huxley stated (Huxley, 2002) that 
these findings would have been made much earlier had they have known of 
the work by Charles Ernest Overton (1902). Hodgkin & Huxley went on to be 
awarded the Nobel Prize for Physiology and Medicine in 1963. One of the most 
important outcomes from their work was the Goldman-Hodgkin-Katz (GHK) 
voltage equation (Figure 1.2). The GHK equation enables the calculation of 
the reversal potential of the membrane in regards to the concentration of ions 
on each side of the membrane. This built upon the Nernst equation 
significantly, as where the Nernst equation only factored in a single permeable 
ion, the GHK equation allows calculation of the reversal potential of a 
membrane that is permeable to multiple ions.  
 
�௠ =  ܴܶܨ ln ቆ��௟[�݈−]� + ��[�+]௢ + ���[ܰܽ+]௢��௟[�݈−]௢ + ��[�+]� + ���[ܰܽ+]� ቇ 
Figure 1.2 – Goldman-Hodgkin-Katz voltage equation 
Goldman-Hodgkin-Katz voltage equation use for the calculation of membrane 
reversal potential which accounts for the difference in ion concentrations either side 
of the membrane. Vm is the membrane potential (V), R is the universal gas constant 
(8.314 J K-1 mol-1), T is the temperature (K), F is Faraday’s constant (C mol-1), Pion is 
the permeability of that ion (m/s), [ion]i is the intracellular concentration of that ion, 
[ion]o is the extracellular concentration of that ion. 
 
The next major leap in electrophysiology occurred 20 years later when, in 
1976, Erwin Neher and Bert Sakmann first demonstrated the patch-clamp 
technique which allowed the recording of current through a single ion channel 
(Neher and Sakmann, 1976). In 1991 Neher and Sakmann were award the 
Nobel Prize for Physiology and Medicine and revolutionised the field of 
electrophysiology and the study of ion channels. To accompany this, the 
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development of recombinant DNA techniques enabled the ability to clone and 
sequence the (primary) structure of the nicotinic acetylcholine receptor 
(nAChR) from an electric ray (Noda, 1982). The same group then, this time 
from an electric eel, published the sequence of a voltage-gated sodium 
channel (Noda, 1984). These two discoveries led to the initial classification of 
the first two ion channel families: voltage-gated ion channels and ligand-gated 
ion channels. 
 
1.2  Ion channels  
Ion channels, or pores, are integral membrane proteins that allow the passage 
of ions across the membrane (either plasma membranes or membranes of 
intracellular organelles; Hille, 2001). Ion channels have three key properties 
which are critical to homeostatic processes in cells: rapid ion conduction; 
selective ion conduction; and regulation in response to stimuli (MacKinnon, 
2004).    
There are over 400 different genes already identified in the human genome 
that encode for ion channel proteins and their alternatively spliced variants 
(Alexander et al., 2015). These channels differ in their localisation, mechanism 
of gating, ionic selectivity, modulation by accessory subunits and signalling 
molecules, all of which contribute to the heterogeneity and many physiological 
roles of ion channels. 
The diversity of ion channels allows the cellular response to multiple stimuli 
including changes in pH, temperature, voltage, ligands and many more (Hille, 
2001). The selectivity of ion channels to permit access of specific ions through 
the channel has been researched for decades, but due to ion channels 
containing many hydrophobic transmembrane domains, they have been very 
difficult to study (Rasband, 2010). One aspect of ion selectivity that has been 
uncovered is the selectivity filter which contains conserved amino acid 
sequences across ion channels. For example, K+ channels contain a ‘TVGYG’ 
conserved sequence. As this sequence becomes less conserved the ion 
selectivity of the channel is reduced, with an eight amino acid sequence 
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‘XXTTXGXG’ required for the channel to be potassium selective (MacKinnon, 
2004). 
A comparison of the amino acid sequence relationship of the minimal pore 
regions of known ion channels, results in structurally related channels being 
separated into seven groups (Figure 1.3). 
 
 
Figure 1.3 – Phylogenetic tree of ion channels  
Amino acid sequence relationship of the minimal pore regions. 143 structurally related 
channels are separated into 7 groups, with the four-domain voltage-gated calcium 
(Cav) and voltage-gated sodium channels (Nav) represented as blue branches. 
Transient receptor potential channels (TRP) and related channels are shown as green 
branches, potassium selective channels are shown as red branches and cyclic 
nucleotide-gated channels shown as magenta branches. (Reproduced from Yu and 
Catterall, 2004). 
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1.3 Potassium Channels 
In humans, K+ channels represent the largest family of ion channels with >78 
mammalian α-subunit and 13 β-subunit genes identified to date.  However, the 
diversity of these channels far exceeds the 78 α-subunit genes identified, due 
to heteromeric assembly within subfamilies, association with auxiliary 
subunits, and channel susceptibility to alternative splicing.  
Production of K+ channel crystal structures identified that K+ channels contain 
four subunits that help form the channel pore. These subunits are α helical 
loops, often named P loops, and are located between two transmembrane 
(TM) helices (Figure 1.4). It is a standard feature of K+ channels to have a 
2TM/P domain but different K+ channels contain further structural differences. 
For example voltage-gate K+ channels characteristically have 4 further TM 
domains (S1-4) that precede their 2TM/P domain, with S4 providing the 
channel with a voltage-sensing ability (Choe, 2002).  
Based upon their structural and physiological characteristics these channels 
have been classified into 3 main subfamilies of K+ channels classified by their 
TM/P structure and are 2TM/P channels which include inward-rectifier K+ 
channels (Kir), 4TM/2P channels which include two-pore domain K+ channels 
(K2P), 6TM/P channels such as voltage-gated K+ channels (KV) and Ca2+-
activated K+ channels (KCa). 
 
1.3.1 Two Transmembrane domain K+ Channels 
The first family of K+ channels are the 2TM/P domain channels, which as they 
have one P loop per subunit require tetrameric formation to generate a 
functioning channel (Figure 1.4). Inwardly rectifying potassium (Kir) channels 
form the majority of 2TM/P channels, which are named justly as their inward 
current (negative current) is much larger than the outward current (positive 
current). Kir channels can be further divided in to four subfamilies based on 
their properties: classical Kir channels, ATP sensitive K+ (KATP) channels, G 
protein-gated Kir (GIRKs) channels and K+ transport channels. Kir channel 
gating is not dependent on the membrane voltage but the electrochemical 
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gradient of K+ ions, resulting in the ability to regulate action potentials and 
maintain resting membrane potential through the blocking of the pore by Mg2+ 
and polyamines (Hibino et al., 2010). Kir channels are found in a diverse range 
of cells including but not limited to neurons, epithelial, cardiac myocytes and 
osteoclasts (Bal et al., 2018; Bardou et al., 2009; López-Izquierdo et al., 2011; 
Wang et al., 2012).  
 
Figure 1.4 – Trademark structure of K+ channels 
Characteristic two transmembrane domain (TM) connected via an α helical loop (P 
loop) – 2TM/P. Four P loops are required to form a K+ channel pore.  
 
1.3.2 Six/Seven Transmembrane domain K+ Channels 
The next family of K+ channels is the 6TM/P domain family, which have 6TM 
domains per pore domain (Figure 1.5). As with 2TM/P domain channels, these 
require tetrameric formation, for a functioning channel. The S4 TM domain is 
responsible for voltage-sensing within 6TM/P K+ channels. The major role of 
6TM/P channels is in regulating action potential duration, via membrane 
repolarisation, following the generation of an action potential (Labro and 
Snyders, 2012). The 6TM/P channel family consists of KV, KCNQ, HERG-like 
K+, Na+-activated K+ (KNa) and KCa channels (BK, IK and SK). Each of these 
are regulated in a variety of ways. KNa and KCa are regulated by cytoplasmic 
Na+ and Ca2+ respectively, however some KCa channels are also voltage-
dependent and contain an extra TM domain at the amino terminus (Miller, 
2000). HERG-like K+ channels, named after their conductance resemblance 
to the human ether-à-go-go-related gene product (HERG), are voltage-
dependent KV channels found mainly within neuron and cardiac cells (Wang 
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and MacKinnon, 2017). KCNQ channels are implicated in many pathways 
such as pain signalling and are inhibited by a variety of Gq/11-coupled 
neurotransmitter receptors (Hernandez et al., 2008). KV channels are voltage-
dependent via the S4 TM domain. This domain has a unique feature within all 
KV channels in that an arginine or lysine residue appears in every third or fourth 
position (Pongs et al., 1988; Miller, 2000). 
 
Figure 1.5 – Typical Kv Channel structure 
Voltage-gated K+ channel structure, each 2TM/P subunit is preceded by four 
transmembrane helices (S1-4) with S4 being responsible for voltage sensing as 
represented with plus signs. 
 
1.3.3 Four Transmembrane domain K+ Channels  
The final superfamily of K+ channels is the 4TM domain family. These K+ 
channels differ from the others in that they have 2 pore-forming regions in one 
alpha subunit, which dimerises with another subunit to form a functioning 
channel, with a single pore (Lesage et al., 1996a; Figure 1.6). The first P loop 
is situated between TM1 and TM2, whilst the second is between TM3 and 
TM4. As each subunit of this family contains two P loops they were named 
two-pore domain potassium (K2P) channels. The M1P1 loop in each K2P 
subunit is characteristically extended and thought to play a key role in 
dimerization. Initially it was proposed that a disulphide bridge was formed 
between the M1P1 loop of each subunit however in recent years, this has been 
shown to not be the case for all K2P channels e.g TASK-1 and TASK-3 
(Niemeyer et al., 2003).   




Figure 1.6 – Four transmembrane domain K+ channel structure 
Four transmembrane (TM) domain channel structure, each subunit contains four TM 
domains with two P loops contributing to the pore region. One functional channel 
requires the dimerization of two subunits. 
 
The first ion channel crystal structure solved was a K+ channel, KcsA, from 
Streptomyces lividans and was produced in 1998 (Doyle et al., 1998). The 
generation of this crystal structure enabled the understanding of K+ channels 
and the selectivity sequence ‘TVGYG’ conserved within K+ channels. K+ ions 
control the cellular osmolarity in respect to its environment, this is a vital role 
for life (Choe, 2002). This TVGYG sequence was shown to form an ‘antiprism’ 
of water molecules which displaces the water molecules surrounding the free 
flowing K+ ion, whilst enabling them to pass through the channel pore and 
excluding alternative ions that are not energetically favourable to pass through 
the selectivity filter, such as Na+ ions (Zhou et al., 2001; Figure 1.7). The 
selectivity filter has also been shown to change conformation depending on 
the extracellular K+ concentration. When internal K+ concentrations are low (2 
mM), the selectivity filter loses a dehydrated K+ ion causing a non-conductive 
structural change (Zhou et al., 2001). Concentrations of K+ above 20 mM is 
enough to cause the selectivity filter to change from a non-conductive state to 
a conductive state, with the entry of a second K+ ion into the selectivity filter. 
Chapter 1.  Introduction 29 
 
The selectivity filter contains four K+ ion binding sites, but experimental studies 
have shown that the selectivity filter has the ability to accommodate a 
maximum of two K+ ions at a given time at positions 1 and 3 or 2 and 4 due to 
electrostatic repulsion between the two K+ ions (Morais-Cabral et al., 2001). 
This electrostatic repulsion between the two K+ ions helps increase the K+ ion 
conduction rate of the K+ channel by reducing the K+ binding affinity to the 
selectivity filter.  
 
 
Figure 1.7 – Conserved amino acid region forming selectivity filter 
Left) Structure of selectivity filter present in K+ channels, two subunits shown. 
Conserved amino acid sequence indicated in single letter code, green spheres 
represent K+ ions, red spheres represent oxygen and numbers correspond to K+ ion 
binding site. Right) Representation of the antiprism formed by TVGYG selectivity 
sequence around K+ ions and the similar environment water molecules created 
(reproduced from Zhou et al., 2001). 
 
1.3.4 K+ channel gating 
K+ channels must have the ability to open and close quickly for brief periods of 
time, due to the rapid speed of K+ ion permeation through K+ channels (in 
neuronal cells, rate is approximately 107 ions per second). If 10 K+ channels 
were open for just one second then the cell would become depleted of K+ ions. 
K+
 
channels have acquired various gating and inactivation mechanisms to 
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prevent this (Choe, 2002). There are three confirmed methods of gating in KV 
and Kir channels, ball and chain inactivation by the amine terminal, activation 
gate conformational change and C-type inactivation. C-type inactivation is a 
slow mechanism of inactivation which involves a constriction at the selectivity 
filter (Kiss and Korn, 1998). In K2P channels, the gating mechanism is yet to 
be fully confirmed but C-type inactivation which occurs in and around the 
selectivity filter is currently proving to be the general consensus for K2P gating 
(Leuthy et al., 2017). A reduced current is observed by protonation of a 
histidine residue at position 98 (H98) which is located next to the selectivity 
filter (Rajan et al., 2000). Within the TWIK-related alkaline pH-activated (TALK) 
K+ channel family, a key arginine residue, R224 has been shown to be critical 
for C-type gating of TASK-2 in a pH sensitive manner similar to that seen within 
TASK-3 and H98 (Niemeyer et al., 2007). The M1P1 loop has also been 
implicated within TASK-3 channel gating and regulation, mutation of loop 
residues such as glutamate-70 (E70) and H98 can alter pH response as well 
as inhibition by Zinc (Clarke et al., 2008). Another residue of TASK-3 shown 
to be involved in channel gating is E30, located at the end of the first TM 
domain (Veale et al., 2005). The position of this glutamate residue at the end 
of the first TM domain is conserved throughout K2P channels and helps 
stabilise the channel in an open conformation. Mutation of this channel therefor 
reduces its ability to form an open conformation and reduces the whole-cell 
current recorded (Veale et al., 2005; Mathie et al., 2010a). Recent studies 
have proposed that the selectivity filter facilitates channel gating in response 
to stimuli, including stimuli that are detected at a distant location from the 
selectivity filter (Niemeyer et al., 2016). 
 
1.4 Two-Pore Domain K+ (K2P) Channels  
In the late 1990’s, over four decades after leak current was first proposed by 
Hodgkin and Huxley it was finally pinpointed that the K2P channel family were 
responsible for this current (Hodgkin and Huxley, 1952; Ketchum et al., 1995; 
Patel et al., 1998). Previous to the attribution of K2P channels to the 
background leak current, this current was seen as insignificant (Niemeyer et 
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al., 2016). The first K2P channel to be discovered was TOK-1, which was 
found in yeast (Ketcum et al., 1995). In more recent years, all identified 
mammalian K2P channels have contained 4TM domains rather than the 8TM 
domains found in TOK-1 (Ketchum et al., 1995). Of the mammalian K2P 
channels there are 15 members that can be further subdivided into six distinct 
subfamilies, based on their structural and functional properties (Figure 1.8). 
Nomenclature for K2P channels is based on three main schemes, KCNKx, K2P 
and a third acronym scheme. The KCNKx scheme is adopted by The Human 
Genome Organisation (HUGO) which uses the KCNK followed by a number 
(x) which denotes the order in which the gene was discovered. The K2P 
nomenclature scheme adopted by The International Union of Basic and 
Clinical Pharmacology (IUPHAR), is similar to the KCNK scheme but the prefix 
is K2P opposed to KCNK. The third scheme uses acronyms based on their 
functional and pharmacological properties: TWIK (Tandem pore Weak Inward 
rectifier K+ channel; Lesage et al., 1996a), TREK (TWIK-related K+ channel), 
TASK (TWIK-related acid-sensitive K+ channel), TALK (TWIK-related alkaline 
pH-activated K+ channel), THIK (TWIK-related halothane-inhibited K+ 
channel) and TRESK (TWIK-related spinal cord K+ channel). As the first two 
methods of classifying K2P channels are non-informative and generally 
ignored by the K2P field, I will not use either the HUGO or IUPHAR 
classification, but instead continue with the original TWIK nomenclature to 
describe the K2P channels. This nomenclature is not without its problems, with 
channels such as TASK-2 and TASK-4 assigned to the TALK family, and not 
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Figure 1.8 – Phylogenetic tree of the K2P family  
Phylogenetic tree showing the 15 members of the K2P family. 6 subfamilies are 
present, divided on their functional properties: TWIK (Tandem pore Weak Inward 
rectifier K+ channel), TREK (TWIK-related K+ channel), TASK (TWIK-related acid-
sensitive K+ channel), TALK (TWIK-related alkaline pH-activated K+ channel), THIK 
(tandem pore halothane-inhibited K+ channel) and TRESK (TWIK-related spinal cord 
K+ channel). Reproduced from Honore, 2007. 
 
Despite there being only 15 K2P mammalian members (around 50 for C-
elegans), these channels are further diversified due to heteromerisation, post-
translational modifications and splicing (Feliciangeli et al., 2015). The first K2P 
channels found to form heterodimers were TASK-1 and TASK-3. These 
heterodimer channels exhibited intermediate properties of the individual 
TASK-1 and TASK-3 channels, including sensitivity to pH. THIK1 and THIK2 
as well as TREK-1, TREK-2 and TRAAK have since been shown to also form 
heterodimers (Czirjak and Enyedi, 2002; Enyedi and Czirjak, 2010; Levitz et 
al., 2016; Blin et al., 2016). In addition to this, TWIK-1 has been shown to form 
heterodimers with TASK-1 and TASK-3 channels (Plant et al., 2012). An even 
further diversification of channel function and regulation occurs with auxiliary 
subunits such as coat protein 1 (COP-1 or COPI), 14-3-3, p11 and syntaxin-8 
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(Dedman et al., 2009). 14-3-3 proteins have been shown to promote channel 
expression on the cell surface where as COPI binding has been shown to 
retain the channel within the endoplasmic reticulum (O’Kelly et al., 2002). 
 
1.4.1 TWIK subfamily 
TWIK-1 (KCNK1) was the first mammalian K2P channel to be identified after 
cloning and subsequent full-length sequencing revealed a two-pore subunit of 
a weak inward rectifying K+ channel (Lesage et al., 1996b). TWIK-1 channels 
have been shown to be the only genuine “leak” K+-selective K2P channel that 
follows GHK equation independently of voltage (Schewe et al., 2016). Other 
K2P family members have been shown to act with a voltage-dependent 
behaviour as opposed to being simply “leaky”. The ability for K2P channels to 
sense voltage changes has been attributed to an ‘ion-flux-gating’ mechanism. 
Ion-flux-gating has been coined to refer to the state of the selectivity filter of 
the K2P in response to both voltage and electrochemical K+ gradients (Schewe 
et al., 2016). Ion-flux-gated K2P channels such as the TREK family can be 
converted to ‘leak’ behaving channels with the application of certain molecules 
such as arachidonic acid (Schewe et al., 2016). It has been proposed that 
TWIK-1 channels distinct selectivity filter is the reason behind its genuine 
GHK-leak behaviour, with changes to other K2P channels selectivity filter 
eradicating its ion-flux-gating ability and converting them to GHK-leak 
channels (Chen et al., 2014). Other members of the TWIK family include 
TWIK-2 (KCNK6) and KCNK7, the latter appears to be non-functional and may 
not act as a K+ channel as the conserved ‘GYG’ region of K+ channels is ‘GLE’ 
within KCNK7 (Salinas et al., 1999). Human TWIK channels are expressed in 
a variety of different tissues, TWIK-1 for example is expressed within the brain, 
kidney and lung (Arrighi et al., 1998; Lesage et al., 1996b). 
Following the discovery of TWIK-1, 14 more K2P channels have been 
identified and named after TWIK-1 (T = TWIK-related). As mentioned earlier 
TWIK-1 was shown to be a voltage-independent K+ channel, with a strong 
outward rectification due to the asymmetry of the K+ gradient across the cell 
membrane that follows GHK equation (Lesage & Lazdunski, 2000a; Goldstein 
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et al., 2001). The latter 14 K2P channels were originally deemed to act in this 
manner however as mentioned previously they have been found to present 
time- and voltage-dependent conductance (Schewe et al., 2016). 
 
1.4.2 THIK subfamily 
The THIK channel subfamily are classified based on their inhibition by the 
volatile anaesthetic, halothane, and encompass two channels, THIK-1 
(KCNK13) and THIK-2 (KCNK12). THIK-2 appears to be non-functional  as it 
is yet to be functionally expressed in its WT form however following the 
deletion of a 19 amino acid region (THIK-2Δ6-24) THIK-2 has been shown to 
be functionally expressed (Renigunta et al., 2014a). Heterodimeric channels 
of THIK-1 and THIK-2 have been shown to be functionally expressed with 
intermediate properties of the WT channels (Blin et al., 2014). THIK-1 may 
play a role within cerebellar Purkinje cells, as the K+ current which is resistant 
to Tetraethylammonium (TEA) in these cells, shares properties that resemble 
THIK-1 channels (Rajan et al., 2001; Bushell et al., 2002).THIK-2 has been 
shown to be more widely expressed than THIK-1, with THIK-2 being widely 
expressed in the brain as well as kidney, liver and lungs and THIK-1 
expression localised to areas in the brain such as granule cell layer of the 
olfactory bulb and hypothalamic and thalamic nuclei (Rajan et al., 2001; 
Lazarenko et al., 2010; Renigunta et al., 2014a). 
 
 
1.4.3 TRESK subfamily 
The most recently discovered subfamily of K2P channels, is the TRESK 
subfamily which so far comprises only one channel, TRESK. A channel was 
identified as TRESK-2 however this was later proven to be just a species 
difference in mice (Kang et al., 2004). TRESK channels were named as 
originally they were found to be only expressed within the spinal cord however 
more recent studies have identified expression within the brain and non-
neuronal tissues such as liver, testis and lung (Sano et al., 2003; Dobler et al., 
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2007). Structurally TRESK is different to traditional K2P channels in that it has 
an additional extended intracellular loop between the M2 and M3 
transmembrane domains (Enyedi et al., 2012). Mutations of TRESK have been 
heavily linked to migraine with aura and TRESK agonists are a current 
therapeutic target for migraine therapy (Lafreniere et al., 2010). 
 
1.4.4 TALK subfamily 
The TALK family were the second subfamily to be discovered and are termed 
due to their sensitivity to pH changes. The channels pH sensitivity is shifted to 
more alkaline pH resulting in larger currents through the channels at a higher 
pH range (Girard et al., 2001). This subfamily is comprised of TALK-1, TALK-
2, and TASK-2 (Girard et al., 2001). TALK-2 was initially named TASK-4 in 
early studies (Decher et al., 2001).TASK-2 was originally found within the 
kidney but mRNA expression has also been identified in the pancreas and liver 
(Reyes et al., 1998; Decher et al., 2001; Kang and Kim, 2004; Talley et al., 
2001). Interestingly, TALK-1 expression is localised to the pancreas and 
TALK-2 highest mRNA expression levels have been found in the pancreas but 
not limited to (Girard et al., 2001; Enyedi and Czirjak, 2010). A mutation in 
TASK-2, TASK-2_T108P is prevalent in patients predisposed to Balkan 
endemic nephropathy (BEN) which is a renal disease that leads to chronic 
renal failure (Toncheva et al., 2014; Veale and Mathie, 2016).  
As the focus of my thesis is upon TASK and TREK channels associated with 
pulmonary disorders I will now describe them in greater detail than the other 
K2P families. 
 
1.5 TWIK-related Acid-Sensitive K+ (TASK) Channels 
The fifth subfamily of K2P channels is the TASK subfamily which comprises of 
TASK-1, TASK-3 and TASK-5. TASK channels are assigned based on their 
sensitivity to extracellular pH within physiological ranges, TASK-1 and TASK-
3 have pK values of approximately 7.5 and 6.8, respectively (Kemp et al., 
2004; Berg et al., 2004). TASK-1 and TASK-3 are closely related sharing 
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approximately 60% identity in their amino acid sequence. They were also the 
first K2P channels seen to form functional heterodimers. This uncovered a new 
range of diversity within the K2P channels, as these heterodimers have 
intermediate properties to the homodimeric channels such as a pK value close 
to 7.3 (Cotton et al., 2006; Czirjak and Enyedi, 2002; Berg et al., 2004). A 
single histidine residue (H98) which is found within the M1P1 loop of TASK-1 
and TASK-3 is responsible for the pH sensitivity of the channel. Mutation of 
this histidine abolishes the sensitivity to extracellular pH changes (Rajan et al., 
2000).  
 
1.5.1 TASK Channel Expression 
TASK-5 has shown no functional expression to date, but has been placed in 
the TASK subfamily based on its structural properties (Enyedi and Czirjak, 
2010). TASK channels have been shown to be expressed throughout the 
central nervous system (CNS), playing a crucial role in background currents. 
TASK-1 channels have been found to be highly expressed within the carotid 
bodies and pulmonary arterial smooth muscle cells (PASMCs; Yamamoto et 
al., 2002; Gurney et al., 2003). Like TASK-1, TASK-3 is widely expressed 
throughout the CNS (Talley et al., 2001). TASK-3 is associated with a range 
of diseases such as cancer, hyperaldosteronism and cognitive impairments 
(Mu et al., 2003; Davies et al., 2008; Linden et al., 2007). 
 
1.5.2 Regulators of TASK Channels  
Auxiliary subunits have been shown to regulate the expression of TASK 
channels on the cell surface. A short sequence within the C-terminus of TASK-
1 and TASK-3 allows for coat protein complexes COPI to bind, binding of 
which has shown to retain TASK-1 and TASK-3 within the endoplasmic 
reticulum (Kilisch et al., 2015). This COPI binding domain is overlapped with 
the binding domain for 14-3-3 proteins and binding of a 14-3-3 protein results 
in an increase in cell surface channel expression (Kilisch et al., 2015). Serine 
residues in the C-terminus have been shown to be important in the binding of 
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14-3-3 proteins, phosphorylation of S373 in TASK-3 and S393 in TASK-1  
have been shown to prevent COPI binding and as a result increase 14-3-3 
protein binding which in turn increases channel expression at the cell surface 
(Kilisch et al., 2016). In TASK-1, if S392 is phosphorylated following the 
phosphorylation of S393 it prevents 14-3-3 binding, further highlighting the 
dynamic regulation of TASK-1 trafficking by auxiliary subunits and kinases.  
As well as 14-3-3 proteins and COPI, TASK-1 interacts with p11 (also known 
as S100A10) and syntaxin-8. p11 is a retention protein, highly expressed 
within the brain, that promotes TASK-1 localisation within the endoplasmic 
reticulum and deletion of its binding domain has shown to increase TASK-1 
currents measured (Renigunta et al., 2006). Syntaxin-8 is a SNARE protein 
that has been found to regulate the endocytosis of TASK-1, with co-expression 
of syntaxin-8 with TASK-1 can reduce current observed by fourfold (Renigunta 
et al., 2014b; Kilisch et al., 2015). TASK channels have also been shown to 
be silenced through sumoylation when expressed as heteromeric channels 
with TWIK-1 (Plant et al., 2012). 
 
1.5.3 Pharmacology of TASK Channels 
TASK channels are not only regulated by pH but other chemical factors such 
as anaesthetics, hypoxia and signalling pathways. The biggest challenge 
faced when studying TASK channels is the lack of selective antagonists and 
agonists available (Bayliss and Barrett, 2008). Endocannabinoids such as 
anandamide and methanandamide have been found to significantly inhibit 
TASK current independent of cannabinoid receptors, which may account for 
adverse effects seen, such as hypokinesia and analgesia (Maingret et al., 
2001; Bayliss et al., 2003). 
Zinc selectively blocks TASK-3 but this inhibition can be abolished by the 
mutation of glutamate at position 70 (E70) or the H98, the pH sensor 
aforementioned, indicating a role of the M1P1 loop in TASK-3 channel activity 
regulation (Clarke et al., 2008). As stated above, a key issue with TASK 
channels is the selectivity of compounds but techniques such as thallium flux 
assay have recently been used to identify more selective compounds, such as 
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terbinafine (Wright et al., 2017). Terbinafine selectively activates TASK-3 with 
no effect upon TASK-1, as well as enhancing the mutated Birk-Barel TASK-3 
channel. One compound with a mechanism of action disputed is doxapram, a 
ventilatory stimulant used primarily in the treatment for post-operative 
respiratory depression (Yost et al., 2008). It has been debated as to whether 
doxapram is more effective against TASK-1 or TASK-3 in the carotid bodies 
(Buckler, 2015; Cotton et al., 2006). 
Kv1.5 channels have been implicated as a target in the treatment of obstructive 
sleep apnoea and atrial fibrillation. Known Kv1.5 blockers have been shown to 
have a higher affinity for TASK-1 channels (Kiper et al., 2015). A293 and 
A1899 were found to be 43- and 68- fold more potent at blocking TASK-1 
current than Kv1.5 current (Kiper et al., 2015). AVE0118 another Kv1.5 blocker, 
has also shown a higher affinity to TASK-1 than Kv1.5 (IC50 values of 603 nM 
and 5.6 µM respectively), indicating TASK-1 may be the primary target of this 
compound in the atrium (Kiper et al., 2015; Gögelein et al., 2004). TASK-1 and 
TASK-3 inhibition within cerebellar granule neurons and sensory neurons by 
hydroxy-α-sanshool has been shown to underlie tingling and numbing feeling 
experienced after eating Szechuan peppercorns (Bautista et al., 2008).  
 
1.5.4 Regulation by Signalling Pathways 
TASK-1 and TASK-3 channels are regulated by Gαq-coupled receptors, 
however the signalling pathway through which this inhibition occurs is debated 
(Olschewski et al., 2017). Earlier studies suggested a direct inhibitory effect of 
Gαq on the TASK-1 channel but more recent studies have indicated that 
phospholipase C (PLC) is essential for inhibition of the TASK-1 channel, with 
diacyleglycerol (DAG) shown to directly mediate TASK channels (Chen et al., 
2006; Schiekel et al., 2013; Wilke et al., 2014). Gαs-proteins have been shown 
to increase TASK-1 and TASK-3 current through increased cell surface 
expression (Mant et al., 2011). PKA phosphorylates the C-terminus of TASK-
1 and TASK-3 restricting COPI binding and in turn retention within the 
endoplasmic reticulum (Mant et al., 2011). Gαi-proteins have also been shown 
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to be involved within TASK-1 current inhibition through PLC activity (Czirjak et 
al., 2001). 
1.5.5 Human Pathologies of TASK Channels 
TASK channels have been implicated in a wide range of diseases. TASK-1 
has been shown to play a pathophysiological role in pulmonary arterial 
hypertension (PAH), hyperaldosteronism and even obesity (Navas et al., 
2016; Antigny et al., 2016; Heitzmann et al., 2008; Chen et al., 2017). In PAH, 
it is proposed that TASK-1 is downregulated and restoration of the channel 
current could provide a therapeutic benefit. Compounds such as the 
prostacyclin anaglogue, treprostinil, (acting through protein kinase A) and the 
phospholipase A2 inhibitor, ONO-RS-082 have been explored (Olschewski et 
al., 2006; Ma et al., 2013). Some patients with PAH have been shown to carry 
genetic mutations in their KCNK3 genes which produce non-functional or lower 
functioning channels (Ma et al., 2013; Navas et al., 2017). TASK-1 has also 
been indicated in the arrhythmogenesis of atrial fibrillation (AF) and heart 
failure, with mice models of both diseases showing atrial expression of TASK-
1 was down-regulated compared to wild-type models (Weidmann et al., 2018).  
The gene for TASK-3, KCNK9, is maternally transmitted (with the paternal 
gene silenced) and a substitution of a glycine residue to an arginine at position 
236 (G236R) and subsequent reduced outward current is seen in Birk-Barel 
syndrome (Barel et al., 2008). Birk-Barel syndrome is a mental retardation 
dysmorphic syndrome that occurs due to dysfunctional TASK-3 channels, 
which in turn cause a migration defect of cortical neurons. Potential therapies 
have been suggested, such as the use of flufenamic acid (FFA) which has 
been shown to significantly enhance channel current (Bando et al., 2014; 
Veale et al., 2014a). TASK-3 has also be found to be over expressed within 
certain cancers such as breast cancer suggesting it plays an important role in 
oncogenesis (Mu et al., 2003). Xenograft studies have shown that antibody 
targeting of TASK-3 looks a promising therapeutic strategy in the treatment of 
lung and breast cancer (Sun et al., 2016). 
TASK-3 has been found to be linked to menarche signals. Maternally inherited 
TASK-3 alleles have been found to increase age at menarche, whereas the 
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paternal allele has no significant effect (Perry et al., 2014). Late menarche has 
been associated with lower body mass index values observed in adults, 
suggesting TASK-3 could have a role in obesity (Prentice and Viner, 2013). 
Further evidence for paternal TASK-3 in obesity has been investigated with 
single nucleotide polymorphisms (SNPs). SNPs on the paternal allele of 
TASK-3 increase BMI compared to SNPs on the maternal allele (Hoggart et 
al., 2014). In addition to TASK-3, TASK-1 has also been linked to obesity, 
however TASK-1 knockout mice have shown resistance to hypothermia and 
obesity (Chen et al., 2017).  
 
1.6 TWIK-related K+ (TREK) Channels 
The TREK (Twik-related K+ Channel) channel subfamily comprises of TREK-
1, TREK-2 and TRAAK (Twik-Related arachidonic-acid-stimulated K+ 
channel). TREK-1 was the second mammalian K2P channel to be identified 
and the first K2P channel to show evidence for existence within neurons (Fink 
et al., 1996). TREK-1 shares 63% identity and 78% homology with TREK-2 
(Noël et al., 2011). TREK-1 and TREK-2 are outward rectifiers whereas 
TRAAK follows GHK rectification (Bayliss and Barrett, 2008).    
 
1.6.1 Expression 
TREK channels are expressed widely throughout the central nervous system 
such as hippocampus and cerebellum but are also expressed in high levels 
within nociceptors showing them to play a role in pain perception (Fink et al., 
1996; Marsh et al., 2012; Alloui et al., 2006). TREK-1 channels are expressed 
in dorsal root ganglion neurons often co-localised with excitatory channels 
such as TRPV1 (Talley et al., 2001; Loucif et al., 2018). TREK-1 channels 
have been found to be expressed within human myometrial smooth muscle 
cells and during labour they are down-regulated to enhance contraction 
(Buxton et al., 2010).  
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1.6.2 Regulators of TREK channels 
TREK channels are widely regulated, one key regulation pathway is due to 
TREK channels being mechanosensitive which means they are regulated by 
tension within the membrane. Stretching of the channel results in activation 
(Patel et al., 1998). Membrane stretching alters the channel conformation 
between an “up” conformation during stretch and “down” when there is not 
sufficient membrane tension (Aryal et al., 2017). TREK channels are also 
activated by temperature, maximum activation of TREK channels occurs at 
physiological temperature (between 30 ºC and 42 ºC) providing optimal control 
over membrane potential (Noël et al., 2011). Polyunsaturated fatty acids 
(PUFA) such as arachidonic acid have been shown to directly regulate TREK 
channels. Arachidonic acid activates TREK channels in a reversible manner 
(Fink et al., 1998). The neuroprotection observed within PUFA therapy has 
since been attributed to TREK channel mediation, highlighting a therapeutic 
target. Like TASK channels, TREK channels are regulated by pH, however 
TREK-1 and TREK-2 are differentially regulated. An extracellular pH change 
to pH 6.9 strongly inhibits TREK-1 current, however strongly activates TREK-
2 (Sandoz et al., 2009). The pH sensing effect is mediated through a 
conserved histidine residue, H126 in TREK-1 and H151 in TREK-2, therefore 
the differential effects of acidification must occur through alternative amino 
acid residues, the P2M4 loop has been implicated with this role (Sandoz et al., 
2009). 
TREK channels are also affected by chaperone proteins such as AKAP150, 
which increases current by anchoring TREK-1 into a postsynaptic scaffold with 
G protein-coupled receptors (GPCRs) and altering its properties (Figure 1.9; 
Noël et al., 2011; Mathie et al., 2010b; Sandoz et al., 2006). TREK-1 becomes 
a leak channel when co-expressed with AKAP150 and is inhibited by Gαs-
proteins at a faster rate. Interestingly, Gαq-protein inhibition of TREK-1 is 
significantly reduced (Sandoz et al., 2006). Another protein, Mtap2, has been 
shown to increase TREK-1 expression and trafficking to the postsynaptic 
membrane. Mtap2 and AKAP150 can both exert their actions simultaneously 
providing a cumulative activation in TREK-1 current density (Sandoz et al., 
2008). 
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Figure 1.9 – Regulation and variants of TREK-1 
Figure shows regulation of TREK-1 by anaesthetics, poly unsaturated fatty 
acids, stretch and temperature. Variants also indicated along channel. 
Channel activating proteins AKAP150 and Mtap2 shown. (Reproduced from 
Noël et al., 2011). 
 
1.6.3 Functional Diversity of TREK channels  
The TREK subfamily can be diversified with the formation of both homodimers 
and heterodimers between each of the family members (Blin et al., 2016; 
Levitz et al., 2016). The TREK subfamily can be further diversified by the 
generation of different isoforms of each channel. A process known as 
alternative translation initiation (ATI) can occur, creating different length 
isoforms of the TREK subfamily channels. ATI occurs when the ribosome skips 
the first translation initiation site due to a non-optimal starting sequence 
otherwise known as a Kozak sequence. After the ribosome has skipped this 
initiation site it will then proceed to start translation of the protein at the next 
optimal methionine (Kozak, 2005). For TREK-1 ATI creates two isoforms, a 
full length (426 amino acid) TREK-1 WT and a shorter form missing the first 
56 residues, TREK-1 Δ1-56 (Thomas et al., 2009). For TREK-2 there are three 
potential isoforms TREK-2 WT, TREK-2 Δ1-54 and TREK-2Δ1-66 (Simkin, 
Cavanaugh and Kim, 2008). TREK subfamily diversity can be increased 
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further by the process of alternative splicing (Noël, Sandoz and Lesage, 2011). 
Alternative splicing is the ability of one gene to produce multiple proteins by 
the inclusion or exclusion of different exons. As TREK channels have the same 
organisation of their respective 7 exons, each channel has similar spliced 
variants. Alternative splicing within the first exon produces channels with 
varying amino-termini (N-terminus) which creates two isoforms of TREK-1 and 
three variants of TREK-2 (Li et al., 2006; Mirkovic and Wickman, 2011). The 
TREK-1 isoforms vary in length, one being 411 residues long and the other 
426, but both exhibit identical functional properties (Li et al., 2006). The TREK-
2 isoforms are labelled TREK-2a, TREK-2b and TREK-2c, with TREK-2a being 
538 residues and TREK-2b and -2c 508 residues long. These TREK-2 variants 
all appear to have similar channel properties, with the differing factor being 
their expression levels and locations (Noël, Sandoz and Lesage, 2011). The 
deletion of exon 4 creates two further isoforms TREK-1ΔEx4 and TRAAKt 
(TRAAK truncated), TREK-1ΔEx4 has no functional activity individually 
however it has been proposed to exert a dominant negative effect, affecting 
full length TREK-1 trafficking to the cell membrane and reducing overall whole 
cell current (Veale et al., 2010). TRAAKt does not show any functional activity 
nor has it been shown to affect wild-type trafficking (Fink et al., 1998). TRAAKt 
and TREK-1 ΔEx4 are 67 and 141 amino acid residues long respectively, with 
both containing the M1 and only part of the P1 loop. TREK subfamily channels 
are mechanosensitive meaning that tension on the cell membrane can have a 
direct effect upon channel activity, they are the only K2P channels that exhibit 
this property (Brohawn, Su and MacKinnon, 2014).  
 
1.6.4 Signalling pathways 
“Nociceptor” is the term used for the neurons that identify noxious stimuli. 
Nociceptors are widely populated within the skin and muscles through the 
peripheral axonal branch as well as the spinal cord through a central axonal 
branch. Cell bodies of nociceptors are found within dorsal root ganglia and 
trigeminal ganglia, it is from these locations that nociceptors span into the 
wider periphery. Nociceptors have the ability to selectively detect a wide range 
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of stimuli that have the potential to cause injury (Tsunozaki and Bautista, 
2009). There are two major classes of nociceptor, Aδ fibres and C fibres. Aδ 
fibres are lightly myelinated and responsible for transmitting acute localised 
pain, C fibres however are unmyelinated and responsible for diffuse pain 
transmission (Plant, 2012). The ability for a fast response to damaging stimuli 
helps prevent injury and maintain homeostasis this occurs at Aδ fibres 
terminals, upon significant noxious stimuli (or potentially noxious), excitatory 
ion channels are opened which can result in action potential generation and 
pain signalling (Waxman and Zamponi, 2014). TRPV1, a thermosensitive 
channel, is an example of an excitatory ion channel that is opened within a 
sensory neuron terminal upon the presence of a stimulus such as heat. The 
opening of TRPV1 then results in the activation of Nav and Kv channels 
resulting in action potential generation (Woolf and Ma, 2007). The targeting of 
TRPV1 channels has provided therapeutic promise within recent years 
(Mathie, 2010). Studies have indicated a role for K2P channels within pain 
perception and as a result TREK-1, TREK-2 and TRESK have become a novel 
target for pain therapy (Mathie and Veale, 2015; Cohen et al., 2009; Acosta et 
al., 2014; Huang et al., 2008). TREK-1, TREK-2 and TRESK channels have 
been shown to be present in sensory neuron terminals and proposed to have 
an opposing effect to TRV1 channels, inhibition of these channels leads to the 
activation of Nav and Kv channels and the subsequent generation of an action 
potential. Activating TREK channels therefore provides a potential pain 
therapeutic avenue to explore, some clinically used drugs act upon TREK 
channels such as riluzole (Duprat et al., 2000). TREK channels can be 
regulated by various stimuli, such as mechanosensitivity, heat, membrane 
depolarisation, G-proteins subunits, pH and arachidonic acid (Maingret et al., 
2000; Patel et al., 1998; Sandoz et al., 2009; Kang et al., 2006; Lesage et al., 
2000). TREK-1 and TREK-2 channels have been shown to be regulated by 
multiple G proteins (Mathie, 2007). As seen in TASK-1 channels Gαq 
activation leads to PKC activation, whilst in TASK-1, DAG and IP3 
manipulations play a role in channel inhibition it appears evidence for this in 
TREK channels is conflicted (Chemin et al., 2005; Lopes et al., 2005). PIP2 
has been shown to be a potent TREK-1 channel opener and hydrolysis of PIP2 
into DAG + IP3 has been shown to inhibit TREK-1 current (Chemin et al., 2007; 
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Chemin et al., 2005) There is a growing consensus that TREK-1 and TREK-2 
inhibition through Gαq activation is due to PKC phosphorylation of the channel 
(Kang et al., 2006; Murbartian et al., 2005). Differentially to TASK-1, TREK 
channels have been shown to be down-regulated by Gαs and up-regulated by 
Gαi, in response to changes in intracellular cAMP levels (Lesage et al., 2000). 
An increase in intracellular levels of cAMP leads to an inhibition of TREK 
channels through the phosphorylation of the C-terminus (Bockenhauer et al., 
2001). In TREK-1 Gαs-activated inhibition, the serine residue at position 333 
(S333) is pivotal, providing alterations in the kinetic properties of the channel 
reducing the open-probability of the channel (Bockenhauer et al., 2001). An 
increase in cAMP activates PKA leading to S333 phosphorylation and results 
in a reduction in open-probability of the channel. A further serine residue, 
S300, has also been indicated in phosphorylation-mediated inhibition with both 
cAMP and PKC inhibition of TREK-1 currents requires phosphorylation of 
S300 (Murbartian et al., 2005). 
 
1.6.5 Pharmacology of TREK channels 
As with their regulation, TREK channels can be targeted by a range of 
pharmacological interventions. With their high importance in pain signalling, 
pharmaceutical development of a compound to selectively activate TREK 
channels has intensified. One class of compounds, fenamates, have been 
shown to enhance TREK-1 activity (Veale et al., 2014b). Fenamate-like 
compounds are being used experimentally to generate more potent activators. 
BL-1249 has been shown to be 30 to 100 fold more potent than flufenamic 
acid on TREK-1 channels (Veale et al., 2014b). One issue with fenamates is 
that they are not selective to TREK channels and regulate many other ion 
channel types (Mathie and Veale, 2015). More recently, rubidium-flux assays 
and electrophysiological experiments have shown GI-530139 to be a more 
selective activator than BL-1249 (Loucif et al., 2018). GI-530139, selectively 
activates both TREK-1 and TREK-2 but not TRAAK or other K+ channels 
(Loucif et al., 2018). One selective TREK channel activator, ML67-33 has been 
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shown to act through a gate near the selectivity filter surmised in TREK 
channel activation (Bagriantsev et al., 2013; Lolicato et al., 2017).  
 
1.6.6 Human Pathologies of TREK channels 
In addition to pain signalling, TREK channels have been implicated in diseases 
including depression and blood-brain barrier dysfunction (Heurteaux et al., 
2006; Bittner et al., 2013). Serotonin-selective reuptake inhibitors (SSRIs) 
were shown to inhibit TREK-1 and TREK-2 channels, this in combination with 
TREK knockout mice exhibiting depression resistant behaviour has led to the 
suggestion that TREK inhibition complements SSRI therapy (Heurteaux et al., 
2006; Enyedi and Czirjak, 2010). TREK-1 has been identified as a possible 
marker and target for prostate cancers due to its high expression that 
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1.7 Objectives of the Study 
The objectives of this research are to investigate the functional and 
pharmacological properties of TASK and TREK K2P channels. I will focus 
upon clarifying the mechanism of action of the ventilatory stimulant, doxapram, 
on TASK-3 channels (Chapter 3). I will then attempt to address the role of 
TASK-1 in pulmonary arterial hypertension and assess its pharmacological 
regulation by therapeutic compounds: ONO-RS-082 (Chapter 4.3); sildenafil 
(Chapter 4.4); riociguat (Chapter 4.4); and treprostinil (Chapter 4.5). Finally I 
will attempt to address the localised pain associated with treprostinil 
administration (Chapter 4.5). A more detailed description of the aims are given 
within each chapter. 
 












2. Materials and Methods  
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2.1 Molecular Biology 
pcDNA3.1 vector constructs (ThermoFisher Scientific, UK) cloned with the 
K2P channel gene of interest (hTASK-1, hTASK-3 and hTREK-1) were 
acquired as a gift from GlaxoSmithKline (UK). The pcDNA3.1 vector encoding 
hTREK-2 was obtained as a gift from Pfizer (UK). Full gene sequences of 
these channels are given in the appendix (6.1 – 6.4). The human prostaglandin 
receptors (DP2, EP2 and IP) were obtained from cDNA Resource Center 
(Pennsylvania, USA), catalogue numbers: PTGDR00000, PER0200000 and 
PTGIR00000, respectively. For confocal microscopy, a pAcGFP1-N1 vector 
(Clontech-Takara Bio Europe) encoding human wildtype or mutant human 
TASK-1 was used which tags a green fluorescent protein to the TASK-1 
channel. For in-cell and on-cell western assays TASK-1 channel was tagged 
with hemagglutinin (HA) on the M1P1 loop between Alanine 50 (A50) and 
Arginine 51 (A51). 
Mutated channels were created using a QuikChange kit (Stratagene, 
Amsterdam, The Netherlands). Short pairs (25-35 bases) complementary 
oligonucleotide primers, encoding the intended mutation, were synthesised 
(Eurofins MWG Operon, Ebersberg, Germany). The QuikChange kit is a site 
directed mutagenesis protocol which mutates the desired site using PCR by 
denaturing the plasmid template and annealing of primer containing the 
desired mutation. After annealing, dsDNA containing mutated site will be 
synthesised leaving both wildtype (WT) and mutated DNA. DPN-1 digestion 
then removes all WT DNA as WT DNA is produced in Escherichia coli (E.coli) 
it is DAM-methylated which can be digested by DPN-1 enzymes, in vitro 
production of DNA does not DAM-methylate DNA. Mutated DNA is then 
transformed into E.coli. The pcDNA 3.1 vector, contains an ampicillin 
resistance gene that can be cultured on ampicillin plates, allowing only 
bacteria containing the vector to grow. To extract the DNA from the E.coli, the 
bacteria are lysed and purified using appropriate kits for the needs of the 
experiments. Kits are based on the quantity of DNA required. For the work 
conducted in this thesis, minipreps or midipreps were used (Qiagen, The 
Netherlands). DNA concentrations of the preparations were determined using 
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a Nanodrop spectrophotometer (Implen, Germany). Mutant DNA constructs 
were sequenced (Eurofins MWG Operon) to confirm the introduction of the 
correct mutated bases. 
2.2 Cell Culture 
All cells were passaged within a HEPA filtered laminar flow hood (HeraSafe, 
Heraeus) using aseptic techniques. The hood was sterilised with 70% ethanol 
before and after use and all items introduced into the hood were sprayed with 
70% ethanol. A lab coat and gloves were worn at all times throughout the cell 
culturing process and gloved hands were sprayed on every entry into the hood. 
All culture products were purchased from Sigma-Aldrich (Dorset, UK) unless 
otherwise stated.  
 
2.2.1 Cell Line 
The cell line used for all work conducted was tsA201 cells. A modified human 
embryonic kidney (HEK) 293 cell line. The tsA201 cells are stably transfected 
with the SV40 large T antigen and were obtained from the European Collection 
of Cell Cultures through Sigma-Aldrich. HEK293 cells are our cell line of choice 
as they have been shown to express high levels of recombinant protein 
(Thomas and Smart, 2005). HEK 293 cells express an epithelial morphology 
with a pyramidal or rhombic shape (Figure 2.1). 
 
2.2.2 Cell Passage 
tsA201 cells were grown in monolayers in 25 cm2  or 75 cm2 vented tissue 
culture flasks and were maintained in 88% (v/v) Dulbecco’s modified Eagles 
media, 10% (v/v) heat-inactivated foetal bovine serum (HIFBS), 1% (v/v) non-
essential amino acid solution, 2 mM L-Glutamine and 1% (v/v) penicillin 
(10,000 U·ml-1) and streptomycin (10 mg·ml-1). Cells were incubated with a 
humidified atmosphere of 95% oxygen and 5% carbon dioxide and at a 
temperature of 37 ºC. Cells were sub-cultured and plated when flasks reached 
80% confluency. In order for the cells to be passaged the media was removed 
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and cells were dissociated from the bottom of the flask using trypsin-EDTA 
(10X, 0.5% trypsin, 0.2% EDTA). After 1 minute incubation at 37 ºC (2 minutes 
for 75 cm2 flask) cells were removed from the bottom of the flask by agitating 
the flasks with several taps. Cells were then suspended in 5 ml of culture 
media to quench the action of trypsin and pipetted up and down repeatedly to 
disperse cell clumps. The cells were then centrifuged at 800 rpm for 3 minutes 
and the supernatant was removed. Cells were then further resuspended in 5 
ml of culture media and 100 µL was taken for cell counting on a FastRead 102 
slide. The appropriate amount of cell suspension was then taken and made up 
to 5 ml with culture media (20 ml for 75 cm2 flasks) so that flasks were seeded 
at a density of 1.5 x 105 cells / ml. New flasks were then placed back into the 
incubator and sub-cultured when they reached 80% confluency. The 
remaining cell suspension was used for cryopreservation or to prepare plates 
for electrophysiological and imaging studies.  
 
2.2.3 Cell Plating 
For electrophysiological and imaging studies, cells were plated on 13 mm 
circular glass coverslips coated with poly-D-lysine hydrobromide (PDL) (0.5 
mg / ml). Cells were plated at a density of 7 x 104 cells / ml to be transiently 
transfected the following day. Each well of the multidish contained 0.5 mls of 
cell suspension.  
 
2.2.4 Transfection 
For electrophysiological experiments transient transfection of K2P channel 
DNA and green fluorescent protein (GFP) DNA into the tsA201 cells was 
conducted using a modified calcium-phosphate protocol, described by Chen 
and Okayama (Chen and Okayama, 1987; Batard, Jordan and Wurm, 2001). 
Plated cells were transfected as follows. Eppendorf A contained 500 ng 
channel DNA, 500 ng GFP DNA and 5.6 µL CaCl2 (2M) per well and was made 
up to 25 µL per well with ddH2O for a final concentration of 225 mM CaCl2 per 
well. Eppendorf B contained 25 µL of phosphate-free HEPES buffered saline, 
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(280 mM NaCl, 50 mM HEPES, pH to 6.95 using NaOH and 0.45 µL of 
phosphate buffer (100 mM Na2HPO4) per well was added.  
The contents of eppendorf B was then added to the contents of eppendorf A 
via the drop-wise method and left to incubate at room temperature for 20 
minutes allowing the formation of the CaPO4/DNA complex. 50 µL of this 
solution was then pipetted into each well and the plate was gently rocked to 
ensure even distribution of the solution. The plates were then incubated for 4 
– 6 hours after which the media was removed and washed twice with 
phosphate buffered saline (PBS), 1 ml per well and then 0.5 ml of fresh culture 
media was added to each well. The cells were then incubated over night at 37 
ºC in 5% CO2. The plates were utilised for electrophysiological or imaging 
studies the following day. For imaging experiments, transfection of DNA using 
TurboFect transfection reagent (ThermoFisher Scientific, UK) was conducted 
as per ThermoFisher Scientific protocol. The protocol involved mixing 0.5 µg 
of DNA (1 µg for pac gene vectors) with 100 µL per well followed by addition 
of 2 µL of TurboFect reagent and incubation for 15-20 minutes. 100 µL of 
mixture was then added to each plate well and incubated at 37 ºC in 5% CO2 
ready for electrophysiological or imaging studies after 24 – 48 hours.  
 
Figure 2.1 – Image of tsA201 cell transfected with GFP 
Image shows tsA201 cell following calcium phosphate transfection with green 
fluorescent protein (GFP). Cells emitting green colour have been successfully 
transfected. Scale bar is equal to 10 µM (Reproduced from Thomas and Smart, 2005). 
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2.2.5 Cryopreservation  
Over time tsA201 cells have been shown to lose efficiency in their ability to be 
transiently transfected. In order to combat this it is pivotal to keep a large stock 
of low passage number cells using cryogenic freezing. To begin, when the 
cells reached 80-90% confluency the culturing media was removed and cells 
were dissociated from the flask using 2 mL trypsin-EDTA and placed back into 
the incubator for 3-5 minutes. After this short incubation, the flasks were gently 
agitated to ensure all cells were dissociated from the flask. Cells were then 
suspended in 10 mL of culture media and pipetted up and down to ensure cells 
were isolated and not in clumps. Cells were centrifuged at 800 rpm for 3 
minutes. The supernatant was then removed, cells were resuspended in 5 mL 
of fresh culture media and centrifuged again at 800 rpm for 3 minutes. The 
supernatant was again removed using a Pasteur pipette and the cells were 
resuspended in cryogenic media (90% HIFBS and 10% dimethyl sulfoxide, 
DMSO) so the cells were at a concentration of 2-4 x 106 cells per mL. The cell 
suspension was then aliquoted into 1 mL volumes per cryogenic vial. Vials 
were then labelled with the cell line, passage number and the date; and then 
placed into a Mr Frosty box (Sigma-Aldrich, UK) containing isopropyl alcohol 
within a -80 ºC freezer. The following day cells were moved to a liquid nitrogen 
storage vessel until required. 
2.2.6 Resuscitation 
To avoid the toxic effects of DMSO the thawing process must be undertaken 
quickly. Using a 70% ethanol soaked tissue the cap of the cryovial was opened 
a quarter turn to release any trapped liquid nitrogen. The vials were then swiftly 
transferred to a water bath at 37 ºC until no ice crystals remained within the 
vial. The contents of the vial were then transferred by pipetting to a 15 mL 
falcon that contained 5 mL of pre-warmed culturing media. The cells were then 
centrifuged at 800 rpm for 3 minutes and the supernatant was removed. Cells 
were then resuspended in 5 mL of culturing media and transferred to a 25 cm2 
filter capped culturing flask. The flask was then placed in an incubator 
overnight at 37 ºC with 5% CO2 and assessed the following day to check 
whether the cells had adhered to the flask. The culturing media was then 
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poured away and 5 mL of fresh culturing media was added. Cells were then 
left to grow in the incubator until 70-80% confluent, at which point they were 
ready to be passaged as previously described.  
 
2.3 Electrophysiology 
Electrophysiological recordings of tsA201 cells and PASMCs were acquired 
using whole-cell patch-clamp method (Figure 2.2). Whole-cell patch clamping 
enables the measurement of ion movements across the membrane of the 
whole cell. The voltage-clamp configuration was adopted for these recordings. 
This involves holding the membrane potential at a constant level and then 
determining the flow of current required to maintain the voltage set. In reality 
the membrane current is not of interest, but it is membrane conductance that 
needs to be determined, as this represents the activity of the ion channel. 
However by creating a constant membrane potential it means that the current 
is linearly proportional to the voltage and therefore of interest to be studied 
(Guide, 2008).  
 
Figure 2.2 – Diagram of process to gain whole-cell configuration  
A) Shows the pipette tip touching the cell membrane. B) After suction the 
formation of a seal between pipette tip and cell membrane with the resistance 
in the giga-ohm (GΩ) region, called giga-seal. C) Once a giga-seal has been 
achieved, further suction using the pulse technique removes the section of 
membrane within the pipette tip allows access to the interior of the cell.   
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2.3.1. Electrophysiological Rig Set-up 
Electrophysiological studies were conducted using the rig set-up shown in 
figure 2.3. To isolate the set-up from external sources of vibration, which can 
affect recordings, the microscope, headstage and manipulator were placed on 
an air table (Technical Manufacturing Corporation). Recordings can be 
affected by interference from a wide range of electrical noise such as radio 
waves, therefore the set-up was encased in a Faraday cage. An additional 
reduction in electrical noise is taken with the grounding of the set-up to single 




Figure 2.3 – Electrophysiological rig set-up 
Layout of the electrophysiological rig set-up. A) Gravity feed perfusion system (ALA-
VM8, ALA Scientific Instruments). B) Inverted microscope (Olympus CKX41). C) 
Amplifier headstage. D) Micro-manipulator (PatchStar, Scientifica). E) PC screen 
used as an oscilloscope (Dell). F) Micro-manipulator controller (Scientifca). G) 
Perfusion channel controller (ALA Scientific Instruments). H) Axopatch 200B amplifier 
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(Molecular Devices). I) Digidata 1440A digitizer (Molecular Devices). J) Micro-
manipulator power source (Scientifica). K) Air table (Technical Manufacturing 
Corporation).  
 
Coverslips prepared with cells grown on them, as previously described, were 
placed into a double-chambered Perspex bath (Figure 2.4). Cells were viewed 
upon an inverted, fixed stage microscope (Olympus CKX41) that has both a 
standard light source and a fluorescence illuminator (X-Cite 120Q, Excelitas 
technologies). Depending on the type of study, external solution (or containing 
the compound to be tested) was either continuously perfused across the 
chamber using the gravity-feed perfusion system or incubated with external 
solution (or compound to be tested) for 20 minutes prior to study and then 
placed in a bath of the same solution used for incubation. Surplus solution 
would flow through a narrow channel in the second chamber where the excess 
solution was removed using a MHRE 200 H.R. flow inducer (Watson-Marlow 
Ltd). The use of the second chamber enabled the reduction of noise to the 
recording system by separating the location of the suction and recording 
pipette. As the two chambers were connected through the narrow channel, the 
bath solution was grounded using a silver chloride pellet. Recordings were 
taken using the borosilicate micropipette encasing a silver wire coated with 
silver chloride. Micropipettes were manufactured using borosilicate glass 
capillaries (Harvard Apparatus, UK) with an outer diameter of 1.5 mm and 
internal diameter of 1.17 mm. The glass capillaries were placed into a vertical 
puller (PC-10, Narishige) generating two micropipettes with an average 
resistance of 5 – 10 MΩ and 1 – 2 µm tip diameter. The micropipette was 
positioned using a PatchStar Micromanipulator (Scientifca, UK) which was 
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Figure 2.4 – Bath chamber arrangement 
Layout of bath chamber. A) First chamber of the bath to which the coverslip is placed 
and cells are viewed using an inverted microscope (B), solution is perfused into this 
first chamber (C). Excess solution passes through a channel into the second chamber 
(D) where excess solution is suctioned out of the bath (E). The bath chamber is 
grounded using a silver chloride pellet (F) placed into the second chamber of the bath. 
Recordings were taken using borosilicate glass micropipettes (G) encasing a silver 
wire coated with silver chloride. 
 
2.3.2 Signal acquisition 
The coating of silver chloride on the silver wire creates a reversible reaction: 
Ag + Cl- ⇌ AgCl + e- 
This reaction enables the flow of ions to be converted to a flow of electrons 
within the silver wire which can then be measured. The micropipettes were 
connected to a headstage amplifier (CV 203BU, Axon Instruments) which in 
turn was linked to an Axopatch 200B amplifier (Axon Instruments). The 
headstage amplifier contained feedback circuitry capable of correcting for 
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series resistance of the micropipette (Rs) as in a model experiment the series 
resistance of the micropipette would be zero. Rs is calculated by the total of all 
resistance occurred between the headstage amplifier and the inside of the cell. 
In essence this equates to: 
Rs = Raccess + Rpipette 
The micropipette (having correctly secured a ‘patch’) has its own potential (VP) 
and transmits a current (IP) to the inverting (current to voltage) input of the 
headstage amplifier (AH). Meanwhile the chosen voltage for the micropipette 
to be clamped at (VCMD) was also applied to AH, however to the non-inverting 
input. This leads to the difference of the inputs (VCMD – VP) generating the 
output of AH (V1) which is a relative measurement of the membrane current 
flow. From V1 a feedback resistor (RF) applies a feedback current (IF) to IP 
which essentially eliminates IP and results in VP equalling VCMD. This enables 
the ability to measure the current of the membrane whilst clamping the 










Figure 2.5 – Headstage series resistance correction 
Diagram to represent the circuitry involved within the headstage of an 
electrophysiological set-up. The differential amplifier (AH) calculates V1, which is 
relative calculation of the membrane current flow, derived from the difference between 
voltage measured at the micropipette (VP) and the desired voltage (VCMD). A positive 
feedback loop through a feedback resistor (RF) provides a current (IF) that 
consequently leads to VP = VCMD, allowing the micropipette to be clamped at the 
desired voltage.  
 
Once the recording reaches the whole cell configuration, the capacitance and 
the resistance of the cell membrane (Cm and Rm, respectively) can be 
calculated. Capacitance is defined as: �݉ =  �0 ∙ �݀  
Where, �0 represents the lipid property of the membrane, d the membrane 
thickness and A the surface area of the cell. As �0 and d remain relatively 
constant therefore Cm can be used as a measurement for the size of the cell. 
With a value of capacitance measured it is possible to normalise the current 
of cell to its size.  
Chapter 2.  Materials and Methods  60 
 
After the signal has been acquired by the headstage they are conveyed to the 
amplifier (Axopatch 200B, Axon Instruments) where it is filtered by the 
application of a 4-pole Bessel low-pass filter that was set at 5 KHz. This filtering 
enables all frequencies above 5 KHz (external noise) to be excluded from the 
final signal output. After being processed by the amplifier the signal is 
transmitted to the digitizer (Digidata 1440A, Axon Instruments) where the 
signal is converted from an analogue signal to a digital signal. From the 
digitizer the signal is passed onto an oscilloscope, in our case the computer. 
The computer using pCLAMP 10 software (Axon Instruments) to records and 
enables analysis of data.  
 
2.3.3 Solutions and compounds 
For electrophysiological experiments using tsA201 cells the external solution 
comprised of 145 mM NaCl, 2.5 mM KCl, 3 mM MgCl2, 1 mM CaCl2 and 10 
mM HEPES with the pH being adjusted to pH 7.4 with the use of 1 M NaOH. 
External solution was then stored at 4 ºC and made fresh 1 – 2 times a week 
as necessary. For experiment using different pH ranges the external solution 
was made using the same composition just adjusted to the desired pH for the 
experiment using NaOH. The internal solution used for tsA201 cells comprised 
of 150 mM KCl, 3 mM MgCl2, 5 mM EGTA and 10 mM HEPES. The pH of the 
internal solution was adjusted to pH 7.4 using 1 M KOH and filtered using 0.2 
µm cellulose acetate filter (Sartorius). Internal solution was aliquoted into 1.5 
ml Eppendorfs and stored at -20 ºC until required. pH 7.4 was selected as the 
pH to conduct experiments at because it represents physiological conditions. 
At this pH range TASK-1 is inhibited ~50% by protons whereas TASK-3 is 
~10% (Bayliss et al., 2015). All fine chemicals and compounds were 
purchased from Sigma-Aldrich unless otherwise stated.  
Drug stock solutions were made up into mM concentrations using DMSO, 
ethanol or distilled water as required, aliquoted and then stored at -20 ºC to be 
defrosted and used when required. Aliquots of the drug stock were diluted in 
external solution as required for the desired experiment and used the same 
day. Any compounds with light sensitivity were maintained in the dark. 
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Compounds used were: Doxapram hydrochloride, Zinc chloride, Gal-054 
(Galleon Pharmaceuticals Inc), ONO-RS-082 (Abcam), Treprostinil (gifted 
from Lucie Clapp at University College London), Riociguat (MedChem 
Express), Sildenafil citrate, IBMX, Forskolin (Abcam), and Pioglitazone 
(Abcam).   
 
2.3.4 The whole-cell patch-clamp technique 
To begin the cells are placed into the bath chamber immersed in external 
solution, when the micropipette, filled with internal solution, is submerged into 
the bath chamber the first stage of producing a recording occurs. A test pulse 
of –5 mV is applied and the current offset of the amplifier is adjusted to 0 
allowing for the calculation of the micropipette resistance. Using Ohm’s law 
the resistance for the micropipette is calculated, for example if the test pulse 
of –5 mV yields a response current of –750 pA then: ܴ� =  −ͷ ݉�0.͹ͷ0 ݊� = ͸.͸͹ ܯΩ 
 
Using the micromanipulator the micropipette is then manoeuvred into the field 
of view of the microscope. Selecting an appropriate cell to patch was the next 
stage of the process, cells chosen were preferably isolated and fluorescing 
green as the channel was co-transfected with GFP. To enable the viewing of 
GFP a fluorescence illuminator (X-Cite 120Q) was used which contained a 
mercury bulb and set at a wavelength of 395 nm. Once a cell has been 
selected the micropipette was lowered onto the cell membrane. The contact 
between the cell and micropipette can be identified by an increased in 
micropipette resistance shown on the PC screen. The application of negative 
pressure to the micropipette via a suction syringe generates a seal between 
micropipette and cell-membrane with a resistance in the GΩ region known as 
a giga-seal. From this position many different patch-clamp techniques can be 
implemented, for this study the whole-cell patch-clamp technique was 
adopted. To go from the giga-seal stage to whole-cell, the holding potential of 
the micropipette was adjusted to –60 mV and further negative pressure 
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‘pulses’ were applied. This further negative pressure breaks the membrane 
below the pipette tip creating low resistance entry to the entire interior of the 
cell. Access to the interior of the cell allows for current measurement of all 
open ion channels on the cell membrane (excluding the very small section 
broken as a result of going whole-cell). All electrophysiological experiments 
were conducted at room temperature (20 – 23 ºC).  
 
2.3.5 Data Analysis  
After the whole-cell patch clamp has been achieved, it is possible to make 
recordings using the PC and pCLAMP software. When recording, a protocol 
can be applied to evoke various characteristics of the ion channel that is being 
investigated and for this work the same protocol was used throughout (Figure 
2.6). The protocol was termed a ‘step-ramp’ protocol as it consisted of both a 
voltage-step phase as well as a ramp. The ramp ensured that current-voltage 
(I – V) relationships could be assessed for the ion channel. The protocol was 
applied once every 5 seconds and a minimum of 5 sweeps were recorded and 
averaged for any given cell current value. 
























Figure 2.6 – Step-Ramp Voltage protocol 
Step-ramp voltage protocol. A) Voltage step from –60 mV (holding potential) to –80 
mV for 100 ms. B) Voltage step from –80 mV to –40 mV for 500 ms. C) Voltage step 
from –40 mV to –120 mV for 100 ms. D) Voltage ramp from –
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500 ms. E) Step from +20 mV to –80 mV for 100 ms. F) Step to holding potential –60 
mV where it is held until protocol is applied again. Protocol was applied once every 5 
seconds.    
pClamp software combined with GraphPad Prism 7 (GraphPad Software Inc., 
CA) was then used to generate graphs. Graphs produced were time-course 
graphs (current vs time), average trace graphs, I – V graphs and current bar 
charts. Results were produced with an average current before and after drug 
application and percentage change, with error given as standard error of the 
mean (SEM). For electrophysiological data n = number of cells recorded. 
Currents for Chapter 3 were recorded as the difference in current between that 
recorded at -80 mV and that at -40 mV whereas for Chapter 4 currents were 
recorded at -40 mV only. Reasoning for this was due to previous data collected 
within the lab surrounding TASK-3 was analysed using this difference, and for 
chapter 4 TASK-1 currents are far smaller meaning the -80 mV current held a 
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2.4 Imaging  
To assess the location of channels within the cells confocal microscopy was 
used. This enabled the production of high resolution images to see whether 
different channels and their respective mutations used in electrophysiological 
studies varied in their cellular locations and quantities. Confocal microscopy is 
an advancement of fluorescence microscopy, which uses specific 
wavelengths of light to cause specific materials (in our case cellular 
components) to emit visible light. By labelling the specific components of the 
cell with selective fluorescent markers you are able to contrast the different 
components and analyse them visually. Confocal microscopy builds on this by 
the addition of a pinhole reduces background fluorescence producing a 
sharper, clearer image. This works as when focussing on a specific part of the 
slide, fluorescence from other areas of the slide not in the focal point still 
managed to be imaged by the objective lens but by applying a pinhole to the 
point of image made from the objective lens at that focal point it is able to block 
the majority of fluorescence generated outside of the focal point (Figure 2.7).  
 
Figure 2.7 – Schematic of confocal microscopy background noise reduction 
Diagram depicts how sources of light outside of the focal point may interfere with final 
image. The use of a pinhole screen used in confocal microscopy reduces this 
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2.4.1 Sample preparation and cell fixation 
Cells used for imaging studies were the same tsA-201 cells used in 
electrophysiological studies and prepared in the same way prior to 
transfection, on PDL-coated coverslips in 4 well dishes. DNA constructs used 
were the same sequences as used for electrophysiological studies however 
placed in a pAcGFP1-N1 vector (Clontech, USA). Cells were transfected with 
desired DNA using TurboFect transfection reagent (ThermoFisher Scientific, 
UK) described above. As the DNA constructs were expressed together with a 
pAcGFP, when expressed the cells fluoresced green. Prior to cell fixation if the 
cells were to have their membranes stained they would be treated with 
CellMask™ deep red plasma membrane stain (ThermoFisher Scientific) as 
per ThermoFisher Scientific protocol. Membrane staining involved incubating 
cells with CellMask™ deep red plasma membrane stain (1 mL of 1X solution 
per well) for 10 minutes at 37 ºC. For cell fixation cells were washed twice with 
room temperature PBS and then immersed in 1 mL of 2% paraformaldehyde 
(PFA) solution and placed in the fridge for 20 minutes. The cells were then 
further washed twice with PBS and if the nuclei were to be stained 500 µL of 
Hoechst solution (2 µL Hoechst 33258 [1 mg/mL in H2O, Sigma-Aldrich] into 1 
mL PBS) was added to each well and incubated at 37 ºC for 10 minutes. Cells 
were again washed twice with PBS and rinsed once with ddH2O to remove salt 
crystals. The coverslips were then placed facedown onto slides containing a 
drop of Vectashield anti-fade mounting medium (Vector Laboratories, UK) and 
sealed.  
 
2.4.2 Confocal microscopy  
Once the slides had been prepared they were imaged using a Zeiss LSM 880 
confocal microscope, placed upon an anti-vibration table, and analysed on a 
connected PC using Zen Black software (Zeiss). Cells were imaged using oil 
immersion under a Plan-Apochromat 63x/1.4 oil DIC M27 objective. The cells 
were excited with an argon laser at 561 nm, 488 nm and 405 nm for the 
CellMask™ deep red plasma membrane stain, pAcGFP-channel and Hoechst 
33528, respectively, to elucidate fluorescence emission.  
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2.4.3 Co-localisation images 
After images were generated and opened within Zen Black, the degree of co-
localisation between the channel of interest and the membrane could be 
determined. It is key to note that of the images generated a region of interest 
(ROI) is selected so that values are conducted across only the cell (or cells) 
you wish to measure and eliminate unwanted measurements. First, control 
images for pAcGFP only and dsRed only cells were taken and used to set the 
crosshairs of the scatter plot, this ensures all pixels within the co-localised 
quadrant are not selected arbitrarily. After the controls have been imaged, ROI 
selected and the crosshairs set, an image from sample containing both 
pAcGFP and dsRed can be analysed. Zen Black generates multiple 
coefficients based on the scatterplot generated and for this study Pearson’s 
Correlation Coefficient (PCC) was used. PCC values range from -1 to 1 and 
show the relationship between the structures, a value of 1 would indicate 
perfect correlation so for every pixel that contained dsRed it would also contain 
pAcGFP. For this study PCC values for each channel required a minimum of 
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2.5 In-cell and on-cell assays 
In cell and on cell assays were conducted in poly-D-lysine coated 96-well 
plates containing a cell density of 2 x 104 cells/well in a 100 µL of media. 
Cultures were incubated for 24 hours at 37 ºC in 5% CO2 prior to transfection. 
Cells were transfected using TurboFect protocol, each well contained 200 ng 
of DNA and 0.4 µL of Turbofect and were incubated for 24 hours at 37 ºC in 
5% CO2. DNA contained each channel tagged with hemagglutinin (HA) on the 
M1P1 loop between Alanine 50 (A50) and Arginine 51 (A51), this area is 
extracellular so can be detected if the channel has reached the membrane. 
Media was then removed and cells were fixed with 40 µL PFA (2%) and 
incubated at room temperature for 20 minutes. Fixing solution was then 
removed and cells were washed with 1X PBS, PBS was then removed and the 
plate was patted dry. For on-cell (membrane staining) assay cells were 
washed with 40 µL (0.1%) Tween-20 PBS (TBST) and shaken on a rotor for 5 
minutes and then TBST was removed, this step was repeated 5 times. For in-
cell (whole cell staining) assay membranes were permeablised using 40 µL 
(0.1%) Triton X-100 (1 mL Triton in 10 mL PBS; Sigma Aldrich, UK), plates 
were then shook on a rotor for 5 minutes and then Triton was removed, this 
step was repeated 5 times. Cells were then incubated at room temperature 
with 100 µL blocking buffer, 2% bovine serum (Sigma Aldrich, UK) in 1X TBST 
for 60 minutes whilst on rotor, this prevents non-specific binding of primary 
antibody. Blocking buffer was then removed and cells were covered with 40 
µL (2µg/µL) monoclonal anti-HA antibody (mouse; Sigma Aldrich, UK) in 2 mL 
blocking solution. Cells were incubated for 2 hours at room temperature with 
gentle rocking on the rotor. All cells (in-cell and on-cell) were then washed with 
0.1% TBST and rocked for 5 minutes, this was repeat 5 times. Washing agent 
was removed and each well was then loaded with a mixture of secondary 
antibody, goat anti-mouse IRDye 800 CW (green; LI-COR, NE, USA) and DNA 
dye, DRAQ5 (5 mM, Abcam, UK) diluted in blocking buffer 1:1000 and 
1:10,000, respectively. After 60 minutes incubation at room temperature and 
gentle rocking cells were washed for 5 minutes with 0.1% TBST and repeated 
5 times. Cells were then dried and imaged. To image the plates they were 
scanned in a LI-COR plate reader at 700 nm and 800 nm (169 m resolution, 7 
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sensitivity, 3.2mm offset and medium quality). Integrated intensity values were 
then recorded and analysed. 
 
2.6 Statistical Analysis 
Statistical analysis were performed using GraphPad Prism 7 (GraphPad 
Software Inc., CA, USA). All values are expressed as mean ± standard error 
of the mean (SEM). For electrophysiological recordings n = number of 
individual cells recorded from. Statistical tests to determine significance 
between three or more groups used was one-way ANOVA followed by 
Dunnett’s post-hoc test. Two-way ANOVA was used when there is more than 
one condition for two or more groups such as two different channels in control 
conditions and in presence of a drug. Student’s t-test were used to analyse 
data from two cell populations, if the cell populations involved the same cells 
just in different conditions a paired Student’s t-test was used however if the 
cell populations were not the same cells an unpaired Student’s t-test was 
performed. Statistical significance was defined at a probability level (p) of < 
0.05. Power calculations were performed using a calculation tool from The 
University of British Columbia which compared inference for means of two 
independent groups (https://www.stat.ubc.ca/~rollin/stats/ssize/n2.html). The 
calculator used the following formula: 
݊ = 2 ቆሺܼఈ +  ఉܼሻ�ܧܵ ቇ 
Where n = required sample, Zα = significance level based on normal 
distribution table, Zβ = power value required according to normal distribution 
table, σ = standard deviation of test sample and ES = difference in the mean 
between the two groups. 
 
 










3. Doxapram Inhibition of TASK-3 K2P Channels 
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3.1 Introduction 
Doxapram hydrochloride (C24H30N2O2, doxapram) is a central respiratory 
stimulant. Doxapram’s analeptic respiratory action is characterised by an 
increase in tidal volume and a slight increase in respiratory rate, when 
administered intravenously. Sold under the name Dopram®, Stimulex and 
Respiram (Bedford Laboratories), doxapram is used clinically in the treatment 
of post-operative respiratory depression, acute respiratory failure, chronic 
obstructive pulmonary disorder and apnoea in premature infants (Lunsford et 
al., 1964, Yost et al., 2008). Doxapram’s proposed mechanism of action is via 
the direct stimulation of peripheral chemoreceptors of type 1 cells within the 
carotid bodies and a subsequent release of catecholamines (Mitchell and 
Herbert, 1975; Nishino et al., 1982). These combined events result in the 
prevention or reversal of CNS depressant or narcotic-induced respiratory 
failure.  
 
3.1.1 Arterial Chemoreceptors 
Arterial chemoreceptors act as a feedback mechanism to inform 
cardiovascular and respiratory control centres in the brainstem of the chemical 
composition of arterial blood. They respond to low O2 (hypoxia), high CO2/H+ 
(acid hypercapnia) and low glucose (hypoglycemia), in order to maintain 
oxygen delivery to the brain and vital organs (Gonzalez et al., 1994, Peers and 
Buckler 1995). They are located in the vicinity of the carotid artery are the 
carotid bodies and the aortic bodies which make up the chemoreceptors 








Figure 3.1: Cellular organization of the rat carotid body 
Graphic representing the cluster of type I cells in close proximity with type II cells. 
Type I cells are innervated by afferent terminals. (Reproduced from Nurse, 2014). 
 
3.1.2 Carotid Bodies 
The carotid bodies are composed of type 1 (glomus) cells that are occasionally 
enveloped by glial-like type 2 (sustentacular) cells (Figure 3.1). Type 1 cells 
both chemically and electrically synapse with afferent nerve terminals of the 
carotid sinus nerve (McDonald, 1981; Eyzaguirre, 2007) and release a variety 
of neurotransmitters and neuromodulators. The carotid bodies are highly 
sensitive to changes in O2, CO2 and acidosis. They have also been found to 
be highly sensitive to mitochondrial poisons (Anichkov and Belen’kii, 1963; 
Mulligan and Lahiri 1981). In response to changes in arterial blood levels of 
chemicals, type 1 cells depolarize and release neurotransmitters such as ATP, 
dopamine, noradrenaline, acetylcholine etc (Nurse, 2005). These 
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neurotransmitters then excite afferent terminals of the carotid sinus nerve and 
afferent signals are relayed to the brainstem, which initiates respiratory and 
cardiovascular reflexes to restore blood homeostasis (Gonzalez et al., 1994). 
Neurotransmitter release by the type 1 cells is thought to occur as a 
consequence of an increase in cytosolic calcium (Ca2+) levels within the 
carotid body, in response to an electrical signal (Gonzalez et al., 1992, 
Montoro et al., 1996). The increase in Ca2+ is mediated by voltage-gated 
calcium channels (L- and P/Q type) that are highly expressed in type 1 cells 
(Rocher et al., 2005). Activation of voltage-gated calcium channels and the 
subsequent increase in intracellular Ca2+ occurs as a consequence of 
membrane depolarization caused by the inhibition of a membrane potassium 
(K) conductance (Peers and Green, 1991; Anderson-Beck et al., 1995; Peers 
and Kemp, 2001). Several K channels have been identified in carotid bodies, 
that can be modulated by chemoreceptive intracellular signaling pathways to 
invoke an electrical response that then results in voltage-gated calcium 
channel activation, extracellular Ca2+ influx and neurotransmitter release.  
 
3.1.3 Role of Potassium Channels 
Electrophysiological studies have identified a number of different potassium 
ion channels in type 1 cells, which includes delayed rectifier K+-channels, 
calcium-activated K-channels (maxi K channels, BKCa), HERG channels, and 
TWIK-related acid-sensitive K+-channels (López-Barneo et al., 1988; Peers, 
1990; Peers and O’Donnell, 1990; Buckler, 1997; Buckler et al., 2000). 
Determining which of these K channels identified in the carotid bodies are 
sensitive to chemical changes in the arterial blood has resulted in a number of 
studies been conducted, many of them concluding that inhibition of various K 
channels, did not then lead to carotid body excitation (Doyle and Donnelly, 
1994; Cheng and Donnelly, 1995; Gomez-Nino et al., 2009; Buckler, 1997; 
Pardel et al., 2000; Ortega-Saenz et al., 2006). In 2000, Buckler and 
colleagues showed that the resting K conductance of carotid bodies was 
predominantly mediated by a TASK-like current which, when inhibited, results 
in an influx of Ca2+ ions and subsequent membrane depolarisation (Buckler, 
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2007; Buckler et al., 2000 and Figure 3.2). Both TASK-1 and TASK-3 are 
expressed in the carotid body (Yamamoto et al., 2002; Kim et al., 2009).  
 
Figure 3.2 – Type 1 cell electrical excitation pathway 
TASK channels, mainly TASK-1/TASK-3 heteromeric channels are responsible for 
the resting potential of the cells. Once a stimuli such as hypoxia or acidosis occurs 
this leads to the inhibition of TASK channels which depolarises the membrane 
activating voltage-gated calcium (Cav) channels. The activation of Cav channel leads 
to the increase of cytosolic Ca2+ levels which stimulates the release of 
neurotransmitters including dopamine, acetylcholine and ATP. 
 
3.1.4 Role of TASK channels 
Carotid bodies have been shown by single channel recordings to contain a 
mixture of homomeric and heteromeric TASK-1 and TASK-3 channels, with 
heteromeric channels being the predominant form (Kim et al., 2009; Turner 
and Buckler, 2013).  
TASK-1 and TASK-3 channels express structural amino acid similarity of 
approximately 60% and were the first K2P channels shown to form 
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heterodimers with intermediate functional properties of homomeric TASK-1 
and TASK-3 (Chokshi et al., 2015; Czirjak and Enyedi, 2002).  
Stimulation of chemoreceptors by doxapram is thought to occur via inhibition 
of a TASK-like K channel (Cotton et al., 2006; Buckler, 2015). However, 
doxapram’s mechanism of action and the type of TASK channel that it inhibits 
is conflicting, depending upon which species is being studied. Early studies 
conducted using rat DNA showed doxapram selectivity favoured TASK-1, 
followed by TASK-1/TASK-3 heterodimeric channels and finally TASK-3 
channels with EC50’s of 410 nM, 9 µM and 37 µM respectively (Cotten et al., 
2006). This selective sensitivity was thought to reside at the carboxy 
intracellular terminal domains of the channels, where homology between 
TASK-1 and TASK-3 is the least (Cotton et al., 2006). It is not clear if this 
differential sensitivity extends into human channels. Furthermore, TASK-1 
expression has been shown to be different in human and pig hearts, when 
compared to rodents (Limberg et al., 2011; Schmidt et al., 2014). A 
concentration of 10 µM doxapram was selected for our experiments as blood 
plasma concentrations of doxapram have been identified at 4 µg/mL following 
intravenous administration and 3.78 µg/mL is equivalent to a 10 µM 
concentration (Robson and Prescott, 1978). 
It would be advantageous for a compound like doxapram to selectively inhibit 
TASK-3 channels and not TASK-1 as an undesirable side effect of inhibiting 
TASK-1, is thought to be the development of hypertension. Hypertension is an 
adverse side effect commonly seen in patients on doxapram therapy 
(Vliegenthart et al., 2017). Reduction in function or expression of TASK-1 has 
been heavily implicated within pulmonary arterial hypertension and is 
discussed in greater detail within Chapter 4 (Antigny et al., 2016). Additionally 
another way to combat this adverse effect would be to combine doxapram 
therapy with a selective TASK-1 activator, although compounds that 
selectively activate K2P channels are scarce. 
3.1.5 Putative Binding Site for Doxapram 
Recent molecular modelling studies of TASK-1 and TASK-3 using inhibitory 
compounds such as A1899, PKTHPP and doxapram have suggested a 
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common intracellular binding site at the pore region of these channels (Streit 
et al., 2011; Kiper et al., 2015; Chokshi et al., 2015). Specific amino acids in 
the pore Leucine (L) 122, Glycine (G) 236, L239 and Valine (V) 242, within rat 
TASK-3 channels (Figure 3.3) can considerably affect the efficacy of selective 
compounds (including doxapram), when mutated to aspartate (D), highlighting 
an important region of the K2P channels for the action of these compounds 
(Chokshi et al., 2015). Interestingly, one of the amino acid sites is G236 is the 




Figure 3.3 – Computer model of human TASK-3 channel with indicated putative 
binding site  
A) Homology model of TASK-3 channel based upon TRAAK crystal structure (PDB 
ID 3UM7, Brohawn et al., 2012) depicting location of the four amino acids that form 
the putative site, L122, G236, L239 and V242. Left panel shows side view of the 
channel and right panel shows view from beneath the channel. B) Amino acid 
sequence alignment of TASK-1 and TASK-3, dashes represent gaps and numbers 
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represent the position of the amino acid where the sequence begins. The amino acids 
that form the putative site are highlighted by a box. 
 
3.1.6 Doxapram 
Doxapram is a racemic mixture of positive (GAL-054) and negative (GAL-053) 
enantiomers (Figure 3.4) and a study conducted by Galleon Pharmaceuticals 
Inc. showed that GAL-054 was the eutomer of doxapram whereas GAL-053 
was the distomer (Golder et al., 2012). The same study showed that the use 
of GAL-054 in isolation produced a greater efficacy than an equivalent dose of 
doxapram, as well as exhibiting fewer adverse side effects.   
 
 
Figure 3.4 – Enantiomers of doxapram 
A) Doxapram (+) enantiomer, known as GAL-054 to Galleon Pharmaceuticals Inc., 
PA, USA. B) Doxapram (-) enantiomer, known as GAL-053 to Galleon 






Chapter 3.  Doxapram Inhibition of TASK-3 K2P Channels  77 
 
3.2 Objectives 
Using an electrophysiological approach the first objective was to record 
currents through human TASK-3 channels and determine the effect of 
doxapram on the whole-cell current under physiological conditions. 
The second objective was to determine whether the mutations identified in rat 
TASK-3 channels (L122D, G236D, L239D and V242D) that were shown to 
influence the effect of a selection of breathing stimulants (Chokshi et al., 2015), 
had the same effect on human TASK-3 channels, using a site-directed 
mutagenesis and an electrophysiological approach. 
As well as studying the effect of doxapram on these intracellular pore 
mutations, a well-known selective TASK-3 antagonist that acts extracellularly, 
zinc hydrochloride, was characterised. 
I also investigated the effect of the different enantiomers of doxapram as 
identified by Galleon Pharmaceuticals on WT TASK-3 and a mutant channel. 
Finally I investigated the role of the M1P1 loop of the TASK-3 channel, on 
doxapram regulation, using a chimera channel, with a substituted M1P1 loop 
from a TALK subfamily member, TASK-2. 
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3.3 Results 
3.3.1 Electrophysiological properties of human TASK-3 
Human TASK-3 (hTASK-3) wildtype (WT) DNA was transiently transfected in 
tsA201 cells and used for whole-cell patch-clamp recordings. The application 
of the step-ramp voltage protocol was used as previously described in the 
methods (Figure 2.6), to evoke hTASK-3 currents (Figure 3.5). hTASK-3_WT 
current was calculated as the difference between the current at -40 mV and -
80 mV.  
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Figure 3.5 – hTASK-3_WT electrophysiological profile.  
A) Representative trace for hTASK-3_WT channel in control conditions exposed to 
the step-ramp voltage protocol. B) Current-voltage representative graph for hTASK-
3_WT in control conditions. 
 
Expression of hTASK-3_WT produced an average current of 1178 ± 108 pA 
(n = 21) with an average reversal potential of -85 ± 1 mV (n = 21). The current-
voltage graph (Figure 3.5B) shows the rectification of the current, whether the 
channel has any voltage-dependency as well as providing an approximation 
for the reversal potential of the current. hTASK-3_WT channels exhibited an 
outwardly rectifying current (Figure 3.5B).  
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3.3.2 Doxapram inhibition of TASK-3 
Acute application of doxapram (10 µM) resulted in a significant inhibition (p < 
0.05; paired t-test) of hTASK-3_WT current (Figure 3.6A) of 55 ± 2 % (n = 8) 
with an average current of 610 ± 66 pA (n = 8) in the presence of the drug. 
The perfusion of doxapram, represented with a solid black line, resulted in a 
partially reversible effect. The reversal potential of hTASK-3_WT was not 
significantly altered (Figure 3.6B) following acute application of doxapram (10 
µM) with a value of -77 ± 3 mV (n = 8). Rectification of hTASK-3_WT remains 
unchanged (outward) in the presence of doxapram (10 µM).  
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Figure 3.6 – Effect of doxapram (10 µM) on hTASK-3_WT 
A) Time course graph showing the effect of doxapram (10 µM) on hTASK-3_WT 
current (pA) over time (s), doxapram perfusion represented by solid line, green 
starting point and red stopping point. B) Current-voltage graph shows the effect of 
doxapram (10 µM) on hTASK-3_WT current over different voltages. Current recorded 
in the presence of doxapram (10 µM) is shown in red.  
 
3.3.3  Doxapram effect on TASK-3 containing mutations (L122D, G236D, 
L239D, V242D). 
To test whether the putative doxapram binding site as suggested by Chokshi 
et al., (2015) in rat, is critical to the observed doxapram effect on human TASK-
3 channels, each amino acid was mutated individually by site-directed 
mutagenesis and assessed electrophysiologically.  
3.3.3.1 hTASK-3_L122D 
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Whole-cell patch-clamping of hTASK-3_L122D yielded an average current 
(Figure 3.7A) of 1044 ± 130 pA (n = 18) with an average reversal potential 
(Figure 3.7B) equal to -83 ± 2 mV (n = 18), neither of which values were 
significantly different compared to hTASK-3_WT (Figure 3.11; p > 0.05; One-
Way ANOVA with post-hoc Dunnett’s test). However, unlike with hTASK-
3_WT, acute application of doxapram (10 µM) did not significantly inhibit the 
current of hTASK-3_L122D (Figure 3.7C), with an average inhibition found to 
be 8 ± 2 % (n = 5; p > 0.05; paired t-test). Doxapram (10 µM) also did not affect 
the current of hTASK-3_L122D over the whole voltage range studied (Figure 
3.7D).  
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Figure 3.7 – hTASK-3_L122D electrophysiological profile and effect of 
Doxapram (10 µM)  
A) Representative trace for hTASK-3_L122D channel in control conditions exposed 
to the step-ramp voltage protocol. B) Current-voltage graph for hTASK-3_L122D in 
control conditions. C) Time course graph showing the effect of doxapram (10 µM) on 
hTASK-3_L122D on current (pA) over time (s), doxapram perfusion represented by 
solid black line, green starting point and red stopping point. D) Typical current-voltage 
Chapter 3.  Doxapram Inhibition of TASK-3 K2P Channels  81 
 
graph showing the effect of doxapram (10 µM) on hTASK-3_L122D current over 
different voltages. Current recorded in the presence of doxapram (10 µM) is shown 
in red. 
3.3.3.2 hTASK-3_G236D 
The Birk-Barel mutation, G236R, has previously been shown to produce an 
inward rectifying current which is significantly reduced compared to the WT 
channel (Veale et al., 2014a). However, the hTASK-3_G236D mutation 
produced an outward rectifying current at an average current of 1077 ± 141 
pA (n = 16) in physiological conditions and an average reversal potential 
measured at -78 ± 2 mV (n = 16, Figure 3.8). Acute application of doxapram 
(10 µM) resulted in a 26 ± 5 % (n = 8) inhibition of the mutant channel, which 
was significantly reduced when compared to hTASK-3_WT (p < 0.05; paired 
t-test; Figure 3.8C). The average reversal potential was not affected by the 
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Figure 3.8 – hTASK-3_G236D electrophysiological profile and effect of 
Doxapram (10 µM). 
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A) Representative trace for hTASK-3_G236D channel in control conditions exposed 
to the step-ramp voltage protocol. B) Current-voltage graph for hTASK-3_G236D in 
control conditions. C) Time course graph showing the effect of doxapram (10 µM) on 
hTASK-3_G236D on current (pA) over time (s), doxapram perfusion represented by 
solid line, green starting point and red stopping point.  
 
3.3.3.3 hTASK-3_L239D 
The next mutation of hTASK-3 to be analysed was hTASK-3_L239D (Figure 
3.9) which had an average current of 904 ± 105 pA (n = 13) and an average 
reversal potential of -82 ± 2 mV (n = 13) in control conditions (Figure 3.9A and 
B). The mutation of L239D in hTASK-3 resulted in the effect of doxapram being 
significantly reduced (Figure 3.12; p < 0.05 One-Way ANOVA with post-hoc 
Dunnett’s test) with acute application of doxapram (10 µM) resulted in a 
significant, irreversible inhibition of 13 ± 3 % (n = 8; p < 0.05; paired t-test; 
Figure 3.9C) and an average reversal potential of -79 ± 6 mV (n = 8). 
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Figure 3.9 - hTASK-3_L239D electrophysiological profile and effect of 
Doxapram (10 µM). 
A) Representative trace for hTASK-3_L239D channel in control conditions exposed 
to the step-ramp voltage protocol. B) Current-voltage graph for hTASK-3_L239D in 
control conditions. C) Time course graph showing the effect of doxapram (10 µM) on 
hTASK-3_L239D on current (pA) over time (s), doxapram perfusion represented by 
solid line, green starting point and red stopping point. 
 
3.3.3.4 hTASK-3_V242D 
The final mutation to be investigated was hTASK-3_V242D (Figure 3.10), 
which had an average current of 1133 ± 152 pA (n = 14) and an average 
reversal potential of -80 ± 2 mV (n = 14; Figure 3.10A and B). Acute application 
of doxapram (10 µM) resulted in a significant inhibition of current of 27 ± 5 % 
(n = 5; Figure 3.10C; p < 0.05; paired t-test), significantly lower than the effect 
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of doxapram (10 µM) on hTASK-3_WT (p < 0.05; Figure 3.12; One-Way 
ANOVA with post-hoc Dunnett’s test).  
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Figure 3.10 - hTASK-3_V242D electrophysiological profile and effect of 
Doxapram (10 µM).  
A) Representative trace for hTASK-3_V242D channel in control conditions exposed 
to the step-ramp voltage protocol. B) Current-voltage graph for hTASK-3_V242D in 
control conditions. C) Time course graph showing the effect of doxapram (10 µM) on 
hTASK-3_V242D on current (pA) over time (s), doxapram perfusion represented by 
solid line, green starting point and red stopping point. D) Current-voltage graph shows 
the effect of doxapram (10 µM) on hTASK-3_V242D current over different voltages. 
Current recorded in the presence of doxapram (10 µM) is shown in red. 
 
The average current recorded through mutant channels was not significantly 
different to that of hTASK-3_WT (p > 0.05; One-way ANOVA with post-hoc 
Dunnett’s test; Figure 3.11). 
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Figure 3.11 – Average absolute current (pA) of hTASK-3_WT and respective 
mutations. 
 
When it came to the comparison of doxapram (10 µM) inhibition on hTASK-
3_WT and the putative binding site mutations, all mutations resulted in a 
significant reduction in doxapram inhibition (Figure 3.12; p < 0.05; One-Way 
ANOVA with post-hoc Dunnett’s test). Acute application of doxapram (10 µM) 
to hTASK-3_WT produced a 55 ± 2 % (n = 8) inhibition of current (Figure 3.12). 
The most significant reduction in doxapram inhibition was seen in the hTASK-
3_L122D mutation which was recorded at 8 ± 2 %(n = 5). The inhibition of 
hTASK-3_L239D, hTASK-3_G236D and hTASK-3_V242D current by 
doxapram (10 µM) were also significantly reduced (13 ± 3 %, n = 8; 26 ± 5 %, 
n = 8; 27 ± 5, n = 5; respectively) compared to hTASK-3_WT (p < 0.05; One-
Way ANOVA with post-hoc Dunnett’s test). 
 


















































Figure 3.12 – Percentage inhibition by doxapram (10 µM) on hTASK-3_WT 
channel and respective mutations (*p < 0.05). 
 
The results generated by the acute application of doxapram (10 µM) on the 
putative binding site suggests that the intracellular pore region of the channel 
may play a role in the binding of doxapram to hTASK-3 channels as well as 
rat channels (Chokshi et al., 2015). The data suggests that hTASK-3_L122D 
and hTASK-3_L239D have the largest effect on doxapram inhibition. Whether 
these mutations directly prevent the binding of doxapram or have a secondary 
mechanism such as altering the gating of the channel is not yet confirmed.  
To address this issue, I used another known TASK-3 inhibitor, zinc, which 
works extracellularly and at different amino acids, to determine whether the 
change seen in the inhibition by doxapram was a consequence of the above 
mutations, rather than a change in the gating of the channel, which could affect 
all inhibitors.   
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3.3.4  Effect of zinc on WT TASK-3 and TASK-3 mutants 
Zinc (100 µM) acutely applied to hTASK-3_WT (Figure 3.13) produced a 
reversible effect (Figure 3.13C), with a maximal inhibition of 71 ± 6 % (n = 7). 
The average hTASK-3_WT current in the presence of zinc (100 µM) was 273 
± 57 pA (n = 7).  
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Figure 3.13 – Effect of zinc (100 µM) on hTASK-3_WT. 
A) Representative trace for hTASK-3_WT channel in both control conditions and zinc 
(100 µM) when exposed to the step-ramp voltage protocol. B) Current-voltage graph 
shows the effect of zinc (100 µM) on hTASK-3_WT current over different voltages. 
Current recorded in the presence of zinc (100 µM) is shown in red. C) Time course 
graph showing the effect of zinc (100 µM) on hTASK-3_WT on current (pA) over time 
(s), zinc perfusion represented by solid black line, green starting point and red 
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When zinc (100 µM) was acutely applied to hTASK-3_L122D it resulted in an 
inhibition of 55 ± 5 % (n = 8) with an average current of 414 ± 53 pA (n = 8; 
Figure 3.14). hTASK-3_L122D inhibition by zinc (100 µM) was reversible upon 
wash off.  
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Figure 3.14 – Zinc inhibition of hTASK-3_L122D. 
A) Representative trace for hTASK-3_L122D channel in both control conditions and 
zinc (100 µM) when exposed to the step-ramp voltage protocol. B) Current-voltage 
graph shows the effect of zinc (100 µM) on hTASK-3_L122D current over different 
voltages. Current recorded in the presence of zinc (100 µM) is shown in red. C) Time 
course graph showing the effect of zinc (100 µM) on hTASK-3_L122D on current (pA) 
over time (s), zinc perfusion represented by solid line, green starting point and red 
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When zinc (100 µM) was applied to the remaining mutations (G236D, L239D 
and V242D) it produced current inhibition of 62 ± 4 % (n = 8), 70 ± 3 % (n = 5) 
and 56 ± 7 (n = 9), respectively (Figure 3.15). No mutation provided a 
significant change in the inhibition of zinc (100 µM) compared to hTASK-3_WT 











































Figure 3.15 - Percentage inhibition by zinc (100 µM) on hTASK-3_WT channel 
and respective mutations. 
 
Therefore as the mutations are not specific to all TASK-3 regulators, these 
mutations demonstrate specificity towards those compounds that act either in 
the pore region or intracellularly.  
 
3.3.5  Investigation of Doxapram Enantiomer Gal-054 on hTASK-3_WT 
and hTASK-3_L122D mutant channel 
Our results have shown that the amino acids identified by molecular docking 
and tested on rat TASK-3 channels, significantly reduces the effect of 
doxapram (10 µM) on the human mutant channel equivalents. As doxapram 
exists as a racemic mix of enantiomers, which have differing effects on WT 
channels (see Appendix 6.5 and 6.6), I felt it prudent to assess if this changes 
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the effect of what appears to be the active enantiomer (Gal-054) of doxapram. 
Gal-054 (10 µM) acutely applied to hTASK-3_WT, produced an average 
inhibition of 67 ± 4 % (n = 6) with an average current of 392 ± 116 pA (n = 6; 
Figure 3.16). The average reversal potential for hTASK-3_WT in the presence 
of Gal-054 (10 µM) was -78 ± 8 mV (n = 6). Inhibition of hTASK-3_WT current 
by GAL-054 (10 µM) was significantly more potent than inhibition by doxapram 
(10 µM; p < 0.05; unpaired t-test).  
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Figure 3.16 – Effect of Gal-054 on hTASK-3_WT 
A) Representative trace for hTASK-3_WT channel in both control conditions and Gal-
054 (10 µM) when exposed to the step-ramp voltage protocol. B) Current-voltage 
graph shows the effect of Gal-054 (10 µM) on hTASK-3_WT current over different 
voltages. Current recorded in the presence of Gal-054 (10 µM) is shown in red. C) 
Time course graph showing the effect of Gal-054 (10 µM) on hTASK-3_WT on current 
(pA) over time (s), Gal-054 perfusion represented by solid line, green starting point 
and red stopping point.  
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I went on to investigate the action of Gal-054 (10 µM) on the mutation, 
L122D, which attenuated the effect of doxapram the most. Acute application 
of Gal-054 (10 µM) on hTASK-3_L122D (Figure 3.17) resulted in a similar 
attenuated effect, as was observed with doxapram. Inhibition by GAL-054 
was 8 ± 4 % (n = 5), with an average reversal potential of -84 ± 1 mV (n = 5).  
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Figure 3.17 - Effect of Gal-054 on hTASK-3_L122D 
A) Representative trace for hTASK-3_L122D channel in both control conditions and 
Gal-054 (10 µM) when exposed to the step-ramp voltage protocol. B) Time course 
graph showing the effect of Gal-054 (10 µM) on hTASK-3_L122D on current (pA) over 
time (s), Gal-054 perfusion represented by solid line, green starting point and red 
stopping point. 
 
3.3.6  Investigating the role of the TASK-3 M1P1 loop on doxapram (10 
µM) inhibition 
The M1P1 loop has been shown to be a regulator of TASK channels as well 
as an essential component for the dimerization of the channels (Clarke et al., 
2008; Lesage et al., 1996; Döring et al., 2006). To investigate whether the 
M1P1 loop plays a role in the binding of doxapram to hTASK-3 channels we 
replaced the M1P1 loop of TASK-3 with that of hTASK-2_WT to form a 
chimeric channel, hTASK-3M1P1T2. Despite its name, TASK-2 belongs to the 
TALK family of K2P channels and its pharmacological regulation and 
expression differs to that of TASK-1 and TASK-3. The effect of doxapram (10 
µM) on hTASK-2_WT was conducted first (Figure 3.18). hTASK-2_WT had an 
average current of 969 ± 258 pA (n = 6) and an average reversal potential of 
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-82 ± 1 mV (n = 6; Figure 3.18A and B) in control conditions. After acutely 
applying doxapram (10 µM) to hTASK-2_WT the average current was reduced 
by 7 ± 5 % (n = 6) with an average reversal potential of -85 ± 2 (n = 6; Figure 
3.18C and D). 
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Figure 3.18 – Electrophysiological profile and effect of doxapram (10 µM) on 
hTASK-2_WT.  
A) Representative trace for hTASK-2_WT channel in control conditions exposed to 
the step-ramp voltage protocol. B) Current-voltage graph for hTASK-2_WT in control 
conditions. C) Time course graph showing the effect of doxapram (10 µM) on hTASK-
2_WT on current (pA) over time (s), doxapram perfusion represented by solid line, 
green starting point and red stopping point. D) Current-voltage graph shows the effect 
of doxapram (10 µM) on hTASK-2_WT current over different voltages. Current 
recorded in the presence of doxapram (10 µM) is shown in red. 
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As doxapram (10 µM) did not significantly inhibit the current of hTASK-2_WT 
I analysed the effect of doxapram upon hTASK-3M1P1T2. The 
electrophysiological profile of hTASK-3M1P1T2 showed an average current of 
790 ± 223 pA (n = 8) and an average reversal potential of -88 ± 4 mV (n = 8; 
Figure 3.19A and B) in control conditions. The acute application of doxapram 
(10 µM) did not significantly alter the current of hTASK-3M1P1T2 (Figure 3.19C 
and D) with an average inhibition of 8 ± 4 % (n = 8) and an average reversal 
potential of -87 ± 5 mV (n = 8).  
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Figure 3.19 - Electrophysiological profile and effect of doxapram (10 µM) on 
hTASK-3M1P1T2.  
A) Representative trace for hTASK-3M1P1T2 channel in control conditions exposed to 
the step-ramp voltage protocol. B) Current-voltage graph for hTASK-3M1P1T2 in control 
conditions. C) Time course graph showing the effect of doxapram (10 µM) on hTASK-
3M1P1T2 on current (pA) over time (s), doxapram perfusion represented by solid line, 
green starting point and red stopping point. D) Current-voltage graph shows the effect 
of doxapram (10 µM) on hTASK-3M1P1T2 current over different voltages. Current 
recorded in the presence of doxapram (10 µM) is shown in red. 
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Doxapram (10 µM) inhibition was significantly reduced in both hTASK-2_WT 
and hTASK-3M1P1T2 compared to hTASK-3_WT (Figure 3.20; p < 0.05; One-
Way ANOVA with post-hoc Dunnett’s test). Both hTASK-2_WT and hTASK-
3M1P1T2 showed similar inhibition values strongly suggesting that the M1P1 



















































Figure 3.20 – Percentage inhibition by doxapram (10 µM) on selected K2P 
channels.  
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3.4  Discussion 
In this study I have confirmed that the breathing stimulant doxapram, is a 
potent antagonist of the human TASK-3 channel when expressed in a 
heterologous expression system (55 ± 2 %, n = 8). Previous data from the lab, 
showed that doxapram was also a potent antagonist of human TASK-1 and 
TASK-3/TASK-1 heterodimeric channels, in identical experimental conditions 
(55 ± 4 %, n = 8 and 49 ± 4 %, n = 6; Appendix 6.5 and 6.7; Cunningham et 
al., 2016). However, for mouse homologues it was found that doxapram was 
a more potent inhibitor of TASK-1 than TASK-3 (63 ± 5 %, n = 4 versus 22 ± 
5 %, n = 4; Appendix 6.8; Cunningham et al., 2016). The difference seen 
between the human and rodent channels, may explain the previous conflicting 
evidence from other studies (Cotton et al., 2006; Cotton et al., 2013). The 
equal potency of doxapram on human TASK channels, as has been identified 
here, is important when considering the compound therapeutically and the 
decline in its use due to the drugs side-effect profile and the availability of safer 
and shorter-acting agents. Inhibition or dysfunction of TASK-1 has been linked 
to the pathogenesis of multiple cardiovascular and pulmonary diseases such 
as pulmonary arterial hypertension, atrial fibrillation and dyspnoea (Golder et 
al., 2013; Olschewski et al., 2017).  
 
3.4.1 Putative binding site for doxapram in the pore region 
Previous work by Streit et al., 2011 on TASK-1 showed that specific amino 
acids lining the intracellular pore vestibule of TASK-1 were involved in the 
inhibition by the breathing stimulant, A1899. Based upon molecular docking 
and homology modelling of TASK-3 by the group, Chokshi et al., 2015 showed 
that specific amino acids (Leu-122, Gly-236, Leu-239) in the region highlighted 
by Streit et al., 2011 on TASK-1, which are highly conserved in TASK-3, were 
also important for the effect of the same and other breathing stimulants. Their 
data suggested that the amino acids Leu-122, Leu-239 on both subunits of 
TASK-3, creates a hydrophobic narrowing of the pore, which affects the 
potency of three breathing stimulants (PKTHPP, A1899 and doxapram) with 
the effect on potency being the least for doxapram. Doxapram has been shown 
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in previous modelling studies to have a high molecular docking score, 
therefore affinity, towards a hydrophobic cleft in TM2 indicating further that 
within TASK channels doxapram will favour binding to the hydrophobic pore 
(Warner et al., 2012). 
By changing these amino acids to aspartate they suggested that this creates 
a hydrophilic (lipid-repelling) barrier in the pore which prevents the access of 
the breathing stimulants to hydrophobic residues deep in the pore. This is in 
part due to either an increase of water and potassium ion occupancy of the 
pore or this region acting as a fulcrum point for channel gating. Although they 
state that neither of these suggestions are mutually exclusive.  
Previous work conducted on TASK-3_L122D has shown the mutation to play 
a vital role in TASK-3 gating (Luethy et al., 2017). It has been proposed that 
binding of an anaesthetic to a specific pocket on either of the subunits of the 
TASK-3 channel produces a conformational change of the pore allowing the 
flow of ions and hence activation of the channel (Conway and Cotten, 2012). 
The previous work on L122D deduced that the mutation of a leucine to an 
aspartic acid at position 122 produces a fixed open conformation diminishing 
the effect of anaesthetics in producing a conformation change (Leuthy et al., 
2017). 
Of the three breathing stimulant compounds tested by Choski et al., 2015 the 
mutations affected the potency of doxapram the least. This they put down to 
doxapram being the smallest and least hydrophobic of the three compounds 
and because of its reduced potency on TASK-3 (Cotton et al., 2006). As this 
work by Choski et al., 2015 was performed on rat TASK-3 and as I have shown 
that for human channels, the effect of doxapram is different to that seen with 
rodent channels (i.e. more potent on human TASK-3), I wanted to determine 
whether these mutations affected the efficacy of doxapram to a higher extent 
than was observed with rat channel derivatives. 
I looked at Leu-122, Gly-236, Leu-239 and Val-242 all of which were 
conserved between the two species. I found that all of the mutations 
significantly attenuated the effect of doxapram on the mutant channels when 
present on both subunits, with Leu-122 and Leu-239 having the biggest effect 
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on doxapram potency. I also looked at these mutations with a well 
characterised antagonist of TASK-3, zinc, which is proposed to exert its action 
at an extracellular site (Clarke et al., 2004, Gonzalez et al., 2013). None of 
these mutations were found to significantly alter the potency of zinc on TASK-
3. 
I have shown that L122D diminishes the effect of doxapram inhibition, but not 
that of zinc and agrees with the consensus that doxapram acts within the 











Figure 3.21 – Illustration of L122D mutation effect on TASK-3 channel gating. 
A) TASK-3 activation by the binding of an anaesthetic to the binding pocket. B) 
Mutation of L122D causes conformational change within the intracellular pore leading 
to fixed open conformation of TASK-3. Use of anaesthetic on TASK-3_L122D fails 
enhance the current further. Proposed action of doxapram on TASK-3_L122D either 
the mutation prevents doxapram from binding to the intracellular pore or doxapram is 
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3.4.2  Isolation of doxapram enantiomers 
As previously mentioned doxapram is a racemic mixture of positive (GAL-054) 
and negative (GAL-053) enantiomers. It has been shown that the eutomer, 
GAL-054, has an improved therapeutic index compared to GAL-053 or 
doxapram, with GAL-053 showing little to no improvement in regards to 
respiratory stimulation, but retaining adverse effects such as dysrhythmias, 
seizures and death (Golder et al., 2012). Therefore the use of GAL-054 holds 
potential to be a better therapy than the racemic mixture, doxapram, as a lower 
dose may be used with a reduction in adverse effects. 
In my data I show that GAL-054 (10 µM) is a more potent antagonist on TASK-
3_WT than doxapram is. Unpublished work undertaken in the lab has revealed 
that there is a significant difference in the effect of the two enantiomers, GAL-
053 and GAL-054, on both wild-type TASK-1 and TASK-3 (Appendix 6.5 and 
6.6). GAL-054 is significantly more potent than GAL-053 with the IC50 of GAL-
053 being over 100-fold higher than the IC50 of GAL-054 for both TASK-1 and 
TASK-3. On human channels the potency of GAL-054 was the same for both 
TASK-1 and TASK-3 (75 ± 2 %, n = 6; 79 ± 2 %, n = 8; at 10 µM, respectively). 
These findings in combination with previous studies that show that adverse 
side effects are retained with GAL-053, but not GAL-054. This may suggest 
that clinical side-effects associated with the use of doxapram, which was 
attributed to the effects of the compound inhibiting TASK-1, may not actually 
be the case. Further studies will be needed with GAL-054 to fully assess its 
therapeutic profile as currently only a small number of rodent studies have 
been conducted. However, the use of the positive enantiomer in humans could 
be beneficial therapeutically. 
 
3.4.3 The Role of Heterodimers 
Both TASK-1 and TASK-3 have been shown to be highly expressed in the 
carotid bodies and the majority of these subunits are thought to form functional 
heterodimers of TASK-1 and TASK-3 (Kim et al., 2009; Turner and Buckler, 
2013). Previous studies and my own work has focused on homodimers of 
either TASK-1 or TASK-3. Unpublished work from the lab, using forced 
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concatamers of human TASK-1 and TASK-3, has shown that doxapram and 
GAL-054 are equally as potent on heterodimers, as homodimers. This is an 
important consideration when assessing the importance of particular amino 
acids, as this may alter the result when considering the combination of two α-
subunits from different channel subtypes. Indeed forced homodimers of TASK-
3, with only one subunit containing one of the outlined mutations, resulted in 
an intermediate effect between that observed for WT and a channel with both 
subunits mutated (see Choskhi et al., 2015, Figure 5). Alignment of TASK-1 
and TASK-3 channels, shows that sequences are nearly identical in the inner 
pore helix (Chokshi et al., 2015, Figure 6), and as such a mutated heterodimer 
of these subunits would be expected to behave similarly to mutated 
homodimers in terms of hydrophobicity. Interestingly though, despite TASK-1 
and TASK-3 have near identical homology for at least 60% of the protein, in 
rats, compounds such as doxapram are much more potent on TASK-1 
channels, than TASK-3. Increased potency can be conferred to TASK-3 when 
the C-terminal is exchanged with that of TASK-1 (Cotten et al., 2006). The C-
terminus has little homology between the two channels and there is differing 
regulation between the two channel subtypes. Phosphorylation sites in the C 
termini of the two channels, for example, are different and thus the 
phosphorylation state of the channel may be an important consideration when 
considering pharmacological sensitivity and may again help explain 
differences seen between species. 
 
3.4.4 M1P1 loop involvement in doxapram inhibition of TASK channels  
K2P channels have an unusual feature in that they have a large pre-pore linker 
known as the M1P1 loop. The M1P1 loop has been identified to play a role in 
channel regulation and the formation of dimers (Clarke et al., 2008; Döring et 
al., 2006; Lesage et al., 1996). The TASK-3 M1P1 loop linkers forms an 
extracellular cap, which plays a role in the regulation of ion entry to the pore. 
Whilst the cap obstructs the extracellular pathway to the selectivity filter it 
provides an extracellular ion pathway which are bilateral ‘tunnels’ leading to 
the selectivity filter (Figure 3.22; González et al., 2013). These bilateral tunnels 
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have been shown to play a major role in TASK-3 gating, with the concentration 
of K ions within these tunnels being a key factor in pH sensitivity. As it only 
requires the protonation of one H-98 sensor to close the gating of the pore, it 
has been proposed that neutralisation of one H-98 sensor leads to an 
increased K+ occupancy in the outermost region of the selectivity filter which 
in turn increases the probability of the second H-98 sensor becoming 




Figure 3.22 – Model of extracellular ion pathway in TASK-3 
TASK-3 model showing extracellular pathway (blue tunnel) leading to selectivity filter. 
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I showed that the substitution of the TASK-3 channel M1P1 loop with that of 
TASK-2 resulted in the loss of effect of doxapram. TASK-2 is a member of the 
TALK subfamily, with the only similar characteristic towards the TASK 
subfamily is that it is acid-sensitive (hence why originally named in the TASK 
family) however the data shown here suggests the M1P1 loop plays a critical 
role in TASK channel inhibition by doxapram. The M1P1 loops of TASK-3 and 
TASK-2 differ considerably and this may alter the structure of the channel. It 
was a surprising result alone that channel activity occurred with the 
substitution in M1P1 loop due to the differences in M1P1. I postulate that 
changing the M1P1 loop affects the ability for doxapram to reach its 
intracellular binding site by forming a cap not conducive to doxapram entry.  
 
3.4.5 Conclusion and further study 
Here I have shown that doxapram and GAL-054 do not selectively favour 
TASK-1 or TASK-3 in humans suggesting TASK-1 may not be responsible for 
the adverse effects seen with doxapram thereapy. I also show GAL-054 to be 
a more potent inhibitor of TASK-3 than doxapram. In previous studies upon 
rodents it has been indicated that GAL-054 does not retain the adverse effects 
seen within doxapram therapy of humans (Golder et al., 2012). Few studies 
have been conducted using GAL-054, none of which are in humans, so it is 
not possible to say if it is free from adverse side effects in people (Golder et 
al,. 2013). It may be that in targeting and inhibiting carotid body residing TASK 
channels, to treat ventilatory depression, this pathway generates the adverse 
effects seen and alternative therapy may be best to avoid these effects. 
Building upon this it would be important for further work looking into the 
enantiomers, particularly GAL-054. Further characterising its effects both with 
electrophysiological studies and within animal models. It should be noted that 
given the data shown here of a mouse species difference, it appears mice 
models would not be a suitable model of choice. This is seen with TASK-1 and 
pulmonary arterial hypertension, where the mouse model differs from rat and 
rabbit models (Manoury et al., 2013). 
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The work in this study shows more evidence contributing to a binding site for 
doxapram on TASK-3 and TASK-1. Mutation of one of the sites, L122D, also 
further contributes to current studies suggesting it stabilises and fixes the pore 
in an open conformation attenuating the effects of anaesthetics and doxapram. 
Zinc inhibition was not affected by changes to this site, agreeing with current 
data for its inhibitory role being attributed to the selectivity filter. This study 
shows that the M1P1 loop is also vital to doxapram inhibition and further 
studies are required to pinpoint the exact mechanism of the loops role in 
doxapram’s effect. To clarify doxapram’s binding site, ideally, a 
crystallographic analysis of TASK-3 with doxapram bound, similarly to that with 
TREK-2 and Prozac, would clarify many of the issues including channel gating, 
doxapram binding and TASK involvement within the carotid bodies (Dong et 
al., 2015). Hypothetically for the therapy to be most effective, it would be of 
importance to selectively target the heterodimer as those are the channels 
most abundant within the carotid bodies and if possible avoid inhibition of wild-
type TASK-1 and TASK-3 (Kim et al., 2009). It could be useful to assess the 
intermediate properties of the TASK-1/TASK-3 heterodimer such as 
hydrophobicity of the channel and try to develop a compound to favour these 
opposed to that of the homodimers, for this computer modelling may be the 


















4. Action of Pulmonary Arterial Hypertension 
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4.1 Introduction 
Pulmonary hypertension encompasses a group of pulmonary vasculature 
diseases all with the common symptom of restricted blood flow. The World 
Health Organisation (WHO) divides pulmonary hypertension into five groups 
based on their pathological findings and similar characteristics. The five 
groups consist of pulmonary arterial hypertension (Group 1), pulmonary 
hypertension by left heart disease (Group 2), pulmonary hypertension due to 
chronic lung disease (Group 3), chronic thromboembolic pulmonary 
hypertension (Group 4) and pulmonary hypertension due to unclear 
mechanisms (Group 5; Simonneau et al., 2013).  
Pulmonary arterial hypertension (PAH, Group 1 pulmonary hypertension) has 
been defined as a progressive increase of pulmonary vascular resistance 
which leads to right ventricular failure and consequently premature death 
(Simonneau et al., 2013). Over 20 years ago, idiopathic pulmonary arterial 
hypertension patients had an average life expectancy of 2.8 years yet even 
with greater focus on PAH research, the 5 year survival rate is at 34% 
(D’Alonzo et al., 1991; Tang et al., 2016). PAH can be defined by a mean 
pulmonary artery pressure greater than 25 mm Hg at rest measured by right 
heart catheterisation (Galie et al., 2015a). Between 15 and 50 patients, per 
million, are affected by PAH with an average patient age of 50 years (Gailè et 
al., 2010; Humbert et al., 2014). A key factor associated with the poor survival 
rates of PAH patients is that it is often masked by co-morbidities and 
diagnosed at a late stage where the disease is more aggressive. In order to 
successfully diagnose PAH, guidelines state a lengthy algorithm process. 
Once pulmonary hypertension (PH) is suspected, the first test a patient will 
receive is a transthoracic echocardiogram (TTE; Barbera et al., 2018). TTE 
are non-invasive and allow an assessment of the condition of the heart. If the 
assessment determines PH probability is intermediate or high, then left heart 
disease or respiratory disease will be considered. Further tests and 
considerations include risk factors, electrocardiogram (ECG), chest X-rays 
and high-resolution computed tomography. If left heart failure and respiratory 
disease are ruled out, the assessment of the circulation within the pulmonary 
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vasculature is conducted using V/Q scintigraphy, which involves using a radio-
isotope aerosol. A PH specialist will then perform further tests to decide 
whether chronic thromboembolic PH is possible or PAH is more probable. 
These final examinations involve invasive techniques, such as right heart 
catheterisation (RHC), hence why they are used after other non-invasive tests 
have been utilised. During these final invasive tests, further vasoreactivity 
testing can be conducted to assess the response of the pulmonary vasculature 
to certain therapies such as calcium channel blockers.  
After diagnosing PAH, determining the subgroup is necessary to outline a 
treatment plan. PAH can be divided into further subgroups based around its 
pathogenesis, these include idiopathic (iPAH), familial or heritable (hPAH), or 
associated with other conditions such as: drug/toxin-induced, HIV infection, 
schistosomiasis, congenital heart disease, connective tissue diseases and 
portal hypertension (Galiè et al., 2015a; Ghofrani et al., 2017). After diagnosis, 
it is important to determine the stage of the disease and how far it has 
progressed in order to tailor therapy. WHO categorise PH patients in to one of 
four classes based on the progression of their PH (Figure 4.1). 
WHO CLASS Criteria 
I 
Patients with PH, physical activity is not limited and does not cause 
dyspnoea, fatigue, chest pain or near fainting. 
II 
Patients with PH, physical activity slightly limited, comfortable 
when resting but does cause dyspnoea, fatigue, chest pain or near 
fainting 
III 
Patients with PH, physical activity is majorly limited, comfortable 
when resting, low level activity causes dyspnoea, fatigue, chest 
pain or near fainting 
IV 
Patients with PH, unable to perform any physical activity, 
symptoms of right-heart failure, possible dyspnoea or fatigue at 
rest. 
 
Figure 4.1 – WHO Classification of Pulmonary Hypertension 
WHO classification for PH patients based on their physical activity capabilities. 
Classification helps determine treatment plans in patients. (Adapted from Popa, 2002) 
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PAH is developed due to a reduction of the pulmonary arterial lumen through 
multiple factors such as inflammation, vasoconstriction, proliferation, 
remodelling and thrombosis, which leads to an increase in pulmonary arterial 
pressure (Galiè et al., 2010). This continuous high pressure within the 
pulmonary artery leads to right ventricular overload which in turn develops 
hypertrophy and then right ventricular failure resulting in death if untreated.  
 
4.1.1 Pulmonary Arterial Structure 
Pulmonary arteries are responsible for carrying blood from the right hand side 
of the heart in to the lungs so it can be oxygenated. Pulmonary arteries are a 
three-layered structure, with each layer containing its own distinct individual 
characteristics (Figure 4.2). The three layers are named intima, media and 
adventitia. Each of these play a role in maintaining vascular homeostasis and 
respond to changes within the vessel (Stenmark et al., 2011).  
The intima layer comprises of a single layer of endothelial cells that line the 
lumen of the artery and extend into an internal elastic lamina. The intima can 
constitute up to 16% of total wall thickness (Townsley, 2013; Chazova et al., 
1995). 
It is the composition of the media layer that defines the classification of the 
pulmonary artery. Two factors affect this classification, elastic lamina presence 
and muscularity. Pulmonary arteries can therefore be classified into five 
categories: muscular, partially muscular, non-muscular, elastic and transitional 
(containing both elastic and muscular arteries). The medial layer consists 
primarily of smooth muscle cells with the addition of collagen and elastin in 
varying quantities. Elastic arteries are categorised due to the high presence of 
elastin and low levels of smooth muscle fibres within the medial layer. In the 
main pulmonary artery, within human lungs, elastin constitutes for 
approximately a quarter of the wall area (Townsley, 2013). Muscular arteries 
contain high levels of smooth muscle cells in the medial layer, in a clearly 
distinct circular layer, with a single layer sheet of elastin found between the 
media and intima.  
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The final layer of the pulmonary artery wall is the adventitia, which has had the 
least research focus in regards to pulmonary hypertension, as its principle 
constituents are neither endothelial cells nor smooth muscle cells. However, 
an increase in focus within recent years has indicated it may play a critical role 
within vessel wall function (Stenmark et al., 2011). The adventitia’s principle 
cell type are fibroblasts, but also contain dendritic cells and progenitor cells, 
as well as being heavily influenced by the extra cellular matrix (ECM). 
Emerging concepts suggest that fibroblasts are the “sentinel cell” and the 
regulation of the pulmonary vascular occurs from the “outside in” as it has been 
shown within hypoxic models that pulmonary arterial fibroblasts are the first 
cell to increase in proliferation (Belknap et al., 1997). 
 
 
Figure 4.2 – Structure and composition of pulmonary artery 
The structure and composition of layers of the pulmonary artery, highlights the three 
layers that form the pulmonary artery – Intima, Media and Adventitia. Key cells such 
as fibroblasts, smooth muscle cells and endothelial are also indicated along with their 
location within the artery. (Reproduced from Fernandez et al., 2012). 
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The initiation pathway of PAH is unknown, however it is widely surmised that 
PAH is commenced by initial damage to the endothelium with many studies 
suggesting a range of stimuli are responsible such as genetic predispositions, 
hypoxia and sheer stress upon the endothelium (Madonna et al., 2015; Clapp 
and Gurung, 2015). A conception differing slightly from this, is that it is not the 
predisposition that initiates vascular injury and PAH, but a specific injury to the 
pulmonary arterial wall initiates PAH and the predisposition leaves the patient 
unable to counteract the cascade of events leading to PAH (Gailè et al., 2010). 
The cascade of events that lead to an increase in vascular tone and cell 
proliferation is vast and these occur within a range of cell types including 
smooth muscle cells, endothelial cells and fibroblasts. In pulmonary arteries 
there are currently three known pathways that have been shown to contribute 
to vascular tone and proliferation, these are the endothelin (ET), nitric oxide 
(NO) and prostacyclin (prostaglandin I2; PGI2) pathways (Hemnes and 
Humbert, 2017). 
 
4.1.2 Pulmonary Arterial Regulatory Pathways 
There are three key pathways that regulate pulmonary arterial tone, these 
pathways have been identified as most PAH patients show an imbalance of 
endogenous vasodilators and vasoconstrictors (summarised in Figure 4.3).  
 
4.1.2.1 Endothelin Pathway 
ET has three different isoforms (ET-1, 2 and 3) which are expressed within a 
variety of tissues and have different binding affinities to ET receptors, coupled 
with G-proteins (Galiè et al., 2004). ET-1, is the most potent vasoconstrictor 
within the pulmonary circulation. The ET pathway within the pulmonary 
circulation consists of ET-1 and the G-protein coupled ET receptors, ETA, ETB1 
and ETB2 (Kedzierski and Yanagisawa, 2001). The ETA receptors are located 
within the smooth muscle cells, whilst ETB1 and ETB2 can be found within the 
endothelium, as well as smooth muscle cells. The primary effect of ET-1 
occurs within smooth muscle cells generating vasoconstriction and 
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proliferation (Sibton and Morell, 2012). Cross-talk between ETA and ETB has 
been shown to occur in ET-1 induced vasoconstriction (Sauvageau et al., 
2007). Conversely, within the endothelium, ET has been indicated to cause 
vasodilation through ETB receptors by stimulating NO and PGI2. However, 
under normal physiological conditions, ETB receptors within the endothelium, 
do not significantly contribute to overall pulmonary arterial vascular tone 
(Chester and Yacoub, 2014; Dupuis and Hoeper, 2008; Dupuis et al., 2000). 
A secondary action of ET-1 is on fibroblasts, where it has be shown to promote 
fibrosis, proliferation and contraction, which may give weight to the ‘outside-in’ 
theory (Stenmark et al., 2012). The outside-in hypothesis is formed on the idea 
of initial damage or inflammation within the adventitia that over time 
progresses in towards the intima (Stenmark et al., 2012).  
Whilst ET receptors are widely distributed, the activity of the ET system has 
been shown to be that of a local autrocrine/paracrine signalling pathway. ET-
1 is formed (by the conversion of big ET-1 [39 amino acid peptide] into ET-1 
[21 amino acid peptide] by ET converting enzyme [ECE]) in situ. Circulating 
levels of ET-1 are below that required to induce vasoconstriction (Iglarz and 
Clozel, 2010; Sibton and Morrell, 2012). ET receptors ETA and ETB are 
coupled with Gαq receptors. The binding of ET-1 to these receptors leads to 
the activation of phospholipase C (PLC)-β, which in turn increases the 
production of intracellular messengers inositol 1,4,5-triphosphate (IP3) and 
diacylglycerol (DAG) from phosphatidylinositol 4,5-biphosphate (PIP2; 
Hisatsune et al., 2005; Figure 4.3). The increase in IP3 leads to the activation 
of ligand gated Ca2+ channels on the sarcoplasmic reticulum, which in turn 
increases intracellular Ca2+ levels promoting vasoconstriction. DAG however 
activates protein kinase C (PKC) which leads to a cascade of signalling protein 
activation, which ends in contraction either through inhibiting myosin light 
chain (MLC) phosphatases or enhancing actin polymerisation (Ward et al., 
2004). 
4.1.2.2 Nitric Oxide Pathway 
Within the pulmonary circulation NO is the principle vasodilator and is 
produced by nitric oxide synthases (NOS) within the endothelium. NO is 
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produced as a result of L-arginine being converted to L-citrulline and it acts 
upon smooth muscle cells. NO promotes vasodilation through the stimulation 
of soluble guanylate cyclase (sGC) which increases intracellular levels of 
cyclic guanine monophosphate (cGMP). The increase of intracellular cGMP 
activates protein kinase G (PKG) which in turn decreases Ca2+ release through 
an increase in sarcoplasmic Ca2+-ATPase and MLC phosphatase promoting 
relaxation within the smooth muscle cell (Etter et al., 2001; Jasińska-
Stroschein and Orszulak-Michalak, 2014). In addition to this, PKG also 
phosphorylates RGS4, which inhibits Gαq proteins, thus reducing intracellular 
levels of IP3 and DAG and promoting relaxation and vasodilation (Murthy, 
2006; Figure 4.3).  
 
4.1.2.3 Prostacyclin Pathway 
The third pathway (Figure 4.3) within PAH pathogenesis is the PGI2 pathway. 
PGI2 is produced within the endothelium and the smooth muscle cells, through 
the oxidation of arachidonic acid by cyclooxygenase enzymes (Clapp and 
Gurung, 2015). The PGI2 receptor, IP, is coupled to adenylyl cyclase (AC) via 
a Gs protein. Binding of this receptor increases the levels of intracellular cyclic 
adenosine monophosphate (cAMP). Increased levels of cAMP induces the 
activation of protein kinase A (PKA) and similarly to PKG, PKA inhibits 
sarcoplasmic Ca2+ release by phosphorylating RGS4, which in turn inhibits 
Gαq.  
PGI2 does not only bind to IP receptors, but multiple prostanoid receptors, 
each with a different affinity. Different prostanoid receptors exert different 
actions. IP, EP2 and DP1 receptors have been shown to be vasodilatory 
receptors by increasing intracellular cAMP levels, through Gs protein coupling. 
EP1 and EP3 are vasoconstricting receptors coupled to Gαq and Gi proteins 
respectively however PGI2 binds most potently to IP receptors, more than 5 
fold more potently than it does to any other prostanoid receptor (Woodward et 
al., 2011; Clapp and Gurung, 2015). With the discovery of PGI2 and the 
prostanoid receptors, recent therapeutic strategies have been to selectively 
target the prostanoid receptors.  




Figure 4.3 – Three Key Pathways in Pulmonary Arterial Hypertension 
Pathogenesis 
The three key pathways established within PAH pathogenesis, endothelin, nitric oxide 
and prostacyclin. Figure indicates how the three pathways interact to regulate the 
arterial tone through contraction and relaxation. Endothelin pathway promotes 
vasoconstriction through increased levels of IP3 and DAG. NO pathway stimulates 
vasodilation through increased levels of cGMP and MLC phosphatase activity. PGI2 
pathway can have altering effects depending on the receptors activated, IP, EP2 and 
DP1 promote vasodilation through increase cAMP levels whereas EP3 reduces cAMP 
levels whilst EP1 follows a similar path to ET by increasing IP3 and DAG levels. Green 
lines represent stimulation, red lines represent inhibition. ET-1 represents endothelin-
1; NO, nitric oxide; PGI2, prostaglandin I2; PLC, Phospholipase C; SR, sarcoplasmic 
reticulum; CaM, calmodulin; MLC, myosin light chain; MLC-p, phosphorylated myosin 
light chain; PDE, phosphodiesterase; PKA, protein kinase A; PKC, protein kinase C; 
PKG, protein kinase G; AC, adenylyl cyclase and GC, guanylyl cyclase.  
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4.1.3 Pulmonary Arterial Hypertension Therapeutics 
The foundation of PAH therapeutics is based upon the three key pathways. 
Different drugs have been developed or utilised for the treatment of PAH in 
order to promote vasodilation within the pulmonary arteries. Due to the 
complexity of PAH and the difficulty in measuring drug efficacy, there is no 
gold-standard treatment plan. Therapeutic response is measured by exercise 
capacity (usually a 6 minute walk test) and echocardiograms (Moonen et al., 
2017). Early strategies were to initiate treatment as a monotherapy and 
following an inadequate response combine with another drug or substitute for 
an alternative treatment. Less than two decades ago treatment was very 
primitive. Support therapy until patient deteriorates significantly and then 
provide IV epoprostenol, a synthetic salt analogue of PGI2 (Hemnes, 2014).  
Differences in PAH subgroups and patient phenotypes creates differences in 
the response to therapies. For some patients monotherapies are adequate to 
see a response, whereas combinational approaches are needed in others 
(Humbert and Ghofrani, 2015). Since 1999, multiple drugs have been 
approved by the United States Food and Drug Administration (FDA) and trials 
at earlier interventions/combinations of drugs have been assessed, such as 
the ET receptor antagonist, bosentan (Galiè et al., 2008). Conventional 
therapies used within PAH therapy are to encourage physical activity (but not 
to exertion), provide oxygen therapy (maintenance of PaO2 over 60 mm Hg), 
diuretics to aid right ventricular preload and left ventricular filling. Some PAH 
patients also receive anticoagulation therapy with vitamin K antagonists and 
calcium channel blockers, such as nifedipine (Humbert et al., 2014; Barbera 
et al., 2018). 
In recent years, tailored therapy has been designed, based on the three 
pathways of pathogenesis of PAH. The vast majority of approved and 
experimental compounds act as either ET receptor antagonists, stimulators of 
secondary messengers (cAMP and cGMP) or prostanoid receptor 
agonists/antagonists (receptor dependent, Figure 4.4). 
 
 
Chapter 4.  Action of PAH Therapeutic Agents on K2P Channels 114 
 
4.1.3.1 Endothelin Receptor Antagonists 
ET-1 receptor antagonists (ERAs) are used to bind and occupy ET-1 receptors 
(ETA and ETB) to prevent ET-1 exerting its vasoconstrictive effects. ERAs can 
be both selective (favouring either ETA or ETB) or dual acting. In theory, 
selective ERAs should be more therapeutically beneficial, as ETB receptors 
have been shown to promote vasodilation. Some approved ERA drugs include 
the dual acting bosentan (marketed as Tracleer by Actelion Pharmaceuticals 
Ltd, Switzerland) and macitentan (marketed as Opsumit by Actelion 
Pharmaceuticals Ltd, Switzerland) and the selective ETA receptor antagonist, 
ambrisentan (marketed in the EU as Volibris by GlaxoSmithKline, UK). 
Bosentan has been indicated for early use in PAH therapy, although it must 
be dosed appropriately, starting at a low dose and increased gradually, due to 
adverse effects of liver damage (Humbert et al., 2007). In Europe, orally 
administered bosentan is used in the therapy of patients with WHO class II 
and III. Macitentan is also administered orally, but does not have the liver 
toxicity associated with bosentan. It does however appear to reduce 
haemoglobin levels (Pulido et al., 2013). Like bosentan, macitentan is used for 
the long-term treatment of WHO class II and III PAH patients. Ambrisentan 
has been approved for use within WHO class II and III PAH patients and in 
theory, the selective ability of ambrisentan should provide a greater 
therapeutic effects than bosentan however, in trials bosentan appears more 
effective. 
 
4.1.3.2 Secondary Messenger Modulators 
As previously described, enhancing intracellular levels of the secondary 
messengers cAMP and cGMP can provide a vasodilatory effect within the 
pulmonary artery. To achieve this effect the pathway can be altered in a variety 
of ways including phosphodiesterase (PDE) inhibitors or (adenylyl or 
guanylate) cyclase stimulators. PDE’s degrade cAMP and cGMP by 
hydrolysing the phosphodiester bond forming AMP or GMP respectively. One 
therapeutic intervention has been to inhibit the action of PDE’s preventing the 
breakdown of secondary messengers and promoting vasodilation. PDE’s can 
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be selective or non-selective to the secondary messenger they degrade, 
PDE1, 2, 3, 10 and 11 act on both cAMP and cGMP whereas PDE4, 7 and 8 
act only on cAMP, and PDE5, 6 and 9 act only on cGMP. One approved PDE 
inhibitor for PAH therapy is sildenafil citrate. Originally marketed under the 
name Viagra (Pfizer), it is used for patients within WHO class II and III. 
Sildenafil citrate is a selective PDE5 inhibitor, which enhances cGMP levels. 
It was originally designed to treat angina and hypertension yet after early 
clinical trials it was noted sildenafil had the ability to enhance erectile response 
in patients, that had previously experienced dysfunction (Boolell et al., 1996). 
Between 2003 and 2017, Pfizer made almost $26.5 bn in revenue from Viagra 
sales alone (Statista, 2018). Long-term sildenafil citrate treatment (3 years) 
has been shown clinically to increase 6 minute walking distance in almost 50% 
of patients as well as stabilise or improve the WHO classification of the 
patients over that time period (Rubin et al., 2011). 
After the success of Viagra, many pharmaceutical companies developed 
PDE5 inhibitors to treat erectile dysfunction. One of those, tadalafil branded 
as Cialis (Eli Lilly and Co) is also approved for PAH therapy. Like sildenafil 
citrate, tadalafil is used to treat WHO class II and III PAH patients. Tadalafil 
and sildenafil citrate are both taken as oral tablets. Tadalafil has a longer half-
life so is only required once daily, compared to three times with sildenafil.  
Another approved PAH drug is riociguat. Marketed under the trade name 
Adempas (Bayer) it acts as a soluble guanylate cyclase (sGC) stimulator 
promoting intracellular levels of cGMP, independently of NO. Riociguat is used 
in PAH patients of WHO class II and III with an up dosing approach taken, until 
optimal dose is reached to prevent symptoms of hypertension. Combining 
riociguat therapy with sildenafil seems like an appropriate route of action in 
PAH therapy, as they both target separate areas of the pathway. However, a 
trial has shown unfavourable safety profiles of the combination, with no 
positive benefit to off-set the risk (Galiè et al., 2015b). 
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4.1.3.3 Prostanoid Receptor Modulators 
As previously mentioned different prostanoid receptors exert different 
signalling pathways within the cell. Prostanoid therapy for PAH must therefore 
selectively target and activate a prostanoid receptor that promotes 
vasodilation (IP, EP2 and DP1). An alternative option is to use an antagonist 
that selectively targets prostanoid receptors, which activates a 
vasoconstricting pathway. The first prostanoid therapy approved was 
epoprostenol. Its uses are held back for later stage PAH (WHO class III and 
IV), who have not had success with conventional therapy (Humbert and 
Ghofrani, 2016). Epoprostenol is administered intravenously and serious care 
must be taken with this drug as fatal adverse effects can occur through the 
central venous line, such as sepsis and thromboembolisms (Barst, 2010).  
Another PGI2 analogue is iloprost. Iloprost has an advantage over 
epoprostenol as it has a longer half-life (20 minutes compared to < 5 minutes) 
and can be administered through inhalation or intravenously. In Europe, only 
inhaled iloprost is approved for PAH patients (WHO class III). Disadvantages 
of inhaled iloprost is that it still requires frequent administration, between 6 and 
9 times a day. In addition iloprost has poor selectivity on prostanoid receptors 
and is equally potent in the activation of IP and EP1 receptors (Whittle et al., 
2012; Clapp and Gurung, 2015).  Activation of EP1 receptors causes 
vasoconstriction via receptor-coupled Gαq proteins, which downstream 
increase intracellular IP3 and DAG, as well as generating an increase in 
intracellular Ca2+ levels by upregulating PDE1 (Schermuly et al., 2007).  
Treprostinil is a PGI2 analogue which can be administered orally, 
subcutaneously, intravenously and inhaled. Treprostinil has a great advantage 
in its mode of delivery, as subcutaneous therapy is approved in Europe for 
WHO class III PAH patients and reduces administration risk, when compared 
to epoprostenol. Treprostinil’s half-life is considerably higher at 4 hours and is 
more stable at room temperature. One disadvantage to treprostinil is the 
severe site pain experienced in patients undergoing subcutaneous 
administration. One trial stated 85% of patients exhibited this pain (Simonneau 
et al., 2002). Experiencing pain during drug administration could be a big factor 
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in patients wishing to discontinue therapy. 8% of patients, in the study that 
report pain, wished to be discontinued from treprostinil treatment (Simonneau 
et al., 2002). Treprostinil favours the binding of the vasodilatory prostanoid 
receptors IP, DP1 and EP2 with binding affinity (Ki) values of 32 nM, 4.4 nM 
and 3.6 nM, respectively, compared to 212 nM and 2505 nM for EP1 and EP3, 
respectively (Clapp and Gurung, 2015). Improvements in patients six minute 
walking distance has been seen in multiple studies, with different delivery 
methods, indicating treprostinil therapy is a beneficial therapy (Simonneau et 
al., 2002; McLaughlin et al., 2010; Jing et al., 2013). 
 
4.1.3.4 Experimental Compounds 
As PAH therapy is still inadequate, many compounds are being developed and 
tested experimentally as well as clinically. Some of these compounds, may not 
be translatable clinically but could help provide beneficial insights for future 
drug design (Figure 4.4). These include selexipag, which is a prodrug, non 
PGI2 analogue and selective IP receptor agonist. Whilst selexipag is selective 
in its binding, it has not shown great efficacy in vasodilating pulmonary 
arteries. One reason for this may be the broad selectivity of other prostanoid 
therapies, which produce a dilatory effect, with a combination of pro-dilatory 
prostanoid receptors being stimulated. Currently selexipag is not approved for 
use in PAH therapy.  
PDE inhibitors have proved useful in PAH therapy. Compounds such as 3 -
isobutyl-1-methylxanthine (IBMX), targets multiple PDE’s (PDE1-5, 7 and 11)’ 
increasing intracellular levels of both cAMP and cGMP.  
An alternative compound to riociguat could be forskolin, which instead of 
activating sGC, activates adenylyl cyclase (AC). Forskolin is used within 
traditional medicine for multiple diseases including cardiovascular, respiratory 
and neuronal, but is not approved clinically for use in the treatment of any 
condition (Henderson et al., 2005).  
Another experimental compound which may be of use is the compound ONO-
RS-082, a reversible phospholipase A2 (PLA2) inhibitor. The use of PLA2 
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inhibitors acts higher up the signalling pathway, than currently approved 
therapies, PLA2 is an enzyme that generates arachidonic acid (AA), which is 
a precursor to PGI2. Experimentally ONO-RS-082 has been shown to increase 
K+ channel current, specifically Twik-Related Acid-Sensitive Channel 1 





Figure 4.4 – Action of Drugs and Compounds on PAH pathways 
Diagram shows where the approved therapies and experimental compounds play a 
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4.1.4 Implications of the Two-Pore Domain K+ Channel (TASK-1) in 
Pulmonary Arterial Hypertension 
As previously mentioned, one major factor in the development of PAH are 
genetic predispositions. 80% of patients with hPAH carry a recognisable 
pathogenic mutation such as bone morphogenetic protein receptor type 2 
(BMPR2), mothers against decapentaplegic homologue 1 (SMAD1), 
Neurogenic locus notch homolog protein 3 (NOTCH3) and two-pore domain 
K+ channel subfamily member 3 (KCNK3; Navas et al., 2016). KCNK3 gene 
encodes the TASK-1 potassium channel and there is now increasing evidence 
for a role of TASK-1 in PAH through the regulation of pulmonary vascular tone.  
In early studies, TASK-1 channels were shown to be expressed within 
mammalian lungs although the specific cell type in which it is located was 
unclear. A few years later TASK-1 was then confirmed to play a major role in 
the resting potential of pulmonary arterial smooth muscle cells (PASMCs) 
within rabbits (Lesage and Lazdunski, 2000; Gurney et al., 2003). Other 
concurrent work highlighted that the background current within PASMCs, 
shared properties of TASK-1 currents, such as a 50% inhibition of current at 
pH 7.3 and activation by halothane (Gurney et al., 2003; Leonoudakis et al., 
1998). TASK-1 was identified as the potential O2 sensor in PASMCs and 
further studies including siRNA silencing of TASK-1 channels confirmed its 
role in the regulation of PASMC membrane potential (Gurney and Joshi, 2006; 
Olschewski et al., 2006).  
An increase in PASMC proliferation and vasoconstriction was observed with 
reduced K+ channel activity, particularly TASK-1 and Kv1.5 (KCNA5; 
Boucherat et al., 2015). In regards to PAH, it has been shown that in human 
patients of PAH, TASK-1 expression is significantly reduced and TASK-1 
inhibition lead to an increase in vasoconstriction, proliferation and 
inflammation (Antigny et al., 2016). The same study also found that within 
experimental models of PAH, pharmacological activation of TASK-1 can 
relieve signs of PAH. The conclusion of this study was that TASK-1 channels 
and therefore loss of TASK-1 function or expression is a key event in PAH 
pathogenesis (Antigny et al., 2016). Further work from the same group 
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identified that within rats, TASK-1 is expressed far more significantly in right 
ventricular (RV) cardiomyocytes compared to the left ventricle and there is a 
reduction in the TASK-1 function prior to the development of RV hypertrophy 
(Lambert et al., 2018). PAH is proposed to arise through TASK-1 
dysfunction/loss which results in PASMC membrane depolarisation, which in 
turn leads to constriction of the pulmonary artery. The pulmonary remodelling 
that occurs within PAH have been attributed to platelet-derived growth factor, 
which has been shown to have higher expression in PASMC, following TASK-
1 inhibition (Humbert, 2013; Antigny et al., 2016).  
In combination with the experimental work implicating TASK-1 as a key 
mediator in PAH, genetic screening has advanced our understanding of the 
mechanisms underlying the disease. Using these screens, mutated genes are 
able to be analysed experimentally to determine their roles and potential 
therapeutic avenues. In TASK-1 channels, six heterozygous mutations were 
first indicated to play a role in PAH having been generated from hPAH and 
iPAH patients (Ma et al., 2013). In this study they showed that mutations 
caused a loss of function, but using the phospholipase A2 inhibitor, ONO-RS-
082, enabled limited recovery of current in homozygous mutant TASK-1 
channels could be observed. This study highlighted a new target in the 
treatment of PAH as well as the first channelopathy within the disease (Girerd 
et al., 2014). More recently, a brief report based on a Spanish cohort of 
patients revealed two novel mutations of TASK-1 present in an aggressive 
form of PAH, this time mutations were homozygous (Navas et al., 2017). The 
two novel mutations are a glycine substituting an arginine at position 106 
(G106R) and a leucine replacing an arginine at position 214 (L214R). Both 
mutations are located extracellularly, with G106R being located between the 
first pore (P) domain and the second transmembrane (TM) domain and L214R 
being located between the second P domain and fourth TM domain (Figure 
4.5). 
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Figure 4.5 – Homology model of novel TASK-1 mutations 
Homology TASK-1 model generated based on crystal structure of TRAAK (PDB ID 
3UM7, Brohawn et al., 2012). G106R mutated amino acids are shown in red, L214R 
mutated amino acids are shown in blue. Left shows a side image of the channel, right 
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4.2 Objective 
The objective for this set of experiments was to characterise the functional 
properties of the novel TASK-1 mutations, G106R and L214R, identified by 
Navas et al., (2017). By generating electrophysiological profiles of the 
channels it was possible to analyse the effects of potential therapeutic options. 
Drugs and compounds used in this study were the phospholipase A2 inhibitor 
(ONO-RS-082), the PDE5 inhibitor (sildenafil), the non-selective PDE inhibitor 
(IBMX), the soluble guanylyl cyclase activator (Riociguat), the adenylyl cyclase 
activator (Forskolin) and the synthetic analogue of PGI2 (Treprostinil). In 
addition to this, protein quantification studies and confocal imaging was 
conducted to determine whether the novel TASK-1 mutations are trafficked to 
the cell membrane as efficiently as WT TASK-1 channels. Finally, the effect of 
treprostinil on TWIK-related K+ channel 1 (TREK-1) and 2 (TREK-2) was 
analysed to determine if these channels play a role in the site pain experienced 
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4.3  Results: Characterisation of Novel TASK-1 
Mutations Implicated in PAH 
4.3.1 Electrophysiological properties of TASK-1 
hTASK-1 WT DNA was transiently transfected into tsA201 cells and used in 
whole-cell patch-clamp electrophysiological recordings. The application of the 
step-ramp voltage protocol (Figure 2.6) previously described ensured the 
generation of currents with TASK-1 electrophysiological characteristics 
(Figure 4.6). TASK-1_WT currents were measured as the current recorded at 
-40 mV.  
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Figure 4.6 – TASK-1_WT electrophysiological profile. 
A) Representative trace for TASK-1_WT channel in control conditions exposed to the 
step-ramp voltage protocol detailed in the methods. B) Current-voltage graph for 
TASK-1_WT in control conditions. 
 
The electrophysiological profile for TASK-1_WT in extracellular solution (2.5 
mM K+, pH 7.4, see methods 2.3.3) yielded an average whole-cell current of 8 
± 1 pA/pF (n = 44) with an average reversal potential of -73 ± 2 mV (n = 13) 
close to the equilibrium potential for K+ ions under these recording conditions 
based on the Nernst equation. TASK-1_WT has an outwardly rectifying 
current, as shown in the exemplar current-voltage graph (Figure 4.6B), at 
higher voltages the current increases significantly as seen from the steep 
curve, this is the activation of endogenous Kv channels within the tsA201 cells. 
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By measuring current at -40 mV it ensures any change in current seen is a 
change of TASK-1 current and not that of endogenous channels. This effect 
was present within TASK-3 currents however TASK-1 currents measured 
were far smaller displaying the effect of Kv activation as an exaggerated effect.   
 
4.3.2 Electrophysiological properties of novel TASK-1 mutants 
The channel functionality of the novel PAH mutants, G106R and L214R, were 
assessed using whole-cell patch-clamp techniques. TASK-1_G106R and 
TASK-1_L214R DNA was transiently expressed in tsA201 cells under 
experimental conditions (2.5 mM K+, pH 7.4, see methods 2.3.3). The 
substitution of a glycine (G) residue with an arginine (R) at position 106 leads 
to the significant reduction (p < 0.05, one-way ANOVA with Dunnett’s Multiple 
Comparisons test) in channel current (Figure 4.7A). The average whole-cell 
current measured at -40 mV for TASK-1_G106R was 2 ± 1 pA/pF (n = 38; p < 
0.05) and an average reversal potential was also significantly changed with a 
value of -33 ± 8 (n = 5; p < 0.05; appendix 6.11 and 6.12). Similarly, L214R, a 
leucine (L) replaced with an arginine (R) at position 214 results in a significant 
reduction in channel current at -40 mV (Figure 4.7A). The average whole-cell 
current measured at -40 mV for TASK-1_L214R was 2 ± 1 pA (n = 27; p < 
0.05) and average reversal potential was also significantly changed with a 
value of -19 ± 3 (n = 5; p < 0.05; appendix 6.11 and 6.12). Cells only 
transfected with GFP had a significantly smaller whole-cell current of 2 ± 1 pA 
(n = 36; p < 0.05; Figure 4.7A) with an average reversal potential of -32 ± 2 
mV (n = 13; p < 0.05; appendix 6.11 and 6.12).  
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Figure 4.7 – Electrophysiological profile of novel TASK-1 mutants 
A) Measurements of whole-cell current normalised against cell capacitance (pA/pF) 
at -40 mV for cells expressing TASK-1_WT, TASK-1_G106R, TASK-1_L214R or 
untransfected cells. Error bars represent the SEM. B) Current-voltage plot of TASK-
1_WT, TASK-1_G106R, TASK-1_L214R and GFP only showing changes in currents 
over a voltage ramp from -120 mV to +20 mV. 
 
4.3.3 Effect of TEA on TASK-1_WT and novel mutants 
As there was substantial outward current seen at more positive potentials of 
the ramp within the step-ramp voltage protocol, tetraethylammonium chloride 
(TEA) was used to inhibit any background KV current, which is found in the 
cells. K2P channels are insensitive to TEA, if current measured was due to the 
TASK-1 channel present then current should remain during the presence of 
TEA (10 mM; O’Connell et al., 2002). Currents were measured at +20 mV as 
this was the highest voltage used in the step-ramp protocol, TASK-1_WT was 
not significantly affected by the use of TEA (10 mM) with values of 38 ± 4 
pA/pF (n = 11) in control conditions and 36 ± 6 pA/pF (n = 8) in TEA (10mM; 
p > 0.05, Two-way ANOVA, Figure 4.8). Both currents within mutated channels 
were significantly reduced in the presence of TEA (10 mM) with TASK-
1_G106R measured at 27 ± 5 pA/pF (n = 6) in control and 7 ± 1 pA/pF (n = 6) 
in TEA (10 mM). Whilst TASK-1_L214R had current of 22 ± 5 pA/pF (n = 6) in 
control and 8 ± 2 pA/pF (n = 6) in TEA (10 mM; p < 0.05, Two-way ANOVA, 
Figure 4.8). Cells transfected only with GFP were significantly reduced at +20 
mV, from 21 ± 2 pA/pF (n = 6) in control conditions to 6 ± 1 pA/pF (n = 6) in 
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TEA (10 mM), suggesting endogenous KV channels are present within the cells 
and represent the outward current seen with the novel mutations, at more 
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Figure 4.8 – Effect of TEA (10 mM) on TASK-1_WT and novel mutants 
Measurements of whole-cell current normalised against cell capacitance (pA/pF) at 
+20 mV for cells expressing TASK-1_WT, TASK-1_G106R,TASK-1_L214R and GFP 
only in control conditions and TEA (10 mM) 
 
4.3.4 Effect of alkalosis on the functionality of TASK-1 WT and novel 
mutants 
After identifying the significantly attenuated current in the mutant channels as 
well as the change in reversal potentials compared to WT TASK-1 the next 
approach was to assess them under the effect of alkalosis. TASK-1 channels 
have a pK of 7.5 and as previously mentioned can therefore be inhibited or 
activated by acidosis and alkalosis respectively (Berg et al., 2004). Our 
approach was to identify whether the mutant channels were still pH sensitive 
and determine if the reduced functionality of the mutant channels could be 
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rescued by an increase in extracellular pH from 7.4 to 8.4. In accordance with 
previous studies, TASK-1_WT current at -40 mV was significantly increased 
(paired t-test, p < 0.05) with outward currents enhancing from 11 ± 1 pA/pF (n 
= 17) at pH 7.4 to 27 ± 3 pA/pF (n = 17) at pH 8.4 (Figure 4.9). The increase 
in extracellular pH had no significant effect (p > 0.05) upon TASK-1_G106R 
current at -40 mV with outward current values of 1 ± 1 pA/pF (n = 12) at pH 
7.4 to 3 ± 1 pA/pF (n = 12) at pH 8.4 (Figure 4.10). A similar result was 
recorded for the TASK-1_L214R mutation, with extracellular alkalosis having 
no significant effect (p < 0.05) on outward channel current at -40 mV, 1 ± 1 
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Figure 4.9 – Functional effects of extracellular alkalosis on TASK-1_WT  
A) TASK-1_WT current values normalised to the cells capacitance (pA/pF) measured 
at -40 mV, recorded at extracellular pH 7.4 (black dots) or pH 8.4 (grey dots). Black 
line links the same cell in either condition. B) Time course graph showing TASK-1_WT 
outward current at -40 mV under the influence of pH 8.4. pH 8.4 application is 
represented at the grey bar, absence of the grey bar represents pH 7.4. C) Current-
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voltage plot of TASK-1_WT in both pH 7.4 (black line) and pH 8.4 (grey line) recorded 
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Figure 4.10 – Functional effects of extracellular alkalosis on TASK-1_G106R  
A) TASK-1_G106R current values normalised to the cells capacitance (pA/pF) 
measured at -40 mV, recorded at extracellular pH 7.4 (black dots) or pH 8.4 (grey 
dots). Black line links the same cell in either condition. B) Time course graph showing 
TASK-1_G106R outward current at -40 mV under the influence of pH 8.4. pH 8.4 
application is represented at the grey bar, absence of the grey bar represents pH 7.4. 
C) Current-voltage plot of TASK-1_G106R in both pH 7.4 (black line) and pH 8.4 (grey 
line) recorded over a voltage ramp from -120 mV to +20 mV.  
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Figure 4.11 – Functional effects of extracellular alkalosis on TASK-1_L214R  
A) TASK-1_L214R current values normalised to the cells capacitance (pA/pF) 
measured at -40 mV, recorded at extracellular pH 7.4 (black dots) or pH 8.4 (grey 
dots). Black line links the same cell in either condition. B) Time course graph showing 
TASK-1_L214R outward current at -40 mV under the influence of pH 8.4. pH 8.4 
application is represented at the grey bar, absence of the grey bar represents pH 7.4. 
C) Current-voltage plot of TASK-1_L214R in both pH 7.4 (black line) and pH 8.4 (grey 
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4.3.5 Cellular localisation of TASK-1 WT and novel mutants 
As a result of a reduced current observed in TASK-1_G106R and TASK-
1_L214R mutant channels compared to TASK-1_WT, as well as a loss of pH 
sensitivity, it was appropriate to investigate whether these changes were due 
to cellular trafficking issues, which resulted in a reduction of channel 
expression at the plasma membrane. A combination of confocal microscopy 
and in/on cell assays were used to determine this. For confocal microscopy 
experiments the channels were tagged within a green fluorescent protein 
(GFP) at the C terminus of the channels and excited at 488 nm. The plasma 
membranes were stained with a membrane specific stain, CellMask™ Deep 
Red and excited at 561 nm. TASK-1_WT channels were shown to principally 
be expressed within the plasma membrane with both stains exhibiting similar 
profiles (Figure 4.12Ai and Aii, respectively) with an overlap image visually 
confirming this (Figure 4.12iii), along with a blue stained nuclei. To quantify the 
co-localisation of channel and membrane Pearson’s correlation coefficient 
(PCC) was adopted, 12 individual cells were analysed originating from 8 
separate plates and 4 different cultures. A PCC value of 0.65 ± 0.04 (n = 12) 
for TASK-1_WT was obtained indicating a strong correlation (PCC value of 1 
= 100% correlation between channel and membrane) between TASK-1_WT 
channel and the plasma membrane (Figure 4.12D). For the two novel mutants 
the same analysis was conducted and both resulted in a similar profile to 
TASK-1_WT. For TASK-1_G106R and TASK-1_L214R, the channels were 
shown visually at the membrane and overlapped with the membrane stain 
(Figure 4.12Bi-iii and Ci-iii respectively). Quantification of TASK-1_G106R and 
TASK-1_L214R resulted in PCC values of 0.75 ± 0.03 (n = 12) and 0.72 ± 0.04 
(n = 12) respectively and no significant difference was observed between 
TASK-1_WT and mutant channels (p > 0.05, one-way ANOVA). These 
findings suggest the trafficking to the plasma membrane and translation of 
mutant channels are equally as efficient as the TASK-1_WT channel under 
these experimental conditions.  
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Figure 4.12 – Visualisation and quantification of cellular localisation of TASK-1 
WT and mutant channels 
Ai) Confocal microscope photomicrograph showing cellular localisation of TASK-
1_WT channels tagged with GFP. Aii) Confocal microscope photomicrograph 
showing location of plasma membrane stained with CellMask deep red. Aiii) Is an 
overlay representation of (Ai) and (Aii) with overlap of channel and plasma membrane 
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appearing yellow. Nuclei were stained with Hoechst 33258 appearing blue. Bi, ii and 
iii) represents TASK-1_G106R as (Ai, ii and iii) does for TASK-1_WT respectively. Ci, 
ii and iii) represents TASK-1_L214R as (Ai, ii and iii) does for TASK-1_WT 
respectively. D) Bar chart depicting the quantification of co-localisation using PCC 
values of TASK-1_WT, TASK-1_G106R and TASK-1_L214R, PCC value of 1 
signifies 100% correlation between membrane and channel. Each point represents 
PCC value for individual cell expressing the respective channel, error bars display 
SEM. Scale bars = 5 µM. 
 
Whilst the Zeiss LSM880 microscope had an axial resolution of 400 nm, the 
cell thickness suggests confocal data alone cannot conclusively confirm the 
co-localisation of GFP-tagged channel and membrane. To further quantify the 
translation and trafficking of TASK-1_WT and mutant channels in-cell and on-
cell assays were utilised. Channels were tagged using a human influenza 
hemagglutinin (HA) tag on the M1P1 loop. The M1P1 loop is an extracellular 
domain, that a primary antibody, anti-HA (mouse, H3663, Sigma Aldrich), can 
bind to and detect channels at the plasma membrane. To quantify the whole-
cell channel expression, cell membranes were permeabilised using Triton X-
100 and anti-HA was applied. A secondary antibody selective to the primary 
antibody and conjugated to a green dye (Goat anti-mouse IRDye 800CW, 
LiCOR) which is excited at 778 nm. DRAQ5 (ThermoFisher), a DNA stain was 
used to quantify the cell count to ensure equal cell numbers were present in 
each data set. Using DRAQ5 showed no difference in cell numbers between 
TASK-1_WT, TASK-1_G106R and TASK-1_L214R (Figure 4.13) with values 
of 408 ± 50 (n = 9), 341 ± 62 (n = 9) and 328 ± 65 (n = 9) respectively (p > 
0.05). For TASK-1_WT, on-cell assay produced channel membrane 
expression values of 487 ± 69 (n = 9) and no significant difference was seen 
in TASK-1_G106R and TASK-1_L214R (Figure 4.13) with values of 443 ± 114 
(n = 9) and 377 ± 27 (n = 9) respectively (p > 0.05, two-way ANOVA). Similarly, 
whole-cell channel expression was also not significantly different (Figure 
4.13), between TASK-1_WT, TASK-1_G106R and TASK-1_L214R, with 
values of 1552 ± 313 (n = 9), 1892 ± 351 (n = 9) and 1219 ± 311 (n = 9) 
respectively (p > 0.05, two-way ANOVA). This data in combination with the 
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confocal imaging and electrophysiological data provides solid evidence that 
under these experimental conditions, the PAH mutations, TASK-1_G106R and 
TASK-1_L214R are trafficked and expressed, with similar efficiency to TASK-
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Figure 4.13 – Analysis of TASK-1_WT and mutant channels cellular localisation 
by in cell and on cell assays 
A) Chart representing integrated intensity values of TASK-1_WT, TASK-1_G106R 
and TASK-1_L214R tagged with hemagglutinin (HA). Membrane values represent 
channels at the membrane of cell. Whole-cell 800 nm values represent total channel 
translation within the cell, generated by permeabilising cell membrane with Triton X-
100 prior to anti-HA antibody binding. Whole-cell DRAQ5 700 nm represent total cell 
count. B) Image of plate wells used for in cell and on cell assays, each row identified 












4.3.6 Effect of a TASK-1 activator, ONO-RS-082, on TASK-1 novel 
mutations 
ONO-RS-082, a phospholipase A2 inhibitor, has been shown to activate 
TASK-1_WT current. More specifically it has been shown that heterozygous 
TASK-1 mutations found in PAH patients which express reduced channel 
current have been shown to have partial current rescued following the acute 
application of ONO-RS-082 (Ma et al., 2013). As found by Ma et al., 2013, 
TASK-1_WT outward current at -40 mV was significantly increased (Figure 
4.14A) by ONO-RS-082 (10 µM) with values of 6 ± 2 pA/pF (n = 6) in control 
conditions and 14 ± 4 pA/pF (n = 6; p < 0.05, paired t-test) under ONO-RS-
082 (10 µM). ONO-RS-082 was shown to be reversible and had an EC50 value 










































0 2 0 0 4 0 0 6 0 0 8 0 0
0
5 0 0
1 0 0 0
1 5 0 0

















O N O -R S -082  (10 M )
-1 2 0 -1 0 0 -8 0 -6 0 -4 0 -2 0 2 0
-1 0 0 0
1 0 0 0
2 0 0 0
3 0 0 0










C o n tro l
O N O -R S -0 8 2  (1 0 M )
A B
C D

























Figure 4.14 – Effect of ONO-RS-082 on TASK-1_WT 
A) Effect of ONO-RS-082 (10 µM) on TASK-1_WT outward current measured at -40 
mV. B) Time course graph showing TASK-1_WT outward current at -40 mV under the 
influence of ONO-RS-082 (10 µM). Application of ONO-RS-082 (10 µM) is 
represented with the grey bar, absence of the grey bar represents cell in control 
conditions. C) Current-voltage plot of TASK-1_WT in both pH 7.4 (black line) and 
ONO-RS-082 10 µM (grey line) recorded over a voltage ramp from -120 mV to +20 
mV. D) Concentration response plot showing the effect of a range of ONO-RS-082 
concentrations between 0.01 µM and 100 µM on TASK-1_WT outward current at -40 
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In contrast to TASK-1_WT and the two heterozygous mutations seen in Ma et 
al., (2013), ONO-RS-082 (10 µM) has no significant effect on TASK-1_G106R 
(Figure 4.15, p > 0.05). TASK-1_G106R in control conditions had an outward 
current measured at -40 mV of 0.76 ± 0.3 pA/pF (n = 7) and under the acute 
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Figure 4.15 – Effect of ONO-RS-082 on TASK-1_G106R 
A) Effect of ONO-RS-082 (10 µM) on TASK-1_G106R outward current measured at 
-40 mV. B) Time course graph showing TASK-1_G106R outward current at -40 mV 
under the influence of ONO-RS-082 (10 µM). Application of ONO-RS-082 (10 µM) is 
represented with the grey bar, absence of the grey bar represents cell in control 
conditions. C) Current-voltage plot of TASK-1_G106R in both pH 7.4 (black line) and 
ONO-RS-082 10 µM (grey line) recorded over a voltage ramp from -120 mV to +20 
mV. 
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Similarly to TASK-1_G106R, ONO-RS-082 (10 µM) also did not have a 
significant effect upon TASK-1_L214R (Figure 4.16; p > 0.05)). In control 
conditions, TASK-1_L214R outward current at -40 mV was 2 ± 1 pA/pF (n = 
7) and under the acute application of ONO-RS-082 (10 µM) was 1.8 ± 1 pA/pF 
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Figure 4.16 – Effect of ONO-RS-082 on TASK-1_L214R 
A) Effect of ONO-RS-082 (10 µM) on TASK-1_L214R outward current measured at -
40 mV. B) Time course graph showing TASK-1_L214R outward current at -40 mV 
under the influence of ONO-RS-082 (10 µM). Application of ONO-RS-082 (10 µM) is 
represented with the grey bar, absence of the grey bar represents cell in control 
conditions. C) Current-voltage plot of TASK-1_L214R in both pH 7.4 (black line) and 
ONO-RS-082 10 µM (grey line) recorded over a voltage ramp from -120 mV to +20 
mV. 
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As ONO-RS-082 failed to enhance current of novel mutations, the next 
approach was to investigate a mutation (TASK-1_E182K) that has been 
reported to recover current under ONO-RS-082 (10 µM) application (Ma et al., 
2013). Compared to TASK-1_WT, TASK-1_E182K had a significantly reduced 
current in control conditions, 8 ± 1 pA/pF (n = 44) and 2 ± 1 pA/pF (n = 30) for 
TASK-1_WT and TASK-1_E182K respectively (p < 0.05, One-Way ANOVA 
with post-hoc Dunnett’s, Figure 4.17A). In our hands, like the novel mutations 
(G106R and L214R) ONO-RS-082 (10 µM) failed to enhance TASK-1_E182K 
current with outward current measured at -40 mV (2 ± 1 pA/pF, n = 10 in 
control; 2 ± 1 pA/pF, n = 10 in ONO-RS-082 10 µM; p > 0.05, paired t-test, 
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Figure 4.17 – Electrophysiological profile and response to ONO-RS-082 (10 µM) 
of TASK-1_E182K 
A) Measurements of whole-cell current normalised against cell capacitance (pA/pF) 
at -40 mV for cells expressing TASK-1_WT and TASK-1_E182K. Error bars represent 
the SEM. B) Effect of ONO-RS-082 (10 µM) on TASK-1_E182K outward current 
measured at -40 mV. C) Time course graph showing TASK-1_E182K outward current 
at -40 mV under the influence of ONO-RS-082 (10 µM). Application of ONO-RS-082 
(10 µM) is represented with the grey bar, absence of the grey bar represents cell in 
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4.4 Results: Effect of Secondary Messenger 
Modulators on TASK-1 WT and Novel Mutations 
 
Having shown that ONO-RS-082 failed to rescue current of the mutated 
channels G106R and L214R, and that the mutated channels were translated 
and trafficked to the plasma membrane as efficiently as the WT TASK-1 
channel, it was decided to assess whether known PAH therapeutics could 
have an effect on TASK-1 and the novel mutations.  
 
4.4.1 Effect of Sildenafil on TASK-1 WT and Novel Mutations 
To assess the action of sildenafil (10 µM) upon TASK-1_WT and novel 
mutations in PAH patients, cells were incubated in either control conditions or 
extracellular solution containing sildenafil (10 µM) for 20 minutes prior to 
electrophysiological experiments. Incubation with sildenafil (10 µM) 
significantly enhanced the current of TASK-1_WT (Figure 4.18, p < 0.05, 
unpaired t-test). In control conditions the average TASK-1_WT outward 
current at -40 mV was 8 ± 1 pA/pF (n = 16) and after incubation 11 ± 1 pA/pF 
(n = 16). The average zero current potential was significantly hyperpolarised 
in the presence of sildenafil (10 µM) with values of -85 ± 2 mV (n = 16) in 
control conditions and -96 ± 2 mV (n = 16) under the influence of sildenafil (10 
µM).  
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Figure 4.18 – Effect of Sildenafil (10 µM) on TASK-1_WT 
A) Measurements of whole-cell current normalised against cell capacitance (pA/pF) 
at -40 mV for cells expressing TASK-1_WT in control conditions and sildenafil (10 
µM). B) Current-voltage plot of TASK-1_WT in both control conditions (black line) and 
sildenafil (10 µM, grey line) recorded over a voltage ramp from -120 mV to +20 mV. 
C) Measurement of reversal potentials (mV) of cells expressing TASK-1_WT in 
control conditions and sildenafil (10 µM). Error bars represent SEM.  
 
By contrast to TASK-1_WT, TASK-1_G106R outward current at -40 mV was 
not significantly affected by the incubation of sildenafil (10 µM, p > 0.05, 
unpaired t-test, Figure 4.19). TASK-1_G106R current in control conditions was 
measured as 1 ± 1 pA/pF (n = 6) and 2 ± 1 pA/pF (n = 6) in sildenafil (10 µM). 
Similarly to TASK-1_WT, the zero current potential of TASK-1_G106R was 
significantly hyperpolarised, however in this case closer to the equilibrium 
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potential for potassium ions under these recording conditions with values 
measured as -55 ± 2 mV (n = 6) in control conditions and -76 ± 9 mV (n = 6) 
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Figure 4.19 – Effect of Sildenafil (10 µM) on TASK-1_G106R 
A) Measurements of whole-cell current normalised against cell capacitance (pA/pF) 
at -40 mV for cells expressing TASK-1_G106R in control conditions and sildenafil (10 
µM). B) Current-voltage plot of TASK-1_G106R in both control conditions (black line) 
and sildenafil (10 µM, grey line) recorded over a voltage ramp from -120 mV to +20 
mV. C) Measurement of reversal potentials (mV) of cells expressing TASK-1_G106R 
in control conditions and sildenafil (10 µM). Error bars represent SEM.  
 
Similarly to TASK-1_G106R, sildenafil (10 µM) failed to increase TASK-
1_L214R current (Figure 4.20). Outward TASK-1_L214R currents were 
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measured at -40 mV and in control conditions had values of 1 ± 1 pA/pF (n = 
5) and in sildenafil (10 µM) 2 ± 1 pA/pF (n = 5). Unlike both TASK-1_WT and 
TASK-1_G106R, sildenafil (10 µM) had no effect on the zero current potential 
of TASK-1_L214R with -57 ± 4 mV (n = 5) in control conditions and -55 ± 2 mV 
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Figure 4.20 – Effect of Sildenafil (10 µM) on TASK-1_L214R 
A) Measurements of whole-cell current normalised against cell capacitance (pA/pF) 
at -40 mV for cells expressing TASK-1_L214R in control conditions and sildenafil (10 
µM). B) Current-voltage plot of TASK-1_L214R in both control conditions (black line) 
and sildenafil (10 µM, grey line) recorded over a voltage ramp from -120 mV to +20 
mV. C) Measurement of reversal potentials (mV) of cells expressing TASK-1_L214R 
in control conditions and sildenafil (10 µM). Error bars represent SEM.  
 
4.4.2  Effect of IBMX on TASK-1_WT 
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As the use of the selective PDE5 inhibitor enhanced WT TASK-1 current, it 
was decided to study a non-selective PDE inhibitor, IBMX. Unlike sildenafil, 
outward TASK-1_WT channel current incubated for 20 minutes with an 
extracellular solution containing IBMX (100 µM), did not significantly increase 
(p > 0.05, unpaired t-test, Figure 4.21). In control conditions at -40 mV, TASK-
1_WT outward current measured was 7 ± 1 pA/pF (n = 17) and after incubation 
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Figure 4.21 – Effect of IBMX (100 µM) on TASK-1_WT 
A) Measurements of whole-cell current normalised against cell capacitance (pA/pF) 
at -40 mV for cells expressing TASK-1_WT in control conditions and IBMX (100 µM). 
B) Current-voltage plot of TASK-1_WT in both control conditions (black line) and 
IBMX (100 µM, grey line) recorded over a voltage ramp from -120 mV to +20 mV. 
 
 
4.4.3 Effect of combining Sildenafil and IBMX on TASK-1_WT 
As sildenafil (10 µM) significantly increased TASK-1_WT current whereas 
IBMX (100 µM) did not, investigating the combination of both compounds and 
its effect on TASK-1_WT was the next approach. The combination of the two 
compounds failed to significantly alter TASK-1_WT outward current at -40 mV 
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(p > 0.05, unpaired t-test, Figure 4.22). In control conditions at -40 mV, TASK-
1_WT outward current measured was 7 ± 1 pA/pF (n = 16) and after incubation 
with sildenafil (10 µM) and IBMX (100 µM) was 8 ± 1 pA/pF (n = 17). 
Interestingly the addition of IBMX (100 µM) abolished the enhancing effects of 
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Figure 4.22 – Effect of Sildenafil (10 µM) + IBMX (100 µM) on TASK-1_WT 
A) Measurements of whole-cell current normalised against cell capacitance (pA/pF) 
at -40 mV for cells expressing TASK-1_WT in control conditions and sildenafil (10 
µM) + IBMX (100 µM). B) Current-voltage plot of TASK-1_WT in both control 
conditions (black line) and sildenafil (10 µM) + IBMX (100 µM, grey line) recorded 




4.4.4 Action of IBMX and Forskolin combination upon TASK-1_WT 
Previous work conducted in our lab has shown that the combination of IBMX 
(100 µM) and forskolin (10 µM) on mouse concatamers of TASK-1 and TASK-
3 has the ability to enhance outward current (appendix 6.10). In human TASK-
1_WT channels the combination of IBMX (100 µM) and forskolin (10 µM) 
significantly enhanced TASK-1_WT current in a similar fashion to the mouse 
Chapter 4.  Action of PAH Therapeutic Agents on K2P Channels 146 
 
concatamers (p < 0.05, unpaired t-test, Figure 4.23). After 20 minutes 
incubation with IBMX (100 µM) and forskolin (10 µM) TASK-1_WT outward 
currents at -40 mV were 14 ± 2 pA/pF (n = 21) compared to 6 ± 1 pA/pF (n = 
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Figure 4.23 – Effect of IBMX (100 µM) + Forskolin (10 µM) on TASK-1_WT 
A) Measurements of whole-cell current normalised against cell capacitance (pA/pF) 
at -40 mV for cells expressing TASK-1_WT in control conditions and IBMX (100 µM) 
+ Forskolin (10 µM). B) Current-voltage plot of TASK-1_WT in both control conditions 
(black line) and IBMX (100 µM) + Forskolin (10 µM, grey line) recorded over a voltage 





4.4.5 Effect of Riociguat on TASK-1 WT and Novel Mutations 
Cells expressing TASK-1_WT were incubated in the soluble guanylyl cyclase 
stimulator, riociguat (10 µM), for 20 minutes prior to electrophysiological 
experiments. The incubation in riociguat (10 µM) significantly increased the 
outward current of TASK-1_WT measured at -40 mV, 11 ± 2 pA/pF (n = 17) 
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compared to 6 ± 1 pA/pF (n = 19) in control conditions (p < 0.05, unpaired t-
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Figure 4.24 – Effect of Riociguat (10 µM) on TASK-1_WT 
A) Measurements of whole-cell current normalised against cell capacitance (pA/pF) 
at -40 mV for cells expressing TASK-1_WT in control conditions and riociguat (10 
µM). B) Current-voltage plot of TASK-1_WT in both control conditions (black line) and 






The reduced outward current at -40 mV through TASK-1_G106R channels 
could not be significantly increased after incubation with riociguat (10 µM) with 
currents measured at 2 ± 1 pA/pF (n = 15) compared to 3 ± 1 pA/pF (n = 19) 
in control conditions (p < 0.05,  unpaired t-test, Figure 4.25). 
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Figure 4.25 – Effect of Riociguat (10 µM) on TASK-1_G106R 
A) Measurements of whole-cell current normalised against cell capacitance (pA/pF) 
at -40 mV for cells expressing TASK-1_G106R in control conditions and riociguat (10 
µM). B) Current-voltage plot of TASK-1_G106R in both control conditions (black line) 









Similarly to TASK-1_G106R, TASK-1_L214R also had no significant outward 
current change at -40 mV after incubation with riociguat (10 µM, Figure 4.26). 
In control conditions, TASK-1_L214R outward currents at -40 mV were 
measured as 2 ± 1 pA/pF (n = 15) and 2 ± 1 pA/pF (n = 19). 
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Figure 4.26 – Effect of Riociguat (10 µM) on TASK-1_L214R 
A) Measurements of whole-cell current normalised against cell capacitance (pA/pF) 
at -40 mV for cells expressing TASK-1_L214R in control conditions and riociguat (10 
µM). B) Current-voltage plot of TASK-1_L214R in both control conditions (black line) 







4.5 Results: Effect of Treprostinil on TASK-1, TREK-
1 and TREK-2 K2P channels 
 
Treprostinil, a synthetic prostacyclin analogue, targets a different pathway (the 
prostacyclin pathway) in PAH, compared to compounds previously explored 
within this study. Vasodilatory tests are used to determine how pulmonary 
blood vessels respond to treatments, it also helps with determining prognosis 
for patients. As treprostinil has been shown to exceed vasodilatory testing 
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predictions, it may have additional mechanisms of action, such as targeting 
and enhancing TASK-1 current (Clapp and Gurung, 2015).  
 
4.5.1 Effect of Acute Application of Treprostinil on TASK-1_WT 
To assess whether treprostinil has a direct effect on the TASK-1_WT channel, 
treprostinil (100 nM) was acutely applied and yielded no significant change in 
TASK-1_WT outward current when measured at -40 mV (p > 0.05, paired t-
test, Figure 4.27). TASK-1_WT current at -40 mV in the presence of treprostinil 
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Figure 4.27 – Effect of Acutely Applied Treprostinil (100 nM) on TASK-1_WT 
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A) Measurements of whole-cell current normalised against cell capacitance (pA/pF) 
at -40 mV for cells expressing TASK-1_WT in control conditions and treprostinil (100 
nM). B) Current-voltage plot of TASK-1_WT in both control conditions (black line) and 
treprostinil (100 nM, grey line) recorded over a voltage ramp from -120 mV to +20 
mV. C) Time course graph showing TASK-1_WT outward current at -40 mV under 
the influence of treprostinil (100 nM). Treprostinil (100 nM) application is represented 





A 10-fold increase in treprostinil concentration to 1 µM, also had no significant 
effect on TASK-1_WT outward current (p > 0.05, paired t-test, Figure 4.28). In 
control conditions TASK-1_WT currents were measured at 6 ± 2 pA/pF (n = 5) 
and after acute application of treprostinil (1 µM) at 6 ± 1 pA/pF (n = 5).  
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Figure 4.28 – Effect of Acutely Applied Treprostinil (1 µM) on TASK-1_WT 
A) Measurements of whole-cell current normalised against cell capacitance (pA/pF) 
at -40 mV for cells expressing TASK-1_WT in control conditions and treprostinil (1 
µM). B) Current-voltage plot of TASK-1_WT in both control conditions (black line) and 
treprostinil (1 µM, grey line) recorded over a voltage ramp from -120 mV to +20 mV. 
C) Time course graph showing TASK-1_WT outward current at -40 mV under the 
influence of treprostinil (1 µM). Treprostinil (1 µM) application is represented at the 
grey bar, absence of the grey bar represents control conditions. 
A further 10-fold increase in treprostinil concentration to 10 µM also had no 
significant effect on TASK-1_WT outward current (p > 0.05, paired t-test, 
Figure 4.29). Under acute application with treprostinil (10 µM), TASK-1_WT 
outward current measured at -40 mV was 12 ± 2 pA/pF (n = 5) compared to 
13 ± 3 pA/pF (n = 5) in control conditions.  
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Figure 4.29 – Effect of Acutely Applied Treprostinil (10 µM) on TASK-1_WT 
A) Measurements of whole-cell current normalised against cell capacitance (pA/pF) 
at -40 mV for cells expressing TASK-1_WT in control conditions and treprostinil (10 
µM). B) Current-voltage plot of TASK-1_WT in both control conditions (black line) and 
treprostinil (10 µM, grey line) recorded over a voltage ramp from -120 mV to +20 mV. 
C) Time course graph showing TASK-1_WT outward current at -40 mV under the 
influence of treprostinil (10 µM). Treprostinil (10 µM) application is represented at the 
grey bar, absence of the grey bar represents control conditions. 
4.5.2 Effect of Treprostinil Pre-Incubation on TASK-1_WT 
As treprostinil appeared to have no direct action upon TASK-1_WT channels 
across a range of concentrations, investigation into whether treprostinil had an 
effect signalling pathways, which affect TASK-1_WT outward current was 
conducted by incubation with treprostinil. Incubation with treprostinil (1 µM), 
as described in the section 2.3.1, significantly enhanced outward TASK-1_WT 
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current at -40 mV being 11 ± 1 pA/pF (n = 15) compared to 7 ± 1 (n = 17) in 
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Figure 4.30 – Effect on TASK-1_WT due to incubation with Treprostinil (1 µM) 
A) Measurements of whole-cell current normalised against cell capacitance (pA/pF) 
at -40 mV for cells expressing TASK-1_WT in control conditions and treprostinil (1 
µM). B) Current-voltage plot of TASK-1_WT in both control conditions (black line) and 
treprostinil (1 µM, grey line) recorded over a voltage ramp from -120 mV to +20 mV. 
C) Measurement of reversal potentials (mV) of cells expressing TASK-1_WT in 
control conditions and treprostinil (1 µM). Error bars represent SEM. D) 
Representation of a raw data trace of TASK-1_WT in control conditions (black line) 
and treprostinil (1 µM, grey line) under the step-ramp voltage protocol. 
 
4.5.3 Co-expression of TASK-1_WT with Prostanoid Receptors 
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As our data suggests that, treprostinil can activate TASK-1_WT is an 
undetermined manner, it would suggest that it acts through an alternative 
secondary messenger-mediated pathway. We investigated whether the 
expression of prostanoid receptors (DP2, EP2 and IP) has an effect on TASK-
1_WT channel functionality and its response to treprostinil. When co-
expressed with the prostanoid receptor DP2, TASK-1_WT outward current was 
not significantly altered (p > 0.05, one-way ANOVA, Figure 4.31). TASK-1_WT 
only outward current at -40 mV was measured at 6 ± 1 pA/pF (n = 22) and co-
expression with DP2 did not significantly affect current at 11 ± 2 pA/pF (n = 
11). In contrast, co-expression with the EP2 receptor significantly increased 
TASK-1_WT outward current with values of 11 ± 1 pA/pF (n = 23; p < 0.05, 
one-way ANOVA, Figure 4.31). Similarly to DP2, co-expression of TASK-1_WT 
with IP receptor did not yield a significant change in outward current at -40 mV, 
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Figure 4.31 – Co-expression of prostanoid receptors DP2, EP2 and IP with TASK-
1_WT 
A) Measurements of whole-cell current normalised against cell capacitance (pA/pF) 
at -40 mV for cells expressing TASK-1_WT (black), TASK-1_WT + DP2 (red), TASK-
1_WT + EP2 (green) or TASK-1_WT + IP (blue). Error bars represent the SEM. B) 
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Representation of a raw data trace of TASK-1_WT (black line), TASK-1_WT + DP2 
(red line), TASK-1_WT + EP2 (green line) and TASK-1_WT + IP (blue line) under the 











4.5.4 Effect of Treprostinil Pre-Incubation on TASK-1_WT Channels Co-
expressed with Prostanoid Receptors  
Pre-incubation of cells expressing TASK-1_WT only with treprostinil (1 µM) 
lead to a significant increase in outward current measured at -40 mV (Figure 
4.30). With the co-expression of TASK-1_WT and DP2, pre-incubating cells 
with 20 minutes incubation in treprostinil (1 µM) did not significantly alter 
outward current measured at -40 mV (p > 0.05, unpaired t-test, Figure 4.32). 
In control conditions outward current values were 12 ± 4 pA/pF (n = 6) and 16 
± 4 pA/pF (n = 6) after incubation with treprostinil (1 µM).  
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Figure 4.32 – Effect of Treprostinil (1 µM) Pre-incubation on Co-expressed 
TASK-1_WT and DP2 receptor 
A) Measurements of whole-cell current normalised against cell capacitance (pA/pF) 
at -40 mV for cells expressing TASK-1_WT and DP2 receptor in control conditions 
and after 20 minutes incubation with treprostinil (1 µM). B) Current-voltage plot of 
TASK-1_WT and DP2 in both control conditions (black line) and after 20 minutes 
incubation with treprostinil (1 µM, grey line) recorded over a voltage ramp from -120 
mV to +20 mV. 
 
 
Co-expression of TASK-1_WT and EP2 receptor leads to an increase in TASK-
1_WT current compared to cells expressing only TASK-1_WT (Figure 4.31). 
This increased current could not be further enhanced with the pre-incubation 
of cells with treprostinil (1 µM). In control conditions TASK-1_WT and EP2 was 
measured at 12 ± 1 (n = 15) compared to 13 ± 2 (n = 16; p > 0.05, in treprostinil, 
unpaired t-test, Figure 4.33). 
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Figure 4.33 – Effect of Treprostinil (1 µM) Pre-incubation on Co-expressed 
TASK-1_WT and EP2 receptor 
A) Measurements of whole-cell current normalised against cell capacitance (pA/pF) 
at -40 mV for cells expressing TASK-1_WT and EP2 receptor in control conditions 
and after 20 minutes incubation with treprostinil (1 µM). B) Current-voltage plot of 
TASK-1_WT and EP2 in both control conditions (black line) and after 20 minutes 
incubation with treprostinil (1 µM, grey line) recorded over a voltage ramp from -120 






Similarly to the co-expression of TASK-1_WT with DP2 and EP2, the co-
expression of TASK-1_WT and IP receptor, could not be enhanced with pre-
incubation of treprostinil (1 µM). In control conditions outward currents 
measured at -40 mV were 8 ± 1 pA/pF (n = 15) and 7 ± 2 pA/pF (n = 16) after 
treprostinil treatment (p > 0.05, unpaired t-test, Figure 4.34). 
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Figure 4.34 – Effect of Treprostinil (1 µM) Pre-incubation on Co-expressed 
TASK-1_WT and IP receptor 
A) Measurements of whole-cell current normalised against cell capacitance (pA/pF) 
at -40 mV for cells expressing TASK-1_WT and IP receptor in control conditions and 
after 20 minutes incubation with treprostinil (1 µM). B) Current-voltage plot of TASK-
1_WT and IP in both control conditions (black line) and after 20 minutes incubation 








Analysis of co-expressed receptors with TASK-1_WT channels highlighted 
only a tonic increase in TASK-1_WT outward current when expressed with 
EP2 receptor (p < 0.05, two-way ANOVA, Figure 4.35). Pre-incubation of cells 
with treprostinil (1 µM), failed to significantly enhance cells co-expressing the 
prostanoid receptors (DP2, EP2 or IP).  
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Figure 4.35 – Measurement of TASK-1_WT current of cells co-expressed with 
prostanoid receptors following incubation with treprostinil (1 µM) 
A) Chart showing measurements of whole-cell current normalised against cell 
capacitance (pA/pF) at -40 mV for cells expressing TASK-1_WT either solo or with 
DP2, EP2 or IP receptor in control conditions and after 20 minutes incubation with 






4.5.5 Effect of Acute Application of Treprostinil on TASK-1_WT 
Channels Co-expressed with Prostanoid Receptors 
 
The effect of treprostinil (1 µM) when applied acutely had no effect upon TASK-
1_WT outward current measured at -40 mV (Figure 4.27-4.29). The co-
expression of prostanoid receptors changed the response of treprostinil (1 µM) 
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acute application on TASK-1_WT current in a receptor dependent manner. 
The co-expression of TASK-1_WT and DP2 receptor did not significantly alter 
outward current measured at -40 mV (p > 0.05, paired t-test, Figure 4.36). In 
control conditions, outward current was 10 ± 2 pA/pF (n = 5) and 10 ± 2 pA/pF 
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Figure 4.36 – Effect of Acute Application of Treprostinil (1 µM) on Co-expressed 
TASK-1_WT and DP2 receptor 
A) Measurements of whole-cell current normalised against cell capacitance (pA/pF) 
at -40 mV for cells expressing TASK-1_WT and DP2 in control conditions and 
treprostinil (1 µM). B) Current-voltage plot of TASK-1_WT and DP2 in both control 
conditions (black line) and treprostinil (1 µM, grey line) recorded over a voltage ramp 
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from -120 mV to +20 mV. C) Time course graph showing TASK-1_WT and DP2 
outward current at -40 mV under the influence of treprostinil (1 µM). Treprostinil (1 
µM) application is represented at the grey bar, absence of the grey bar represents 
control conditions. D) Representation of a raw data trace of TASK-1_WT and DP2  in 
both control conditions (black line) and treprostinil (1 µM, grey line) under the step-




Acute application of treprostinil (1 µM) significantly enhanced TASK-1_WT 
current when co-expressed with the EP2 receptor (p < 0.05, paired t-test, 
Figure 4.37). In control conditions, outward current of TASK-1_WT channels 
in cells expressing TASK-1_WT + EP2 was 7 ± 2 (n = 8) and after acute 
application of treprostinil (1 µM) was 9 ± 2 (n = 8).  
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Figure 4.37 – Effect of Acute Application of Treprostinil (1 µM) on Co-expressed 
TASK-1_WT and EP2 receptor 
A) Measurements of whole-cell current normalised against cell capacitance (pA/pF) 
at -40 mV for cells expressing TASK-1_WT and EP2 in control conditions and 
treprostinil (1 µM). B) Current-voltage plot of TASK-1_WT and EP2 in both control 
conditions (black line) and treprostinil (1 µM, grey line) recorded over a voltage ramp 
from -120 mV to +20 mV. C) Time course graph showing TASK-1_WT and EP2 
outward current at -40 mV under the influence of treprostinil (1 µM). Treprostinil (1 
µM) application is represented at the grey bar, absence of the grey bar represents 
control conditions. D) Representation of a raw data trace of TASK-1_WT and EP2  in 
both control conditions (black line) and treprostinil (1 µM, grey line) under the step-
ramp voltage protocol. 
 
Interestingly, co-expression of TASK-1_WT and IP receptor had the opposite 
effect to EP2 when exposed to acute application of treprostinil (1 µM) with a 
significant reduction in TASK-1_WT current (p < 0.05, paired t-test, Figure 
4.38). In control conditions, outward current of TASK-1_WT channels in cells 
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expressing TASK-1_WT + IP was 10 ± 2.6 (n = 6) and after acute application 
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Figure 4.38 – Effect of Acute Application of Treprostinil (1 µM) on Co-expressed 
TASK-1_WT and IP receptor 
A) Measurements of whole-cell current normalised against cell capacitance (pA/pF) 
at -40 mV for cells expressing TASK-1_WT and IP in control conditions and 
treprostinil (1 µM). B) Current-voltage plot of TASK-1_WT and IP in both control 
conditions (black line) and treprostinil (1 µM, grey line) recorded over a voltage ramp 
from -120 mV to +20 mV. C) Time course graph showing TASK-1_WT and IP outward 
current at -40 mV under the influence of treprostinil (1 µM). Treprostinil (1 µM) 
application is represented at the grey bar, absence of the grey bar represents control 
conditions. D) Representation of a raw data trace of TASK-1_WT and IP
 
 in both 
control conditions (black line) and treprostinil (1 µM, grey line) under the step-ramp 
voltage protocol. 
 
4.5.6 Action of Treprostinil on TREK-1 and TREK-2 
Patients undergoing treprostinil therapy often experience severe site pain at 
the infusion site. We investigated if TREK-1 and TREK-2 channels, which are 
capable of regulating sensory neuron excitability, are affected by treprostinil 
treatment.  
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4.5.6.1 Electrophysiological characterisation of TREK-1 WT 
hTREK-1 WT DNA was transiently transfected in tsA201 cells and used for 
whole-cell patch-clamp recordings. The application of the step-ramp voltage 
protocol (Figure 2.6) previously described elicited TREK-1 electrophysiological 
characteristics (Figure 4.39). TREK-1_WT current was measured from the 
current values given when at -40 mV.  
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Figure 4.39 – TREK-1_WT electrophysiological profile. 
A) Representative trace for TREK-1_WT channel in control conditions exposed to the 
step-ramp voltage protocol detailed in the methods. B) Current-voltage graph for 
TREK-1_WT in control conditions. 
 
The electrophysiological profile for TREK-1_WT in extracellular solution (2.5 
mM K+, pH 7.4, see methods 2.3.3) yielded an average whole-cell current of 
40 ± 4 pA/pF (n = 23) with an average reversal potential of -93 ± 1 mV (n = 
23). 
4.5.6.2 Acute Application of Treprostinil on TREK-1_WT 
Acute application of treprostinil (1 µM) on cells expressing TREK-1_WT 
channels generated a reversible, potent inhibitory effect on TREK-1_WT 
outward current measured at -40 mV. TREK-1_WT current was significantly 
reduced from 33 ± 8 pA/pF (n = 5) in control conditions to 6 ± 3 pA/pF (n = 5) 
in treprostinil (1 µM; p < 0.05, paired t-test, Figure 4.40).  
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Figure 4.40 – Effect of Acute Application of Treprostinil (1 µM) TREK-1_WT 
A) Measurements of whole-cell current normalised against cell capacitance (pA/pF) 
at -40 mV for cells expressing TREK-1_WT in control conditions and treprostinil (1 
µM). B) Current-voltage plot of TREK-1_WT in both control conditions (black line) and 
treprostinil (1 µM, grey line) recorded over a voltage ramp from -120 mV to +20 mV. 
C) Time course graph showing TREK-1_WT outward current at -40 mV under the 
influence of treprostinil (1 µM). Treprostinil (1 µM) application is represented at the 
grey bar, absence of the grey bar represents control conditions. D) Representation of 
a raw data trace of TREK-1_WT in both control conditions (black line) and treprostinil 
(1 µM, grey line) under the step-ramp voltage protocol. 
 
A 10-fold reduction in treprostinil to a concentration of 0.1 µM still resulted in 
a significant reversible, potent inhibition of TREK-1_WT current (p < 0.05, 
paired t-test, Figure 4.41). TREK-1_WT current was significantly reduced from 
43 ± 5 pA/pF (n = 5) in control conditions to 13 ± 4 pA/pF (n = 5) in treprostinil 
(0.1 µM).  
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Figure 4.41 – Effect of Acute Application of Treprostinil (0.1 µM) TREK-1_WT 
A) Measurements of whole-cell current normalised against cell capacitance (pA/pF) 
at -40 mV for cells expressing TREK-1_WT in control conditions and treprostinil (0.1 
µM). B) Current-voltage plot of TREK-1_WT in both control conditions (black line) and 
treprostinil (0.1 µM, grey line) recorded over a voltage ramp from -120 mV to +20 mV. 
C) Time course graph showing TREK-1_WT outward current at -40 mV under the 
influence of treprostinil (0.1 µM). Treprostinil (1 µM) application is represented at the 
grey bar, absence of the grey bar represents control conditions. D) Representation of 
a raw data trace of TREK-1_WT in both control conditions (black line) and treprostinil 
(0.1 µM, grey line) under the step-ramp voltage protocol 
Two further concentrations of treprostinil, 0.03 µM and 0.01 µM were 
investigated. Acute application of treprostinil (0.03 µM) significantly reduced 
TREK-1_WT current (control: 47 ± 11 pA/pF, n = 7 and treprostinil 0.03 µM: 
31 ± 9, n = 7; p < 0.05, paired t-test, Figure 4.42A and B) whereas 0.01 µM 
failed to do so (control: 34 ± 6 pA/pF, n = 5 and treprostinil 0.01 µM: 32 ± 5, n 
= 5; p > 0.05, paired t-test, Figure 4.42 C and D). Concentration-response 
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curve was fitted revealing an IC50 value of 0.03 µM for treprostinil on TREK-
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Figure 4.42 – Effect of Acute Application of Treprostinil on TREK-1_WT 
A) Measurements of whole-cell current normalised against cell capacitance (pA/pF) 
at -40 mV for cells expressing TREK-1_WT in control conditions and treprostinil (0.03 
µM). B) Current-voltage plot of TREK-1_WT in both control conditions (black line) and 
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treprostinil (0.03 µM, grey line) recorded over a voltage ramp from -120 mV to +20 
mV. C) Measurements of whole-cell current normalised against cell capacitance 
(pA/pF) at -40 mV for cells expressing TREK-1_WT in control conditions and 
treprostinil (0.01 µM). D) Current-voltage plot of TREK-1_WT in both control 
conditions (black line) and treprostinil (0.01 µM, grey line) recorded over a voltage 
ramp from -120 mV to +20 mV. E) concentration-response plot for treprostinil 
inhibition on TREK-1_WT current. Error bars represent SEM. 
 
4.5.6.3 Electrophysiological characterisation of TREK-2 WT 
Like TREK-1 channels, TREK-2 channels have been shown to play a role in 
sensory neuron pain signalling, therefore we looked at treprostinil on TREK-2 
channels. hTREK-2 WT DNA was transiently transfected in tsA201 cells and 
used for whole-cell patch-clamp recordings. The application of the step-ramp 
voltage protocol (Figure 2.6), previously described, generated TREK-2 
electrophysiological characteristics (Figure 4.43). TREK-2_WT current was 
measured from the current values given when at -40 mV.  
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Figure 4.43 – TREK-2_WT electrophysiological profile. 
A) Representative trace for TREK-2_WT channel in control conditions exposed to the 
step-ramp voltage protocol detailed in the methods. B) Current-voltage graph for 
TREK-2_WT in control conditions. 
 
The electrophysiological profile for TREK-2_WT in extracellular solution (2.5 
mM K+, pH 7.4, see methods 2.3.3) yielded an average whole-cell current of 
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55 ± 10 pA/pF (n = 22) with an average reversal potential of -89 ± 1 mV (n = 
22). 
 
4.5.6.4 Acute Application of Treprostinil on TREK-2_WT 
Acute application of treprostinil (1 µM) on cells expressing TREK-2_WT 
channels generated a reversible, potent inhibitory effect on TREK-2_WT 
outward current measured at -40 mV. TREK-2_WT current was significantly 
reduced from 38 ± 6 pA/pF (n = 5) in control conditions to 17 ± 5 pA/pF (n = 5) 
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Figure 4.44 – Effect of Acute Application of Treprostinil (1 µM) TREK-2_WT 
A) Measurements of whole-cell current normalised against cell capacitance (pA/pF) 
at -40 mV for cells expressing TREK-2_WT in control conditions and treprostinil (1 
µM). B) Current-voltage plot of TREK-2_WT in both control conditions (black line) and 
treprostinil (1 µM, grey line) recorded over a voltage ramp from -120 mV to +20 mV. 
C) Time course graph showing TREK-2_WT outward current at -40 mV under the 
influence of treprostinil (1 µM). Treprostinil (1 µM) application is represented at the 
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grey bar, absence of the grey bar represents control conditions. D) Representation of 
a raw data trace of TREK-2_WT in both control conditions (black line) and treprostinil 
(1 µM, grey line) under the step-ramp voltage protocol. 
 
A 10-fold reduction in treprostinil to a concentration of 0.1 µM still resulted in 
a significant reversible, potent inhibition of TREK-2_WT current (p < 0.05, 
paired t-test, Figure 4.45). TREK-2_WT current was significantly reduced from 
88 ± 29 pA/pF (n = 5) in control conditions to 57 ± 25 pA/pF (n = 5) in treprostinil 
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Figure 4.45 – Effect of Acute Application of Treprostinil (0.1 µM) TREK-2_WT 
A) Measurements of whole-cell current normalised against cell capacitance (pA/pF) 
at -40 mV for cells expressing TREK-2_WT in control conditions and treprostinil (0.1 
µM). B) Current-voltage plot of TREK-2_WT in both control conditions (black line) and 
treprostinil (0.1 µM, grey line) recorded over a voltage ramp from -120 mV to +20 mV. 
C) Time course graph showing TREK-2_WT outward current at -40 mV under the 
influence of treprostinil (0.1 µM). Treprostinil (1 µM) application is represented at the 
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grey bar, absence of the grey bar represents control conditions. D) Representation of 
a raw data trace of TREK-2_WT in both control conditions (black line) and treprostinil 
(0.1 µM, grey line) under the step-ramp voltage protocol. 
Two further concentrations of treprostinil, 0.03 µM and 0.01 µM were 
investigated. Acute application of treprostinil (0.03 µM) significantly reduced 
TREK-2_WT current (control: 41 ± 14 pA/pF, n = 6 and treprostinil 0.03 µM: 
34 ± 12, n = 6; p < 0.05, paired t-test, Figure 4.46A and B) whereas 0.01 µM 
failed to do so (control: 49 ± 11 pA/pF, n = 5 and treprostinil 0.01 µM: 43 ± 11, 
n = 5; p > 0.05, paired t-test, Figure 4.46 C and D). Concentration-response 
curve was fitted revealing an IC50 value of 0.04 µM for treprostinil on TREK-
2_WT current (Figure 4.46E). 
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Figure 4.46 – Effect of Acute Application of Treprostinil on TREK-2_WT 
A) Measurements of whole-cell current normalised against cell capacitance (pA/pF) 
at -40 mV for cells expressing TREK-2_WT in control conditions and treprostinil (0.03 
µM). B) Current-voltage plot of TREK-2_WT in both control conditions (black line) and 
treprostinil (0.03 µM, grey line) recorded over a voltage ramp from -120 mV to +20 
mV. C) Measurements of whole-cell current normalised against cell capacitance 
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(pA/pF) at -40 mV for cells expressing TREK-2_WT in control conditions and 
treprostinil (0.01 µM). D) Current-voltage plot of TREK-2_WT in both control 
conditions (black line) and treprostinil (0.01 µM, grey line) recorded over a voltage 
ramp from -120 mV to +20 mV. E) concentration-response plot for treprostinil 
inhibition on TREK-2_WT current. Error bars represent SEM. 
 
4.5.6.5 Effect of Acute Application of Treprostinil on TREK-1_Δ1-41 
To assess whether N-terminus plays a role in treprostinil inhibition we studied 
TREK-1_Δ1-41, where the first 41 amino acids of the N-terminus are removed. 
Similar to previous literature, TREK-1_Δ1-41 showed a significantly reduced 
current compared to TREK-1_WT (p < 0.05, unpaired t-test, Figure 4.47; Veale 
et al., 2010). TREK-1_Δ1-41 had an outward current of 2.2 ± 0.7 pA/pF (n = 
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Figure 4.47 - TREK-1_Δ1-41 Electrophysiological Profile Compared to TREK-
1_WT 
A) Measurement of whole-cell current normalised against cell capacitance (pA/pF) at 
-40 mV for cells expressing TREK-1_WT or TREK-1_Δ1-41. B) Current-voltage plot 
of TREK-1_WT (black line) and TREK-1_Δ1-41 (grey line) in control conditions 
recorded over a voltage ramp from -120 mV to +20 mV. 
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As acute application of treprostinil (1 µM) potently inhibited TREK-1_WT, we 
investigated whether acute application of treprostinil (1 µM) had an inhibitory 
effect upon the already significantly reduced current of TREK-1_Δ1-41 
channels. TREK-1_Δ1-41 current measured at -40 mV was significantly 
reduced in the presence of treprostinil (1 µM) with values of 2 ± 1 pA/pF (n = 
5) compared to 0 ± 1 pA/pF (n = 5) in control conditions (p < 0.05, paired t-
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Figure 4.48 – Inhibitory Effect of Acute Application of Treprostinil (1 µM) on 
TREK-1_Δ1-41 
A) Measurements of whole-cell current normalised against cell capacitance (pA/pF) 
at -40 mV for cells expressing TREK-1_Δ1-41 in control conditions and treprostinil (1 
µM). B) Current-voltage plot of TREK-1_Δ1-41 in both control conditions (black line) 
and treprostinil (1 µM, grey line) recorded over a voltage ramp from -120 mV to +20 
mV. C) Time course graph showing TREK-1_Δ1-41 outward current at -40 mV under 
the influence of treprostinil (1 µM). Treprostinil (1 µM) application is represented at 
the grey bar, absence of the grey bar represents control conditions. D) 
Representation of a raw data trace of TREK-1_Δ1-41 in both control conditions (black 
line) and treprostinil (1 µM, grey line) under the step-ramp voltage protocol. 
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4.6 Discussion 
TASK-1 has been indicated as the major TASK channel present in human 
PASMCs and the main regulator of PASMCs excitability (Olschewski et al., 
2006). A reduction in TASK-1 expression and function has been suggested as 
a key event in the pathogenesis of PAH (Antigny et al., 2016). The 
phospholipase A2 inhibitor, ONO-RS-082, has been shown to treat PAH in rat 
models by reversing inflammation, proliferation and vasoconstriction (Antigny 
et al., 2016). In addition to this, two TASK-1 mutations (T8K and E182K) 
known to cause PAH were able to have channel current partially recovered 
with ONO-RS-082 treatment, further pinpointing TASK-1 importance in PAH 
in patients (Ma et al., 2013). To address the role of TASK-1 in PAH it was 
essential to characterise the novel homozygous mutations (G106R and 
L214R) identified within patients of aggressive PAH. 
In this study, it has been shown that the two novel mutations of TASK-1 
produce a significant reduction in their outward currents, compared to the wild-
type. The clear reduction in TASK-1 channel currents seen in the mutated 
channels were not found to be caused by trafficking or translation of the 
channel to the membrane, as imaging and quantification experiments showed 
equal distribution between mutant and WT channels at the membrane. This 
indicates the mutations affect the structural and functional properties of the 
TASK-1 channel to reduce current. Both pathogenic mutations are located 
extracellularly on the channel. G106R between the first pore and the second 
transmembrane domain and L214R being located between the second P 
domain and fourth transmembrane domain. In both cases an arginine 
substitution occurs, which is a large, positively charged, hydrophilic amino 
acid. In G106R, the glycine residue is a small, uncharged amino acid and in 
L214R the leucine is a small, hydrophobic amino acid. It has previously been 
suggested that within TASK-1 channels the arrangement of the histidine at 
amino acid 98 (H98) and the aspartic acid at 204 (D204) in both subunits is 
vital not only for pH sensing but for the channel to function as a selective K+ 
channel (Yuill et al., 2004). It is thought that D204 optimises TASK-1 sensitivity 
to pH changes by providing a more optimal conformation, within the selectivity 
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pathway opposed to a direct pH sensor as in the case of H98. The H98-D204-
H98-D204 ring is situated at the mouth of the selectivity filter. Both G106R and 
L214R lie close to this ring and an arginine replacement may alter the optimal 
structure causing a blockade of the selectivity filter due to the increased 
residue size. It may be that the arginine substitution creates a structure that 
closes off the selectivity filter, preventing ion flow through the channel. As both 
H98 and D204 play a role in TASK-1 pH sensing, disruption to their structure 
through either the G106R or L214R mutation may explain the loss in sensitivity 
to alkalosis observed. 
Enhancement of the current through the mutant channels, G106R and L214R, 
could not be achieved with ONO-RS-082 (10 µM) as seen in previous 
mutations (Ma et al., 2013). This may be due to the closure of the selectivity 
filter, as previously suggested, meaning the enhancing effects of ONO-RS-
082 does not alter channel structure sufficiently to open the selectivity filter in 
these mutations. It must be noted that not all mutations previously treated with 
ONO-RS-082 were able to be recovered such as the mutation G203D (Ma et 
al., 2013). Furthermore, we were unable to replicate the enhancement seen 
for TASK-1_E182K with ONO-RS-082 (10 µM). This may be due to the current 
being measured at -40 mV, rather than +60 mV, as in Ma et al., 2013. To 
investigate the current at more positive voltages, where you see a contribution 
from endogenous voltage-gated Kv channels, we used TEA, which K2P 
channels are insensitive to. Application of TEA (10 mM) abolished current at 
positive voltages and identified that this current was due to the presence of 
endogenous Kv channels present within the tsA201 cells (Jiang et al., 2002). 
With our data despite a reduction in current seen at +20 mV with the novel 
mutations, with the cells expressing TASK-1_WT only no inhibition at +20 mV 
was observed, this may be due to the presence of TASK-1 dominating the +20 
mV current and the Kv current change being too small in comparison. It could 
be suggested that the current seen in the previous study with TASK-1_E182K 
may be due to the endogenous channels within the cells, as the cell line used 
in the study, COS-7, cells have been shown to express endogenous potassium 
channels (Kang et al., 2006). Also the reversal potentials of the mutations, T8K 
and E182K, were shifted close to 0 mV suggesting the where the channel does 
Chapter 4.  Action of PAH Therapeutic Agents on K2P Channels 178 
 
not carry current, other non-selective leak currents dominate and shift the 
reversal potential towards 0 mV which could indicate the enhancement may 
be an enhancement of a non-potassium current, therefore ONO-RS-082 
therapy may only exacerbate symptoms caused by the mutations in PAH 
patients (Ma et al., 2013).  
One key feature of the two novel mutations, G106R and L214R, were that both 
reversal potentials were significantly shifted towards 0 mV. This suggests that 
in patients this shift in reversal potentials could lead to a depolarisation of the 
pulmonary artery and resultant vasoconstriction. Depolarised membrane 
potentials has been observed in PASMCs of PAH rat models (Antigny et al., 
2016). The shift in reversal potential suggests a reduction in K+ ion selectivity, 
of the channels however further experiments from within the lab indicated a 
reduction in permeability to a number of ions (Appendix 6.11 and 6.12). This 
reduction further suggests a structural block of the channel pore caused by 
these novel mutations.  
 
Another possibility as to why ONO-RS-082 was effective on mutations seen 
previously but not in this study, may be due to the hetero or homogeneity of 
the mutation (Ma et al., 2013). Both novel mutations G106R and L214R are 
homozygous and display a very aggressive form of PAH, the first to be 
reported within PAH patients (Navas et al., 2017). It has been suggested that 
the dimerization of TASK channels leads to the lung-specific phenotypes 
observed within PAH patients with KCNK3 mutations (Bohnen et al., 2017). 
TASK-3 is not expressed within human lung PASMC and a patient with 
heterozygous mutation of PAH will express a combination of three isoforms of 
TASK-1 within the lungs – TASK-1_WT/TASK-1_WT, TASK-
1_mutated/TASK-1_WT and TASK-1_mutated/TASK-1_mutated. Whereas 
outside of the lungs where TASK-3 is expressed, TASK-1 can further dimerize 
with TASK-3 allowing two further TASK-1 dimers – TASK-1_WT/TASK-3_WT 
and TASK-1_mutated/TASK-3_WT. The increased diversity of TASK-1 
outside of the lungs, in tissues such as carotid bodies and atrial 
cardiomyocytes may provide protection to TASK-1 dysfunction (Bohnen et al., 
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2017; Kim et al., 2009; Rinne et al., 2015). With this in mind only homozygous 
mutated TASK-1 channels would be expressed within the lungs, but in other 
tissues, there could be heterozygous channel expression through 
heterodimerisation. This may explain the aggressive nature of the disease 
seen within homozygous carrying patients (Navas et al., 2017). The initial 
study on TASK-1_E182K appears to present the heterozygous mutation as 
having the ability to recover current in the presence of ONO-RS-082 when 
expressed in a homozygous manner (Ma et al., 2013). A further study from the 
same group provided supplementary data showing homozygous expression 
of TASK-1_E182K could not be enhanced by ONO-RS-082 however a forced 
concatamer expressing TASK-1_WT/TASK-1_E182K was able to be (Bohnen 
et al., 2017). This indicates further that in the initial study it may not have been 
clear that they co-expressed TASK-1_WT cDNA and TASK-1_E182K with the 
action of ONO-RS-082 acting on the WT subunit of the channel (Ma et al., 
2013). 
Sildenafil is a PDE5 inhibitor that promotes an increase in intracellular levels 
of cGMP. Originally developed to treat angina, it was noted to have a greater 
therapeutic effect in treating erectile dysfunction (Boolell et al., 1996). The 
increase in cGMP levels leads to an increase in PKG activation which in turn 
acts to reduce intracellular Ca2+ levels and inhibit smooth muscle contraction 
(Ghofrani et al., 2017). Activation of PKG has been previously described to 
upregulate TASK-1 channel activity within the brain by altering the Kd values 
required for protonation of the H98 residue (Toyoda et al., 2010). As PDE5 
levels are high within the lungs, almost equal to that in the penile corpus 
cavernosum, sildenafil was proposed as a possibly treatment for PAH (Corbin 
et al., 2005). This study indicates for the first time that sildenafil enhances 
current through WT TASK-1 channels and this may contribute to the beneficial 
effects seen within PAH therapy. Sildenafil had no effect on the novel 
mutations, G106R and L214R, nor did it have an effect on TASK-1_E182K 
current. This may mean that sildenafil use could be strategized in PAH 
therapy. Despite this study showing it had no effect upon TASK-1_E182K it 
may be that sildenafil will still provide some therapeutic benefit through TASK-
1 current activation when expressed in a heterozygous manner. Depending on 
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whether the primary therapeutic action of sildenafil is generated through the 
action of TASK-1 channels or whether TASK-1 activation is a beneficial 
secondary action of sildenafil, would be critical to strategizing sildenafil 
treatment. If TASK-1 current activation is the primary action of sildenafil it may 
be that alternative therapies would prove more beneficial to PAH patients 
carrying the G106R or L214R mutation.  
Similarly to sildenafil this study shows that, for the first time that riociguat acts 
in the same manner, enhancing TASK-1_WT currents but failing to have an 
effect on the novel mutated channels. Riociguat acts along the same pathway 
as sildenafil by stimulating soluble guanylyl cyclase and promoting PKG 
activation through increased intracellular levels of cGMP and inhibiting smooth 
muscle cell contraction (Ghofrani et al., 2017). Once again, it may be that 
riociguat could be tailored for patients as suggested above (with sildenafil) that 
if TASK-1 activation was the main source of therapeutic benefit, alternative 
therapies may provide a better outcome for PAH patients carrying the G106R 
or L214R mutation. A previous study looking into cGMP and TASK-1 activation 
has indicated TASK-1 is not activated by the NO/cGMP pathway. However, in 
that study the duration of 8-Br-cGMP application is not stated (Lloyd et al., 
2009). A more recent study has shown PKG-loaded HEK293 cells had 
enhanced TASK-1 WT current at pH 7.3, similarly to the application of riociguat 
and sildenafil in this study, further indicating a role of PKG in TASK-1 WT 
regulation (Toyoda et al., 2010).  
IBMX was used experimentally as it non-selectively targets multiple PDE’s, 
IBMX failed to enhance WT TASK-1 current indicating that the wide range of 
PDE’s IBMX targets, may reduce its efficacy on PDE’s that affect TASK-1 
channel current. IBMX has been shown to increase both cAMP and cGMP 
levels and activate PKA and PKG respectively (Yamaki et al., 1992). 
Interestingly, combining IBMX with sildenafil abolished the enhancement seen 
with sildenafil treatment on its own. The eradication of sildenafil’s effect on 
TASK-1_WT when combined with IBMX suggests the possibility that inhibition 
of an alternative PDE that IBMX inhibits may counteract the effect of sildenafil. 
Sildenafil has been shown to have an IC50 value of 3.6 nM on human PDE5 
compared to IBMX with 5.7 µM (Wang et al., 2001). Another possibility may 
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be that where sildenafil selectively targets PDE5, IBMX although a PDE 
inhibitor, may competitively block sildenafil on PDE5 and exert a less potent 
effect, reducing enhancement seen through sildenafil treatment alone.  
Interestingly, IBMX combined with the adenylyl cyclase activator, Forskolin, 
increased TASK-1_WT current. Previous work within the lab showed that 
concatamers of mouse TASK-1_WT with TASK-3_WT varied the response of 
IBMX and Forskolin to channel current based on the orientation of the 
concatamer. Having the concatamer with the C-terminus of TASK-3 fused to 
TASK-1 at the N-terminus results in IBMX and Forskolin enhancing the 
channel current whereas the reverse formation leads to an inhibition of 
channel current (Appendix 6.10). Forskolin and IBMX applied individually had 
no effect on the construct with TASK-1 at the N-terminus (Appendix 6.9). This 
suggests the arrangement of heterodimers has a significant effect on the 
response of channels to compounds, this has been shown in previous work by 
Cotton et al., 2006, where different arrangement of TASK-1 and TASK-3 have 
a varied response to doxapram inhibition and also in Blin et al., 2016 with 
TREK-1 and TREK-2 heterodimers exhibiting different pharmacological 
properties. These differences generated by subunit arrangement highlights the 
importance of the C-terminus. In the forced concatamers the availability of one 
C-terminus may be lower due to the first having its C-terminus fused to the N-
terminus of the second subunit. In vivo, heterodimers may act differently, as 
both C-termini should be available for interaction (Czirjak and Enyedi, 2002). 
In both TASK-1 and TASK-3, phosphorylation of serine residues (Serine 393 
and Serine 373 for TASK-1 and TASK-3 respectively) in the ‘trafficking control 
region’ of the C-terminus is critical in determining the ability of channel to be 
transported to the cell surface (Kilisch et al., 2016). Within the trafficking 
control region, the 14-3-3 binding domain and coat protein complex I (COPI) 
binding domain overlap. Binding of COPI to the COPI binding domain, within 
the C-terminus retains, TASK channels within the early secretory pathway 
(O’Kelly et al., 2002). Phosphorylation of the serine residues prevents COPI 
binding to a specific domain on the C-terminus. This enables the binding 
domain of 14-3-3 proteins to remain available for binding. Bound 14-3-3 
proteins facilitate the TASK-1 channels to leave the endoplasmic reticulum 
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(O’Kelly et al., 2002; Zuzarte et al., 2009). It has recently been identified that 
a second serine residue (S392) within the trafficking control region of TASK-1 
may have effects on channel surface expression. Whilst phosphorylation of 
S393 has been identified as promoting 14-3-3 binding, promoting cell surface 
expression. Phosphorylation of S392 is inhibitory to 14-3-3 binding, preventing 
cell surface expression of TASK-1 (Kilisch et al., 2016). TASK-1 C-terminus 
phosphorylation has been attributed to PKA, with both serine residues of the 
TASK-1 C-terminus having been shown to be phosphorylated by PKA In vitro. 
More recently, PKA has been shown to prevent COPI interaction even in the 
absence of 14-3-3, indicating its vital role in TASK-1 channel cell surface 
expression (Mant et al., 2011; Kilisch et al., 2016). It may be that the enhanced 
current seen in TASK-1_WT channels, after the application of IBMX and 
forskolin is due to an increase in channel surface expression following the 
activation of PKA. 
As an enhancement of PKA through the use of a combination of IBMX and 
forskolin increased TASK-1_WT channel current, treprostinil, a synthetic 
prostacyclin analogue which has been shown to enhance TASK-1_WT current 
through PKA activation in human PASMCs was investigated (Olschewski et 
al., 2006). I showed that acute application of treprostinil over a range of 
concentrations failed to enhance TASK-1_WT current, however incubation 
with treprostinil did enhance TASK-1_WT current. This difference in effect of 
treprostinil may be due to the incubation, enabling adequate time for PKA 
phosphorylation of TASK-1 to occur and a subsequent increase in cell surface 
expression of TASK-1 channels. A greater cell surface expression would result 
in higher current seen with electrophysiological experiments. This increase in 
channel surface expression may explain the improvements in PAH patients 
(Clapp and Gurung, 2015). The enhancement in TASK-1 cell surface 
expression will lead to an increase in the number of voltage-gated calcium 
channels being closed which reduces intracellular Ca2+ and promotes smooth 
muscle cell relaxation. This effect compliments the proposed main action of 
treprostinil to promote protein kinase A (PKA) activation, leading to an 
reduction of sarcoplasmic Ca2+ release (through RGS4 phosphorylation and 
Gαq inhibition) and ultimately a promotion in smooth muscle cell relaxation 
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(Olschewski et al., 2006). This proposed main pathway of treprostinil action 
could thus occur through TASK-1 channels. The inhibition of Gαq, results in an 
inhibition of phospholipase C (PLC) activity, which in turn reduces the 
production of the intracellular messengers diacylglycerol (DAG) and inositol 
triphosphate (IP3). This PLC inhibition may be critical to TASK-1 enhancement 
as it has been shown that a change in intracellular levels of DAG (and not its 
metabolites) can directly regulate TASK-1 activity (Wilke et al., 2014). 
Prostaglandins are produced after phospholipase A2 generates arachidonic 
acid from membrane phospholipids. Subsequent metabolism through 
cyclooxygenase (COX) synthases and prostaglandin synthases, results in the 
generation of prostaglandins (prostaglandin D2, PGD2; prostaglandin E2, 
PGE2; prostaglandin F2α, PGF2α and prostacyclin, PGI2). Prostaglandins are 
greatly increased after acute inflammation and in low levels within uninflamed 
tissues (Ricciotti and FitzGerald, 2011). Each prostaglandin can bind to 
prostaglandin receptors with different affinities and coupled with a variety of 
G-proteins that initiate different cellular pathways. Prostaglandin receptors 
present in vascular smooth muscle cells include DP1+2, EP1-4 and IP receptors 
(Parameswaran et al., 2007; Pluchart et al., 2017). Interestingly DP2 has an 
alternative name, CRTH2, as it belongs to another family of receptors (the 
chemoattractant receptors) and was first identified within T helper 2 cells 
hence CRTH2. Receptors analysed in this study were DP2, EP2 and IP, as 
mentioned previously prostaglandin receptors are coupled to different G-
proteins, DP2 is coupled to Gi proteins which decrease cAMP levels and 
promote intracellular Ca2+ levels. EP2 is coupled with Gs proteins which 
promotes intracellular levels of cAMP which promotes smooth muscle cell 
relaxation through activation of PKA. IP receptors have been found to have 
multiple G-proteins coupled to the receptor. Prostacyclin analogues have been 
shown to promote relaxation by activating adenylyl cyclase through Gs 
proteins, in a dose-dependent manner. Whereas it would appear higher 
concentrations of IP ligands have the opposite effect, promoting smooth 
muscle contraction through PLC and Gq-coupled proteins (Smyth et al., 2000; 
Bley et al., 1998). PLC activation promotes increases in intracellular IP3 and 
leads to an inhibition of myosin light chain (MLC) phosphatase and promotes 
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release of sarcoplasmic Ca2+. In this study we showed that co-expression of 
TASK-1_WT with EP2 receptor significantly enhanced baseline TASK-1_WT 
current. The increase in TASK-1_WT current suggests that the presence of 
the EP2 receptor within the cells naturally activates PKA and its downstream 
effects of increased channel expression on the cell surface and reduction in 
DAG levels, as a result of RGS4 phosphorylation and Gαq inhibition. Co-
expression of TASK-1_WT with IP or DP2 receptors did not alter TASK-1_WT 
current significantly. After co-expression with any of prostaglandin receptors 
(DP2, EP2 and IP), further incubation with treprostinil failed to affect TASK-
1_WT current any further. As DP2 appeared to have a similar trend to EP2, I 
conducted post-hoc power analysis of the data to determine the power of the 
study using power calculation software outlined in section 2.6. Data collected 
for DP2 co-expression had a power of 0.31 and required an n = 41 (30 more 
repeats) to gain a power of 0.8. EP2 co-expression had a 0.92 and only 
required an n = 16 to gain a power of 0.8 whereas IP co-expression required 
an n = 142 with a power of 0.20. Further experiments, particularly with DP2 co-
expression may help fully determine whether a significant difference is present 
opposed to a trend seen similar to that of EP2. 
Interestingly, I found that acute application of treprostinil altered TASK-1_WT 
current in a receptor dependent manner. Co-expression of TASK-1_WT and 
DP2 did not respond to the acute application of treprostinil, treprostinil has yet 
to be shown to bind DP2 receptors, but has high affinity for EP2, DP1 and IP 
(Clapp and Gurung, 2015). Acute application of treprostinil upon cells 
expressing both TASK-1_WT and EP2 generated a significantly enhanced 
TASK-1_WT current. This enhancement, although significant is small and 
gradual indicating that it may be an increase in cell surface expression of 
TASK-1_WT, through PKA activation as described previously. Application of 
treprostinil on TASK-1_WT and IP generated a significant decrease in TASK-
1_WT current. IP receptors are proposed to act as activators of adenylyl 
cyclase and PKA in a dose-dependent manner (Smyth et al., 2000). At higher 
concentrations it has been proposed IP receptors can activate PLC. It may be 
that the inhibition seen for TASK-1_WT current during this acute application is 
due to the concentration of treprostinil activating PLC (and DAG as a result) 
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through Gq coupling and not the desired Gs proteins (Bley et al., 1998). Further 
evidence for this has been shown from prostacyclin treatments that affect the 
pathway activated in HEK293 cells. A short, high dose PGI2 treatment 
activated PKC whereas a long, low dose PGI2 treatment, resulted in PKA 
activation (Moriyama et al., 2005). With this in mind the pathways involved in 
PAH pathogenesis can be updated to indicate the biphasic effects of IP 
receptors (Figure 4.49). IP receptors have been shown to form heterodimers 
with thromboxane receptors (TP). TP receptors are Gαq-coupled and activate 
PLC (and PKC downstream) which may provide insight to the inhibitory actions 
of IP receptors (Pluchart et al., 2017). Another insight is the EC50 for treprostinil 
action upon IP receptors is 1.9 nM whereas the concentration used within 
these experiments was at 1 µM (Whittle et al., 2012).  
Compounds, analysed in this study suggest that their mechanism of action is 
primarily to act through G-coupled receptors and C-terminus phosphorylation. 
In regards to the therapy for patients expressing the novel mutations, G106R 
and L214R, it would appear that this therapeutic target would not be a prudent 
line of therapy. The novel mutations appear to block the selectivity filter 
through large changes in amino acid structure and charge. It is this block of 
the selectivity filter that needs to be addressed in order to alleviate non-
functionality seen within the mutated TASK-1 channels as increasing cell 
surface expression of a non-functioning channel will not generate an increase 
in TASK-1 current. One possible approach to rectify this would be to use 
homology modelling to analyse the G106R and L214R areas and develop 
compounds that could structurally alter the channel to open the selectivity filter. 
Alternatively the rise of CRISPR-Cas9 and other gene-editing tools could hold 
promise to repairing disease-causing mutations in ion channels (Snowball, 
2015). Finally stimulating alternative ion channels and pathways may 
compensate for loss of TASK-1 activity. 
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Figure 4.49 – Updated Key Pathways in Pulmonary Arterial Hypertension  
Updated version of Figure 4.3, indicating the dual pathways of IP receptor upon PGI2 
binding. High concentrations of prostacyclin results in activation of Gαq couple proteins 
and the constrictive pathway whereas low concentrations activates Gs coupled 
proteins and relaxation pathway.  
As treprostinil therapy causes severe site pain in 85% of patients undergoing 
subcutaneous infusion, causing 8% to withdraw from treatment, known K2P 
channels involved in pain signalling, were investigated for modulation by 
treprostinil (Simmonneau et al., 2002). Current therapeutic strategies are to 
apply pain relief in the form of lidocaine, topically to the infusion site, however 
the pain is still experienced, which indicates lidocaine is not an adequate pain 
preventative approach. TREK-1 and TREK-2 have been implicated heavily in 
the pain signalling pathway and are expressed abundantly within nociceptors 
(Marsh et al., 2012; Alloui et al., 2006). Like TASK-1, TREK-1 and TREK-2 
channels have been shown to be regulated by multiple G proteins (Mathie, 
2007). In this study I have shown that acute application of treprostinil, potently 
and reversibly inhibits WT TREK-1 and TREK-2 currents. Some applications 
of treprostinil showed an over recovery of current following wash-off of 
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treprostinil, this is commonly seen with TREK inhibitors and current comes 
back down to baseline after a short period of time. The TREK-1 variant 
TREK1Δ1-41, has been shown previously to have reduced current levels, 
which can be recovered through histidine-modifying agents (Veale et al., 
2010). In this study we have shown that despite the reduced current of TREK-
1Δ1-41, treprostinil still has a significant inhibition on whole-cell current. Whilst 
it appears the N-terminus influences functional and trafficking properties of the 
channel, the findings from this study indicating that the N-terminus does not 
play a role in treprostinil inhibition of TREK-1 (Thomas et al., 2008; Simkin et 
al., 2008; Veale et al., 2010). As mentioned previously that S333 
phosphorylation is crucial to the open probability of the channel and these 
findings further suggest that the inhibitory action of treprostinil on TREK 
channels occurs through PKA and S333 phosphorylation (Bockenhauer et al., 
2001).  
Due to the speed of the effect seen by treprostinil it appears to have a direct 
action upon the channel. A secondary mechanism of action for treprostinil, 
may occur through the increase in cAMP levels and subsequent PKA 
activation. TREK channels are down-regulated by Gαs coupling as well as Gαq 
activation and subsequent PKC phosphorylation (Lesage et al., 2000; Kang et 
al., 2006; Murbartian et al., 2005). Treprostinil acts primarily on IP receptors. 
Signalling pathways activated by treprostinil on IP receptors are dose-
dependent. IP receptors couple with either Gαs or Gαq proteins both of which 
promote TREK channel inhibition. This provides a useful option for enhancing 
patient comfort during therapy. Application of a TREK activator at the site of 
administration may alleviate the pain experienced. Another possibility is to co-
treat patients with a cAMP inhibitor, such as a topical cream localised to the 
site of infusion. It may be that the effect of treprostinil is an unfortunate, but 
necessary side effect, as an increase in cAMP levels is the desired effect to 
promote vasorelaxtion, anti-proliferation and anti-thrombotic effects. However 
possible pain-relieving sources should be explored providing they do not 
hinder the benefits of treprostinil. 
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5. Consolidation 
Pulmonary disorders are a major cause of deaths within the United Kingdom 
with 20% of all deaths a consequence of a pulmonary disorder (British Lung 
Foundation, 2012). In this study multiple K2P channels have been investigated 
in their relation to pulmonary disorders. Doxapram, a ventilatory stimulant, is 
used in multiple pulmonary disorders including post-operative respiratory 
depression, acute respiratory failure chronic obstructive pulmonary disorder 
and apnoea (Yost et al., 2008). We studied the effect of doxapram upon TASK-
3 channels as well as any differences in action of the GAL-054, the eutomer 
of doxapram.  
The second part of my study focused on pulmonary arterial hypertension 
(PAH) and how TASK-1 may play a role in the disease state. PAH is an 
incurable disease and current research indicates that three key pathways are 
involved in its pathogenesis – endothelin (ET), nitric oxide (NO) and 
prostacyclin (PGI2). These pathways provide the major therapeutic targets in 
the treatment of PAH, which currently, are not sufficient for long-term patient 
survival.  In chapter 4, novel genetic mutations of TASK-1 found in patients 
with an aggressive form of PAH, were characterised for the first time and 
known therapeutic compounds investigated to determine if that therapeutic 
effect occurs via the modulation of TASK-1 channels. Finally, I looked into 
whether a commonly used PAH therapeutic, treprostinil, had an effect upon 
known pain signalling K2P channels, TREK-1 and TREK-2. 
 
5.1. Pharmacological action of doxapram on TASK-3 and future 
perspectives 
TASK-3 channels are widely distributed but play a major role within the central 
nervous system (Goldstein et al., 2005). The pharmacological action of 
doxapram is disputed with conflicting evidence between animal and human 
studies. Previous data obtained within the lab has shown that doxapram is 
equally potent on both human TASK-1 and human TASK-3 (Cunningham et 
al., 2016). Furthermore it is suggested that putative site on TASK-3, previously 
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proposed on rat TASK-3 channels may be responsible for the action of 
doxapram. Two key mutations, L122D and L239D, suggest that a change 
within a ‘hydrophobic cuff’ of TASK-3 is responsible for preventing doxapram 
having its desired inhibitory effect. In addition to doxapram, we analysed GAL-
054, an isolated eutomer of doxapram. Previous studies have indicated GAL-
054 retains the therapeutic effects of doxapram with a reduction in adverse 
side effects (Golder et al., 2012). Previous work within our lab showed that 
GAL-054 inhibited TASK-1 and TASK-3 channels equally (Appendix 6.5 and 
6.6).  
The M1P1 loop, a large extracellular pre-pore linker, has been widely 
implicated in K2P channel function as it lies close to the channel pore (Clarke 
et al., 2008). It has also been shown to be vital for channel dimerization and 
certain residues have been found to be critical in channel regulation such as 
H98 in pH sensing (Lesage et al., 1996; Morton et al., 2002). We showed in 
this study that the M1P1 loop was critical to doxapram inhibition of TASK-3, 
by replacing the M1P1 loop with that of TASK-2, a similar but different K2P 
subfamily, the effect of doxapram was significantly reduced. I postulate that 
the structure of the TASK-3 M1P1 loop is vital to doxapram gaining access to 
a binding site on the channel and alteration of the loop results in a 
conformation that is non-conducive, to doxapram entry.  
It would be insightful to look into the effects of doxapram on the heterodimeric 
channel TASK-1/TASK-3 and introduce the point mutations of the putative 
binding site. Currently very few studies have been conducted using GAL-054 
to identify its full therapeutic profile. It is clear that TASK channels within the 
carotid bodies are a potential target for regulating ventilatory response, with 
new studies showing expression of TASK channels, enhanced following 
activation of pathways to increase oxygen supply, in response to hypoxic 
conditions (Yuan et al., 2018). 
 
5.2 TASK-1 involvement in pulmonary arterial hypertension 
TASK-1 channels have been identified as the major contributor to pulmonary 
arterial smooth muscle cell (PASMC) resting membrane potential (Olschewski 
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et al., 2006). TASK-1 expression has been shown to be reduced with PAH and 
this has a vital role in the disease (Antigny et al., 2016). Whole exome 
screening of patients with PAH have identified mutations residing on TASK-1 
(Ma et al., 2013). A parallel example of TASK channels in disease states is 
shown in TASK-3, where it has been found to play a key role in neuronal 
development (Bando et al., 2012). Birk Barel mental retardation syndrome is 
caused by a single mutation (G236R) on the KCNK9 gene which is maternally 
transmitted and results in the developmental disorder observed in patients 
(Barel et al., 2008). TASK-3_G236R currents are significantly smaller and 
inwardly rectifying compared to WT TASK-3 channels and can be partially 
recovered using pharmacological intervention (Veale et al., 2014a).  
With this in mind, studies have shown TASK-1 channels containing loss of 
function mutations, can also lead to PAH. It has been shown that the 
phospholipase A2 inhibitor, ONO-RS-082, can enhance TASK-1 channel 
activity and provide a potential avenue for PAH therapy (Ma et al., 2013). In 
chapter 4, I characterised two novel mutations, G106R and L214R, found in 
patients with an aggressive form of PAH. These channels, appeared to be 
non-functional, however were translated and expressed with the same 
efficiency as TASK-1_WT at the membrane therefore it suggests that these 
channels are structurally closed, one possibility is that the selectivity filter has 
collapsed which prevents ion flow through the channel (See Appendix 6.11). 
As pharmacological recovery of these channels may be impossible, an 
alternative may be genome editing, such as CRISPR/CAS-9. Unfortunately, 
this still seems a long way from clinical use. One key aspect may be the hetero 
or homozygous nature of the mutation. Homozygous mutations are more 
aggressive and less susceptible to pharmacological regulation and further 
research will be required to improve therapeutic options for homozygous 
patients. 
 
5.3 K2P involvement in PAH therapy 
PAH therapeutics aim to promote the increase of intracellular secondary 
messengers, cAMP and cGMP, either through G-coupled receptors or direct 
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activation of a cyclase. It has been shown that cAMP and cGMP have 
vasodilatory and anti-proliferative effects (Stewart et al., 1999; Fukumoto et 
al., 2018; Buys et al., 2018; Haynes Jr et al., 1992). The action of secondary 
messengers on TASK-1 occurs through phosphorylation of the C-terminus. 
Phosphorylation of TASK-1 increases cell surface expression and would keep 
the pulmonary artery hyperpolarised. However in the case of G106R and 
L214R mutated TASK-1 channels, which sits at depolarised potentials, this is 
not a satisfactory therapeutic intervention. Increasing the amount of non-
functioning channels expressed at the membrane will fail to create the normal 
negative membrane potential, meaning the cells will sit at a less polarised 
potential. TASK-1 is inhibited by Gαq-coupled and activated by Gαs-coupled 
receptors. In this study we show that activation of EP2 receptors enhances 
TASK-1 current. However, IP receptor activation, can inhibit TASK-1, despite 
being Gαs-coupled. This is probably due to IP receptors coupling also with Gαq-
proteins. Whilst treprostinil potently binds to EP2 receptors, it also binds to IP 
receptors with high affinity (Clapp and Gurung, 2015; Patel et al., 2018). 
Binding to IP receptors may hinder the maximum therapeutic effects of 
treprostinil, as IP receptors have been shown to form heterodimeric receptors 
with TP receptors, which are also Gαq-coupled receptors (Pluchart et al., 2017). 
In this study I also showed that co-expression with receptors has an inhibiting 
or enhancing effect on baseline TASK-1 current. This may occur through 
natural elevation of cAMP. It has been identified that within cAMP production, 
receptor expression is the main limiting factor in the cAMP production pathway 
(Alousi et al., 1991). 
I show that treprostinil has a direct and potent action upon TREK channels. 
TREK channels have implicated in pain signalling, having been identified in 
nociceptors (Alloui et al., 2006). Patients undergoing treprostinil therapy 
experience severe site pain at the site of infusion, causing them to withdraw 
from therapy. Finding a therapeutic intervention to combat this pain is vital, in 
order to allow patients to comply with treatment. Whilst the experimental work 
shown in this study is at an early stage, the results presented and previous 
studies in TREK channels highlight a promising area of exploration. Patient 
comfort is a key area within drug delivery. Alleviating pain suffered by patients 
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would be a big step particularly in a disease with very few effective treatment 
options.  
5.4  Future Experiments 
With the work in this study being conducted in heterologous mammalian cell 
cultures, the next step would be to conduct testing within isolated human 
and/or animal tissues or animal models. To date, there is already a substantial 
amount of work conducted on the role of TASK-1 within the PASMCs of 
different species. Whilst TASK-1 properties have shown similarities in human, 
rabbit and rat PASMCs there are differences revealed in mice (Olschewski et 
al., 2006; Gurney et al., 2003; Antigny et al., 2016; Manoury et al., 2011). Mice 
with the TASK-1 gene knocked out do not show phenotypic signs of PAH and 
the cardiovascular phenotype observed is due to hyperaldosteronism, rather 
than vascular impairment (Manoury et al., 2011; Heitzmann et al., 2008). 
Therefore when selecting appropriate models of PAH and TASK-1, mice 
models/PASMCs would not be a prudent choice to translate the results in 
regard to human PAH and pulmonary physiology. Mice TASK-1 channels 
appear to act in a different way to those of rats, rabbits and humans. Species 
differences were also seen by Manoury et al., 2013, with regard to doxapram 
as binding shown in Chapter 3. 
 
5.5 Concluding remarks 
PAH is a progressive and ultimately fatal disease, establishing effective 
therapeutic interventions remains paramount for future research. To 
summarise this study, with the use of electrophysiological and imaging 
techniques, I have characterised two novel mutations of TASK-1 present in 
PAH patients. The mutations cause a non-functioning channel which could not 
be recovered with current pharmacological tools and is, likely to play a role in 
the pathogenesis of the disease. I show that therapeutic compounds such as 
sildenafil and riociguat enhance TASK-1_WT current, but fail to recover 
current through disease causing mutations suggesting, they may not be useful 
therapies for these particular PAH patients. Increasing cell surface expression 
of TASK-1 channels, may prove helpful for low-functioning channels, but has 
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little benefit in non-functional channels such as G106R and L214R. Further 
work is required on the precise action of PAH therapeutics on TASK-1 
channels. TASK-1 and its regulation appears to be receptor dependent in its 
response to treprostinil. Further work to clarify prostanoid receptor interaction 
with TASK-1 is required, also, further research into TREK channel involvement 
in the local site pain experienced during treprostinil therapy will need to be 
conducted however this study has indicated a possible cause and therefore 
treatment option for the pain. The use of a TREK channel activator, such as 
























6. Appendix  




6.1 Human TASK-1 amino acid sequence 
        10         20         30         40         50 
MKRQNVRTLA LIVCTFTYLL VGAAVFDALE SEPELIERQR LELRQQELRA  
        60         70         80         90        100 
RYNLSQGGYE ELERVVLRLK PHKAGVQWRF AGSFYFAITV ITTIGYGHAA  
       110        120        130        140        150 
PSTDGGKVFC MFYALLGIPL TLVMFQSLGE RINTLVRYLL HRAKKGLGMR  
       160        170        180        190        200 
RADVSMANMV LIGFFSCIST LCIGAAAFSH YEHWTFFQAY YYCFITLTTI  
       210        220        230        240        250 
GFGDYVALQK DQALQTQPQY VAFSFVYILT GLTVIGAFLN LVVLRFMTMN  
       260        270        280        290        300 
AEDEKRDAEH RALLTRNGQA GGGGGGGSAH TTDTASSTAA AGGGGFRNVY  
       310        320        330        340        350 
AEVLHFQSMC SCLWYKSREK LQYSIPMIIP RDLSTSDTCV EQSHSSPGGG  
       360        370        380        390  
GRYSDTPSRR CLCSGAPRSA ISSVSTGLHS LSTFRGLMKR RSSV  
 
Figure 6.1 – Human TASK-1 amino acid sequence 
Uniprot entry ID: O14649, Length: 394 amino acids, molecular weight: 43.5 kDa  
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6.2 Human TASK-3 amino acid sequence 
        10         20         30         40         50 
MKRQNVRTLS LIVCTFTYLL VGAAVFDALE SDHEMREEEK LKAEEIRIKG  
        60         70         80         90        100 
KYNISSEDYR QLELVILQSE PHRAGVQWKF AGSFYFAITV ITTIGYGHAA  
       110        120        130        140        150 
PGTDAGKAFC MFYAVLGIPL TLVMFQSLGE RMNTFVRYLL KRIKKCCGMR  
       160        170        180        190        200 
NTDVSMENMV TVGFFSCMGT LCIGAAAFSQ CEEWSFFHAY YYCFITLTTI  
       210        220        230        240        250 
GFGDYVALQT KGALQKKPLY VAFSFMYILV GLTVIGAFLN LVVLRFLTMN  
       260        270        280        290        300 
SEDERRDAEE RASLAGNRNS MVIHIPEEPR PSRPRYKADV PDLQSVCSCT  
       310        320        330        340        350 
CYRSQDYGGR SVAPQNSFSA KLAPHYFHSI SYKIEEISPS TLKNSLFPSP  
       360        370  
ISSISPGLHS FTDHQRLMKR RKSV   
 
Figure 6.2 – Human TASK-3 amino acid sequence 
Uniprot entry ID: Q9NPC2, length: 374 amino acids, molecular weight: 42.3 kDa 
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6.3 Human TREK-1 amino acid sequence 
        10         20         30         40         50 
MLPSASRERP GYRAGVAAPD LLDPKSAAQN SKPRLSFSTK PTVLASRVES  
        60         70         80         90        100 
DTTINVMKWK TVSTIFLVVV LYLIIGATVF KALEQPHEIS QRTTIVIQKQ  
       110        120        130        140        150 
TFISQHSCVN STELDELIQQ IVAAINAGII PLGNTSNQIS HWDLGSSFFF  
       160        170        180        190        200 
AGTVITTIGF GNISPRTEGG KIFCIIYALL GIPLFGFLLA GVGDQLGTIF  
       210        220        230        240        250 
GKGIAKVEDT FIKWNVSQTK IRIISTIIFI LFGCVLFVAL PAIIFKHIEG  
       260        270        280        290        300 
WSALDAIYFV VITLTTIGFG DYVAGGSDIE YLDFYKPVVW FWILVGLAYF  
       310        320        330        340        350 
AAVLSMIGDW LRVISKKTKE EVGEFRAHAA EWTANVTAEF KETRRRLSVE  
       360        370        380        390        400 
IYDKFQRATS IKRKLSAELA GNHNQELTPC RRTLSVNHLT SERDVLPPLL  
       410        420  
KTESIYLNGL TPHCAGEEIA VIENIK  
 
Figure 6.3 – Human TREK-1 amino acid sequence 
Uniprot entry ID: O95069, length: 426 amino acids, molecular weight: 47.1 kDa 
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6.4 Human TREK-2 amino acid sequence 
        10         20         30         40         50 
MFFLYTDFFL SLVAVPAAAP VCQPKSATNG QPPAPAPTPT PRLSISSRAT  
        60         70         80         90        100 
VVARMEGTSQ GGLQTVMKWK TVVAIFVVVV VYLVTGGLVF RALEQPFESS  
       110        120        130        140        150 
QKNTIALEKA EFLRDHVCVS PQELETLIQH ALDADNAGVS PIGNSSNNSS  
       160        170        180        190        200 
HWDLGSAFFF AGTVITTIGY GNIAPSTEGG KIFCILYAIF GIPLFGFLLA  
       210        220        230        240        250 
GIGDQLGTIF GKSIARVEKV FRKKQVSQTK IRVISTILFI LAGCIVFVTI  
       260        270        280        290        300 
PAVIFKYIEG WTALESIYFV VVTLTTVGFG DFVAGGNAGI NYREWYKPLV  
       310        320        330        340        350 
WFWILVGLAY FAAVLSMIGD WLRVLSKKTK EEVGEIKAHA AEWKANVTAE  
       360        370        380        390        400 
FRETRRRLSV EIHDKLQRAA TIRSMERRRL GLDQRAHSLD MLSPEKRSVF  
       410        420        430        440        450 
AALDTGRFKA SSQESINNRP NNLRLKGPEQ LNKHGQGASE DNIINKFGST  
       460        470        480        490        500 
SRLTKRKNKD LKKTLPEDVQ KIYKTFRNYS LDEEKKEEET EKMCNSDNSS  
       510        520        530  
TAMLTDCIQQ HAELENGMIP TDTKDREPEN NSLLEDRN  
 
Figure 6.4 – Human TREK-2 amino acid sequence 
Uniprot entry ID: P57789, length: 538 amino acids, molecular weight: 59.8 kDa 
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6.5 Effect of Doxapram and its enantiomers (GAL-
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Figure 6.5 – Effect of doxapram, GAL-053 and GAL-054 on human TASK-1_WT 
channels 
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6.6 Effect of Doxapram and its enantiomers (GAL-
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Figure 6.6 - Effect of doxapram, GAL-053 and GAL-054 on human TASK-3_WT 
channels 
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Figure 6.7 – Effect of Doxapram on TASK-1/TASK-3 Heterodimeric channels 
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Figure 6.8 – Effect of Doxapram on mouse TASK-1 and TASK-3 channels 
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Figure 6.9 – Effect of Forskolin and IBMX on Mouse TASK-3/TASK-1  
Unpublished work conducted within the lab. 
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6.10  Effect of Concatamer Arrangment on Forskolin 






Comparison of effect of Forskolin + IBMX 






















Figure 6.10 – Effect of Concatamer Arrangment on Forskolin and IBMX Action 
Arrangement of TASK-1/TASK-3 alters the effect of forskolin and IBMX, TASK-1 n 
terminus results in enhancement of channel current whereas TASK-3 n terminus 
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6.11 Permeability of TASK-1 WT and Novel Mutants 
 
Figure 6.11 – Permeability of TASK-1_WT and Novel Mutant channels 
Permeability of cells expressing either TASK-1_WT, TASK-1_G106R, TASK-
1_L214R or GFP to 2.5 mM K+ (black line), 25 mM K+ (blue line), 25 mM Cs (red line) 
and 25 mM Rb (green line). Permeability of channels are recorded over voltages 
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6.12 Effect of permeating ion on TASK-1 channel 




Figure 6.12 – Effect of Permeating Ion on TASK-1 Channel Current 
Reversal potentials (in mV) obtained for TASK-1, TASK-1_G106R, TASK-1_L214R 
and GFP alone transfected cells when the external solution contained 2.5 mM K, 25 
mM K, 25 mM Cs, or 25 mM Rb.  
 
 
 2.5 mM K 25 mM K 25 mM Cs 25 mM Rb 
TASK-1 -73 ± 2 (n = 
13)  
-38 ± 1 (n = 10)  -64 ± 2 (n = 8)  -41 ± 3 (n = 7)  
TASK-
1_G106R 
-33 ± 8 (n = 5)  -28 ± 4 (n = 5)  -29 ± 5 (n = 5)  -25 ± 3 (n = 5)  
TASK-
1_L214R 
-19 ± 3 (n = 5)  -17 ± 2 (n = 5)  -18 ± 4 (n = 5)  -15 ± 3 (n = 5)  
GFP alone -32 ± 2 (n =13)  -25 ± 3 (n = 6)  -31 ± 4 (n = 5)  -27 ± 3 (n = 5)  
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